Anti-CD48 antibodies, antibody-drug conjugates and uses thereof
Patent Information
- Application Number
- JP2023530586
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-24
- Filing Date
- 2021-11-23
- Publication Date
- 2024-12-03
AI Technical Summary
There is a need for additional therapeutic compounds that target CD48, as existing antibody drug conjugates demonstrate rapid internalization and repopulation on tumor cells, limiting their efficacy in treating hematological malignancies.
Development of anti-CD48 antibodies and antibody-drug conjugates with specific CDR sequences that bind to CD48, linked through cleavable or non-cleavable linkers to deliver cytotoxic agents, selectively targeting CD48-expressing cells.
The anti-CD48 antibodies and antibody-drug conjugates effectively reduce tumor growth by 10-99% and inhibit cancer cell populations, providing therapeutic benefits for hematological cancers and other malignancies.
Smart Images

Figure 2022112942000001 
Figure 2022112942000002 
Figure 2022112942000003
Abstract
Description
Technical field
[0001] Cross-reference of related applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 117,817, filed November 24, 2020, the entire contents of which are incorporated herein by reference.
[0002] The present disclosure relates to anti-CD48 antibodies and antigen-binding fragments thereof, antibody-drug conjugates thereof, and their use for treating cancer in a patient in need thereof.
[0003] Sequence list This application contains a sequence listing submitted electronically in ASCII format, which is incorporated herein by reference in its entirety. Its ASCII copy (created on November 18, 2021) is named PAT058966_SL.txt and is 79,220 bytes in size. [Background technology]
[0004] CD48 (also known as BLAST-1 and SLAMF2) is an adhesion and costimulatory molecule involved in a variety of innate and adaptive immune responses, ranging from granulocyte activation and allergy to T-cell activation and autoimmunity (McArdel et al. (2016) Clin Immunol 164:10-20). In normal blood tissues, CD48 helps regulate the activation and differentiation of lymphocytes, dendritic cells, and endothelial cells. In oncology, CD48 is used in a wide range of B It is well established that in cellular malignancies it is markedly upregulated at both RNA and protein levels.
[0005] CD48 is important because it is absent from normal non-hematopoietic tissues, is expressed exclusively on mature lymphocytes and monocytes, and is markedly upregulated in a range of hematological malignancies. It is an attractive target for antibody drug conjugates. Antibodies and antibody drug conjugates targeting CD48 have previously demonstrated antitumor activity in preclinical models of hematological cancers. Previous therapeutic efforts have shown that CD48 can be rapidly internalized upon antibody engagement, transported to lysosomes, and rapidly repopulated on the surface of tumor cells after internalization. There remains a need for additional therapeutic compounds that target CD48. [Summary of the invention]
[0006] Antibodies or antigen-binding fragments thereof that bind human CD48 are disclosed herein. In one embodiment, the anti-CD48 antibody or antigen-binding fragment thereof comprises three heavy chain CDRs and three light chain CDRs selected from: (i) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 1, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (ii) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 4, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (iii) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 5, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 6, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 19 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 20 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 21; (iv) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 7, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 8, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 9; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 22 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 20 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (v) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 27, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 28, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 42 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 43 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 44; (vi) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 30, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 28, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 42 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 43 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 44; (vii) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 31, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 32, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 45 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46 and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 47; or (viii) Heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 33, heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 34, heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 35; light chain CDR1 (LCDR1) consisting of SEQ ID NO: 48 , light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46, and light chain CDR3 (LCDR3) consisting of SEQ ID NO: 44. In another embodiment, the anti-CD48 antibody or antigen-binding fragment thereof is (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23; or (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; including.
[0007] In another embodiment, the anti-CD48 antibody is (a) Heavy chain amino acid sequence of SEQ ID NO: 12 and light chain amino acid sequence of SEQ ID NO: 25; (b) the heavy chain amino acid sequence of SEQ ID NO: 14 and the light chain amino acid sequence of SEQ ID NO: 25; (c) heavy chain amino acid sequence of SEQ ID NO: 63 and light chain amino acid sequence of SEQ ID NO: 25; (e) heavy chain amino acid sequence of SEQ ID NO: 38 and light chain amino acid sequence of SEQ ID NO: 51; (f) the heavy chain amino acid sequence of SEQ ID NO: 40 and the light chain amino acid sequence of SEQ ID NO: 51; or (g) Heavy chain amino acid sequence of SEQ ID NO: 65 and light chain amino acid sequence of SEQ ID NO: 51 including.
[0008] In yet another embodiment, the anti-CD48 antibody or antigen-binding fragment thereof is a Fab fragment, Fab' fragment, F(ab')2 fragment, single chain Fv (scFv), disulfide bonded Fv (sdFv), Fd fragment, Fv fragments, dAb fragments, single domain antibodies, maxibodies, minibodies, nanobodies, intracellular antibodies, bispecific antibodies, half antibodies, one-arm antibodies, monoclonal antibodies, bispecific antibodies, bispecific T cell engaging antibodies, Including multispecific antibodies, chimeric antigen receptor T cells or radioimmunoconjugates.
[0009] Nucleic acids encoding antibodies or antigen-binding fragments thereof as disclosed herein are also disclosed. In one embodiment, the nucleic acid comprises a sequence encoding a variable heavy chain (VH) or variable light chain (VL) of an antibody selected from SEQ ID NO: 11, SEQ ID NO: 37, SEQ ID NO: 24, or SEQ ID NO: 50. In other embodiments, the nucleic acids disclosed herein encode heavy and light chains of antibodies and include sequences selected from SEQ ID NO: 13, 15, 39, 41, 75, 77, 26, or 52. include.
[0010] Vectors comprising any of the nucleic acids as provided herein, cell lines comprising any of the vectors as provided herein, and using the nucleic acids, vectors and cell lines provided herein. Also disclosed are methods of making such antibodies or antigen-binding fragments thereof. In one embodiment, the method of producing an anti-CD48 antibody or antigen-binding fragment thereof comprises using any of the cell lines as provided herein under conditions suitable for expressing the antibody or antigen-binding fragment thereof. propagation and subsequent purification and isolation of the antibody or antigen-binding fragment thereof.
[0011] In another embodiment, this application also discloses an antibody drug conjugate of formula (I): A-(L B -(D) n ) y (I); During the ceremony, A is an antibody or antibody antigen-binding fragment thereof that specifically binds human CD48 as disclosed herein; L B is a linker; D is a cytotoxic agent; n is an integer from 1 to 10; y is an integer from 1 to 10; where the linker drug moiety (L B -(D) n) is covalently linked to the antibody or antigen-binding fragment thereof (A). In some embodiments, n is 1, 2, 3, 4, 5, 6, 7 or 8. In some embodiments, y is 1, 2, 3 or 4. In one embodiment, L B are independently selected from cleavable linkers or non-cleavable linkers. In some embodiments, each L B is a cleavable linker. In other embodiments, each L B is an uncleavable linker.
[0012] In some embodiments, the drug moiety is an Eg5 inhibitor, a V-ATPase inhibitor, an HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auristatin, a dolastatin, a maytansinoid. , MetAP (methionine aminopeptidase), inhibitor of nuclear export of protein CRM1, DPPIV inhibitor, inhibitor of phosphoryl transfer reaction in mitochondria, protein synthesis inhibitor, kinase inhibitor, CDK2 inhibitor, CDK9 inhibitor, proteasome inhibitor, kinesin inhibitor, HDAC inhibitor, DNA Damaging agents, DNA alkylating agents, DNA intercalating agents, DNA minor groove binders, RNA polymerase inhibitors, amanitin, spliceosome inhibitors, topoisomerase inhibitors, DHFR inhibitors or apoptosis promoting agents, but BCL-2 inhibitors, MCL-1 inhibitors and exclude BCL-XL inhibitors. In some embodiments, the drug moiety is auristatin.
[0013] In one embodiment, drug moiety D has the formula (A): [ka] (In the formula, R 1 teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 (independently selected from alkyl) is a cytotoxic agent selected from the compounds of; or D is the formula (B): [ka] (In the formula, R 1 teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 (independently selected from alkyl) A cytotoxic agent selected from compounds of.
[0014] As used herein, formula (E): [ka] Also disclosed are antibody-drug conjugates comprising the structure: A represents an antibody or antigen-binding fragment thereof that specifically binds human CD48 as disclosed herein; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * ,-NR 6 S(=O) 2 CH 2 CH 2 - * ,-NR 6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 independently selected from and -OH; Each R 12 H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and -C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0015] In some embodiments, the antibody drug conjugate is [ka] selected from, in the formula, A represents an antibody or antigen-binding fragment thereof that specifically binds to human CD48 as disclosed herein, and y is an integer from 1 to 10.
[0016] In some embodiments, the antibody drug conjugate has the formula (G): [ka] including the structure, where: A represents an antibody or antigen-binding fragment thereof that specifically binds human CD48 as disclosed herein; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 )m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * ,-NR 6 S(=O) 2 CH 2 CH 2 - * ,-NR 6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 independently selected from and -OH; Each R 12 H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and -C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0017] In some embodiments, the antibody drug conjugate is [ka] selected from, in the formula, A represents an antibody or antigen-binding fragment thereof that specifically binds human CD48 as disclosed herein, and y is an integer from 1 to 10.
[0018] In another embodiment, the antibody drug conjugate is [ka] selected from, in the formula, A represents an antibody or antigen-binding fragment thereof that specifically binds human CD48 as disclosed herein, and y is an integer from 1 to 10.
[0019] Also disclosed herein are pharmaceutical compositions comprising any of the anti-CD48 antibodies or antigen-binding fragments thereof or antibody drug conjugates disclosed herein and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition includes one or more additional therapeutic agents. In some embodiments, the pharmaceutical composition is a lyophilized product.
[0020] The present application relates to a method of treating cancer in a subject, a method of reducing or inhibiting the growth of a tumor in a subject, or a method of reducing or slowing the growth of a cancer cell population in a subject, comprising: a method of treating cancer in a subject; Also disclosed are methods comprising administering to a subject an anti-CD48 antibody or antigen-binding fragment thereof, antibody-drug conjugate, or pharmaceutical composition, as described above. In some embodiments, the method reduces tumor growth by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, reducing or inhibiting by at least about 80%, at least about 90%, at least about 95% or at least about 99%. In other embodiments, the method provides at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, reducing or slowing the growth of a cancer cell population by at least about 90%, at least about 95% or at least about 99%. In some embodiments, the cancer, tumor or cancer cell population expresses CD48. In some embodiments, the cancer is a tumor or hematological cancer, preferably the cancer is breast cancer, multiple myeloma, B-cell lymphoma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, Bladder cancer, brain tumor, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphocytic leukemia, follicular lymphoma, lymphoid malignancy derived from T cells or B cells, melanoma, Myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or spleen cancer.
[0021] Also disclosed herein are antibodies that compete with any of the antibodies disclosed herein, including NY920 or NY938, for binding to human CD48. In some embodiments, the antibody binds to the same or overlapping epitope of human CD48 as NY920 or NY938. In one embodiment, the antibody binds to one or more amino acids within residues 54-64 or 105-121 of human CD48 (SEQ ID NO: 53). In other embodiments, the antibody is selected from residues 54, 58, 60, 61, 62, 64, 105, 107, 119, 111, 114, 115, 117, 119 or 121 of human CD48 (SEQ ID NO: 53). binds to one or more amino acids. In some embodiments, the antibody contacts one or more amino acids within 4.0 Å.
[0022] The present disclosure also provides diagnostic agents comprising any of the anti-CD48 antibodies or antigen-binding fragments thereof or antibody-drug conjugates as disclosed herein. In some embodiments, the anti-CD48 or antigen-binding fragment thereof or antibody drug conjugate is labeled or conjugated with a radioactive label, fluorophore, chromophore, contrast agent, or metal ion. Also disclosed is a method of detecting human CD48 in a tissue or cell, the method comprising contacting the tissue or cell with a diagnostic agent and detecting binding of the diagnostic agent to the tissue or cell. [Brief explanation of drawings]
[0023] [Figure 1-1] Figure 1: Figure 1 displays binding curves of three anti-CD48 antibodies to various constructs of the extracellular domain of the human CD48 protein. Construct #2248 carries mutated residues at amino acids 50-55 (ENYKQ (SEQ ID NO: 78) was modified to GSSKQ (SEQ ID NO: 79)). Construct #2249 carries mutated residues at amino acids 70-74 (DSRK (SEQ ID NO: 80) was modified to AAGK (SEQ ID NO: 81)). Construct #2250 carries mutated residues at amino acids 103-105 (KKTGNE (SEQ ID NO: 82) was modified to KKDASG (SEQ ID NO: 83)). FIG. 1A is a graph displaying the binding of anti-CD48 antibody NOV3731 (parent antibody of NY920) to the construct. FIG. 1B is a graph displaying the binding of anti-CD48 antibody NY254 (parent antibody of NY938) to the construct. FIG. 1C is a graph displaying the binding of humanized anti-CD48A (also known as MEM102) to the construct. The graph shows that NOV3731 and NY920 do not bind to the same CD48 extracellular domain construct as CD48a. [Figure 1-2] (As above.) [Figure 1-3] (As above.) [Figure 2-1] Figure 2: Figure 2A is a dose-response curve of anti-CD48 antibody in internalization and cell proliferation assays against the endogenous cancer cell line KMS-27. NY938 and NY920 anti-CD48 antibodies were more potent than anti-CD48A antibodies in this assay. Figure 2B is a dose response curve of anti-CD48 antibody in internalization and cell proliferation assays against the endogenous cancer cell line NCI-H929. NY938 and NY920 anti-CD48 antibodies were more potent than anti-CD48A antibodies in this assay. Figure 2C is a dose response curve of anti-CD48 antibody in internalization and cell proliferation assays against the endogenous cancer cell line KMS-21-BM. NY938 and NY920 anti-CD48 antibodies were more potent than anti-CD48A antibodies in this assay. [Figure 2-2] (As above.) [Figure 2-3] (As above.) [Figure 3] It is a graph displaying the binding kinetics of NY920 WT antibody to human CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 4] FIG. 2 is a graph displaying the binding kinetics of NY920 DAPA antibody to human CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 5] FIG. 2 is a graph displaying the binding kinetics of NY938 DAPA antibody to human CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 6] It is a graph displaying the binding dynamics of NY920 WT antibody to monkey CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 7] FIG. 2 is a graph showing the binding kinetics of NY920 DAPA antibody to monkey CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 8] FIG. 2 is a graph showing the binding kinetics of NY938 DAPA antibody to monkey CD48 antigen. Two experiments (Exp#1 and Exp#2) were conducted. [Figure 9-1] Figure 9: Figure 9A is a dose response curve of anti-CD48 MMAE ADC in cell proliferation and survival assays against endogenous cancer cell line KMS-21-BM. Non-targeting IgG-VC-MMAE ADC was used as a negative control. Figure 9B is a dose response curve of anti-CD48 MMAE ADC in cell proliferation and survival assays against endogenous cancer cell line KMS-27. Non-targeting IgG-VC-MMAE ADC was used as a negative control. Figure 9C is a dose response curve of anti-CD48 MMAE ADC in cell proliferation and survival assays against endogenous cancer cell line NCI-H929. Non-targeting IgG-VC-MMAE ADC was used as a negative control. Figure 9D is a dose response curve of anti-CD48 MMAE ADC in cell proliferation and survival assays against endogenous cancer cell line KMS-20. Non-targeting IgG-VC-MMAE ADC was used as a negative control. [Figure 9-2] (As above.) [Figure 9-3] (As above.) [Figure 9-4] (As above.) [Form for carrying out the invention]
[0024] The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to CD48. In some embodiments, the CD48 antibody or antigen-binding fragment thereof is part of an antibody-drug conjugate, and the antibody or antibody fragment that specifically binds human CD48 is a drug moiety (e.g., a cytotoxic agent, a targeting inhibitor). , including immunomodulatory compounds, but excluding BH3 mimetic inhibitors), optionally linked through a linker. These antibody drug conjugates selectively deliver drug moieties to cells that express CD48, such as B lymphoblasts, thereby treating these cells in a patient, such as a patient with B cell lymphoma. The present disclosure provides pharmaceutical compositions comprising the antibodies or antigen-binding fragments disclosed herein, antibody-drug conjugates thereof, and methods of making and using such pharmaceutical compositions to treat patients in need thereof. further provide.
[0025] definition Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings:
[0026] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Unless explicitly stated otherwise, the terms "of," "including," and "containing," such as "comprising," "having," "of chemical formula," and the like, are used in open terms (i.e. (including, but not limited to) should be construed as meaning "including, but not limited to." Additionally, whenever "comprises" or another open-ended term is used in an embodiment, the same embodiment also uses the intermediate term "consisting essentially of" or the closed term "consisting of." It should be understood that more narrow claims can be made.
[0027] The term "about" or "approximately" when used in reference to numerical values and ranges refers to the enumerated range such that the embodiment functions as intended, as will be apparent to those skilled in the art from the teachings contained herein. refers to a value or range that is close to or approximates a value or range that has been previously determined. Approximately means plus or minus 20%, 15%, 10%, 5%, 1%, 0.5% or 0.1% of the numerical value. In one embodiment, the term "about" refers to a range of values that is greater than or less than 10% of the specified value. In another embodiment, the term "about" refers to a range of values that is greater than or less than 5% of the specified value. In another embodiment, the term "about" refers to a range of values that is greater than or less than 1% of the specified value.
[0028] The term "alkyl" refers to a monovalent saturated hydrocarbon chain having the specified number of carbon atoms. For example, C 1 ~C 6 Alkyl refers to an alkyl group having 1 to 6 carbon atoms. Alkyl groups can be straight or branched. Representative branched alkyl groups have 1, 2 or 3 branches. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, sec-butyl and t-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl.
[0029] The term "antibody" as used herein refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds an antigen. Antibodies may be polyclonal or monoclonal, multi-chain or single-chain, intact immunoglobulins, and may be derived from natural or recombinant sources. Naturally occurring "antibodies" are glycoproteins that contain at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains, CH1, CH2 and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is composed of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability called complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FR). VH and VL are each composed of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of heavy and light chains contain binding domains that interact with antigen. The constant regions of antibodies may mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g. effector cells) and the first component of the classical complement system (C1q). ). The antibodies may be monoclonal, human, humanized, camelid or chimeric. Antibodies can be of any isotype (eg, IgG, IgE, IgM, IgD, IgA, and IgY), class (eg, IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass.
[0030] "Complementarity determining domain" or "complementarity determining region" ("CDR") interchangeably refers to the hypervariable regions of VL and VH. CDRs are the target protein binding sites of antibody chains, which possess specificity for such target proteins. Three CDRs (numbered sequentially from the N-terminus, CDRs 1-3) are present in each human VL or VH and constitute approximately 15-20% of the variable domain. CDRs can be referred to by their region and order. For example, "VHCDR1" or "HCDR1" both refer to the first CDR of the heavy chain variable region. CDRs are structurally complementary to the epitope of the target protein and are therefore directly responsible for binding specificity. The remaining ranges of VL or VH, the so-called framework regions, show less variation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4. W.H. Freeman & Co., New York, 2000).
[0031] The precise amino acid sequence boundaries of a given CDR can be determined using any of several well-known schemes, such as Kabat et al. (1991), “Sequences of Proteins of Immunological Interest”, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme) and ImMunoGenTics (IMGT) numbering (Lefranc, M. - P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) (“IMGT” numbering scheme) For example, for the classical format, under Kabat, the CDR amino acid residues in the heavy chain variable domain (VH) are 31-35 (HCDR1), 50-65 (HCDR2) and 95-102 ( HCDR3); and the CDR amino acid residues in the light chain variable domain (VL) are numbered 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3). Under Chothia, CDR amino acids in VH are numbered 26-32 (HCDR1), 52-56 (HCDR2) and 95-102 (HCDR3); and amino acid residues in VL are numbered 26-32 (HCDR3); LCDR1), 50-52 (LCDR2) and 91-96 (LCDR3). By combining both Kabat and Chothia's CDR definitions, the CDRs are numbered amino acid residues 26-35 (HCDR1) in human VH. , 50-65 (HCDR2) and 95-102 (HCDR3), and amino acid residues 24-34 (LCDR1), 50-56 (LCDR2) and 89-97 (LCDR3) in human VL. The CDR amino acid residues in VL are numbered approximately 26-35 (CDR1), 51-57 (CDR2) and 93-102 (CDR3), and the CDR amino acid residues in VL are numbered approximately 27-32 (CDR1). ), numbered 50-52 (CDR2) and 89-97 (CDR3) (numbering according to "Kabat"). Under IMGT, the CDR regions of an antibody can be determined using the program IMGT / DomainGap Align.
[0032] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used functionally. In this regard, of course, the variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of light chains (CL) and heavy chains (CH1, CH2 or CH3 and optionally CH4) are responsible for important biological properties such as secretion, transplacental motility, Fc receptor binding, FcRn receptor binding, half-life and pharmacokinetics. By convention, the numbering of constant region domains increases with increasing distance from the antigen-binding site or amino terminus of the antibody. The N-terminus is the variable region and the C-terminus is the constant region; the CH3 and CL domains actually contain the carboxy-terminal domains of the heavy and light chains, respectively.
[0033] As used herein, the term "antibody fragment" or "antigen-binding fragment" refers to an epitope of an antigen (e.g., CD48) that specifically (e.g., binds, sterically hindrances, stabilizes / destabilizes, spatially distributes) ) Refers to one or more portions of an antibody that retain the ability to interact. Examples of antibody fragments include, but are not limited to, Fab fragments that are monovalent fragments consisting of VL, VH, CL, and CH1 domains; Fab fragments that are monovalent fragments that consist of VL, VH, CL, CH1 domains, and the hinge region; Fab' fragment; F(ab')2 fragment that is a bivalent fragment that contains two Fab fragments connected by a disulfide bridge in the hinge region; a single heavy chain and a single light chain connected by a disulfide bridge half-antibodies containing; one-arm antibodies containing a Fab fragment linked to the Fc region; CH2 domain-deleted antibodies containing two Fab fragments linked to a CH3 domain dimer (Glaser, J Biol Chem. 2005; 280(50): 41494-503); single-chain Fv (scFv); disulfide-bonded Fv (sdFv); Fd fragment consisting of a VH domain and a CH1 domain; Fv fragment consisting of a single-arm VL and VH domain of an antibody; dAb consisting of a VH domain fragments (Ward et al., Nature 341:544-546, 1989); as well as isolated complementarity determining regions (CDRs) or other epitope-binding fragments of antibodies. For example, a Fab fragment may contain amino acid residues 1 to 222 (EU numbering) of the heavy chain of the antibody; whereas a Fab' fragment may contain amino acid residues 1 to 236 (EU numbering) of the heavy chain of the antibody. . Fab or Fab' fragments of antibodies can be produced recombinantly or by enzymatic digestion of a parent antibody. Recombinantly produced Fabs or Fab's can be engineered to introduce amino acids for site-specific binding, such as cysteine (Junutula, J.R. et al., Nature biotechnology 2008,26,925), pyrroline-carboxy- Lysine (Ou, W. et al., Proc Natl Acad Sci USA 2011;108(26):10437-42) or unnatural amino acids (e.g. Tian, F. et al., Proc Natl Acad Sci USA 2014,111, 1766, Axup, J.Y. et al., Proc Natl Acad Sci USA.2012, 109, 16101). Similarly, mutations or peptide tags can be used to promote binding to phosphopantetheine transferase (Grunewald, J. et al., Bioconjugate chemistry 2015,26,2554), formylglycine-forming enzyme (Drake, P.M. et al. ,Bioconjugate chemistry 2014,25,1331), transglutaminase (Strop,P.et al.,Chemistry&biology 2013,20,161), sortase (Beerli,R.R.;Hell,T.;Merkel,A.S.;Grawunder,U.PloS one 2015, 10, e0131177) or other enzymatic conjugation strategies. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be joined by a synthetic linker using recombinant methods, which connects the two domains to the VL and VH regions. can be produced as a single protein chain that pairs to form a monovalent molecule (known as a single-chain Fv (“scFv”); e.g., Bird et al., Science 242:423-426, 1988; and Huston et al., Proc. Natl. Acad. Sci. 85:5879-5883, 1988). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding fragment." These antigen-binding fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for utility in the same manner as are intact antibodies.
[0034] Antibody fragments or antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFvs (e.g. Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can be grafted into polypeptide-based scaffolds, such as fibronectin type III (Fn3) (see US Pat. No. 6,703,199 (describing fibronectin polypeptide monobodies)).
[0035] Antibody fragments or antigen-binding fragments can be incorporated into single-chain molecules comprising a pair of tandem Fv segments (VH-CH1-VH-CH1), which together with a complementary light chain polypeptide form an antigen-binding region. (Zapata et al., Protein Eng. 8:1057-1062, 1995; and US Pat. No. 5,641,870).
[0036] As used herein, the terms "monoclonal antibody" or "monoclonal antibody composition" refer to polypeptides that have substantially the same amino acid sequence or are derived from the same genetic source and that are antibodies and antigen-binding fragments that have substantially the same amino acid sequence or are derived from the same genetic source. Can be mentioned. The term also includes preparations of antibody molecules of single molecular composition. Monoclonal antibody compositions exhibit a single binding specificity and affinity for a particular epitope.
[0037] The term "human antibody" as used herein includes antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. Additionally, if the antibody contains a constant region, the constant region may also be, for example, a human germline sequence or a mutated version of a human germline sequence or, for example, Knappik et al., J.Mol.Biol.296:57-86 derived from human sequences, such as the antibody-containing consensus framework sequences derived from human framework sequence analysis, as described in J.D., 2000.
[0038] Human antibodies of the present disclosure include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or somatic mutagenesis in vivo) or stability or manufacturing conservative substitutions).
[0039] As used herein, the term "recognize" refers to an antibody or antigen-binding fragment thereof that locates and interacts with (e.g., binds to) its epitope, whether the epitope is linear or It does not matter whether it is conformational. The term "epitope" refers to a site on an antigen to which an antibody or antigen-binding fragment of the present disclosure specifically binds. Epitopes can be formed from both contiguous amino acids or non-contiguous amino acids juxtaposed by tertiary folding of the protein. Epitopes formed from contiguous amino acids are typically retained immediately after exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost immediately after treatment with denaturing solvents. Epitopes typically include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more in a unique spatial conformation. Contains more than 100 amino acids. Methods for determining the spatial conformation of an epitope include techniques in the art, such as X-ray crystallography and two-dimensional nuclear magnetic resonance (e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. (See Morris, Ed. (1996)). A "paratope" is the portion of an antibody that recognizes an epitope on an antigen.
[0040] The phrase "specifically binds" or "selectively binds" when used in connection with describing the interaction of an antigen (e.g., a protein) with an antibody, antibody fragment, or antibody-derived binding agent , refers to a binding reaction that is critical to the presence of an antigen in a heterogeneous population of proteins and other biologicals, e.g. in a biological sample, e.g. blood, serum, plasma or tissue sample. Therefore, under a given specific immunoassay condition, an antibody or binding agent with a particular binding specificity will bind to a particular antigen at least twice background and substantially eliminate other antibodies present in the sample. Does not bind to antigen in large quantities. In one embodiment, under specified immunoassay conditions, an antibody or binding agent with a particular binding specificity binds a particular antigen at least 10 times background and substantially does not bind to large amounts of antigens. Specific binding to an antibody or binding agent under such conditions may require that the antibody or agent be selected for its specificity for a particular protein. If desired or appropriate, this selection can be accomplished by subtracting antibodies that cross-react with the molecule from other species (eg, mouse or rat) or other subtypes. Alternatively, in some embodiments, antibodies or antibody fragments are selected that cross-react with a particular desired molecule.
[0041] The term "affinity" as used herein refers to the strength of interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable regions of the antibody "arms" interact with the antigen at multiple sites through weak non-covalent forces; the more interactions, the stronger the affinity.
[0042] The term "isolated antibody" refers to an antibody that is substantially free of other antibodies with differing antigen specificities. However, isolated antibodies that specifically bind one antigen may have cross-reactivity to other antigens. Furthermore, an isolated antibody may be substantially free of other cellular substances and / or chemicals.
[0043] The term "corresponding human germline sequence" refers to a reference variable as determined in comparison to the amino acid sequences of all other known variable regions encoded by the human germline immunoglobulin variable region sequence. Refers to a nucleic acid sequence encoding an amino acid sequence or subsequence of a human variable region that shares the highest amino acid sequence identity with the amino acid sequence or subsequence of the region. The corresponding human germline sequence is the amino acid sequence of the human variable region that has the highest amino acid sequence identity with the reference variable region amino acid sequence or subsequence when compared to all other variable region amino acid sequences evaluated. It can also refer to arrays or subarrays. The corresponding human germline sequences may include framework regions only, complementarity determining regions only, framework and complementarity determining regions, variable segments (as defined above) or other sequences or subsequences containing variable regions. It can be a combination. Sequence identity may be determined using the methods described herein, such as aligning two sequences using BLAST, ALIGN or another alignment algorithm known in the art. . The corresponding human germline nucleic acid or amino acid sequence has at least about 90%, 91%, 92%, 93%, 94%, 95% sequence identity with the reference variable region nucleic acid or amino acid sequence, It can be 96%, 97%, 98%, 99% or 100%.
[0044] A variety of immunoassay formats can be used to select antibodies that are specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies that are specifically immunoreactive with a protein. For a description of the conditions, see, eg, Harlow & Lane, Using Antibodies, A Laboratory Manual (1998)). Typically, a specific or selective binding reaction will generate a signal at least twice the background signal, more typically at least 10-100 times the background signal.
[0045] The term “equilibrium dissociation constant (Kd[M])” refers to the association rate constant (ka[s -1 ,M -1 ]) divided by the dissociation rate constant (kd[s -1 ]). Equilibrium dissociation constants can be measured using any method known in the art. Antibodies of the present disclosure typically have an equilibrium dissociation constant of about 10. -7 or 10 -8 less than M, e.g. about 10 -9 M or 10 -10 less than M, in some embodiments about 10 -11 M, 10 -12 M or 10 -13 It will be less than M.
[0046] The term "bioavailability" refers to the systemic availability (ie, blood / plasma levels) of a given amount of a drug administered to a patient. Bioavailability is an absolute value that measures both the time (rate) and the total amount (extent) of drug reaching the systemic circulation from an administered dosage form.
[0047] As used herein, the phrase "consisting essentially of" refers to the genus or species of active agent included in the method or composition and any excipients that are inert with respect to the intended use of the method or composition. In some embodiments, the phrase "consisting essentially of" explicitly excludes the inclusion of one or more additional active agents other than the antibody drug conjugates of the present disclosure. In some embodiments, the phrase "consisting essentially of" explicitly excludes the inclusion of one or more additional active agents other than the antibody drug conjugate of the present disclosure and a co-administered second agent. .
[0048] The term "amino acid" refers to naturally occurring, synthetic and unnatural amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code as well as those that have been subsequently modified, such as hydroxyproline, γ-carboxyglutamate and O-phosphoserine. Amino acid analogs are compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e. hydrogen, a carboxyl group, an amino group and an α-carbon attached to an R group, such as homoserine, norleucine, methionine sulfoxide, methionine methyl. Refers to sulfonium. Such analogs have modified R groups (eg, norleucine) or modified peptide backbones, but retain the same basic chemical structure as the naturally occurring amino acids. Amino acid mimetics refer to compounds that have a structure that differs from the general chemical structure of amino acids, but that function similarly to naturally occurring amino acids.
[0049] The term "conservatively modified variants" is used for both amino acid and nucleic acid sequences. With respect to a particular nucleic acid sequence, conservatively modified variants refer to nucleic acids that encode the same or essentially the same amino acid sequence or, if the nucleic acids do not encode amino acid sequences, essentially the same sequence. Due to the degeneracy of the genetic code, many functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG and GCU all code for the amino acid alanine. Therefore, at every position where an alanine is specified by a codon, the codon can be changed to any of the corresponding codons described without changing the encoded polypeptide. Such nucleic acid mutations are "silent mutations," which are a type of conservatively modified mutation. Every nucleic acid sequence herein that encodes a polypeptide also describes every possible silent variation of the nucleic acid. Those skilled in the art will appreciate that each codon in a nucleic acid (other than AUG, which is usually the only codon for methionine, and TGG, which is usually the only codon for tryptophan) can be modified to produce a functionally the same molecule. You will recognize it. Thus, each silent variation of a polypeptide-encoding nucleic acid is latent within each described sequence.
[0050] For polypeptide sequences, "conservatively modified variants" include individual substitutions, deletions, or additions to the polypeptide sequence that replace amino acids with chemically similar amino acids. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are also in addition to, and do not exclude, polymorphic variants, interspecies homologs, and alleles. The following eight groups contain amino acids that are conservative substitutions for each other: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y) , tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M) (see, eg, Creighton, Proteins (1984)). In some embodiments, the term "conservative sequence modifications" is used to refer to amino acid modifications that do not significantly affect or significantly alter the binding properties of the antibody containing the amino acid sequence.
[0051] As used herein, the term "optimized" refers to a production cell or organism, usually a eukaryotic cell, such as a yeast cell, a Pichia cell, a fungal cell, a Trichoderma cell, a Chinese Refers to a nucleotide sequence that has been altered to encode an amino acid sequence using codons preferred in hamster ovary cells (CHO) or human cells. An optimized nucleotide sequence is engineered to retain completely, or as much as possible, the amino acid sequence originally encoded by the starting nucleotide sequence, also known as the "parent" sequence.
[0052] The term "percent same" or "percent identity" in the context of two or more nucleic acid or polypeptide sequences refers to the extent to which two or more sequences or subsequences are the same. Two sequences are "the same" if the sequence of amino acids or nucleotides is the same over the region being compared. When two sequences are compared and aligned for maximum match over a comparison window or designated region using one of the following sequence comparison algorithms or by manual alignment and visual inspection, the amino acid A specified percentage of residues or nucleotides are the same (i.e. 60% identity, optionally 65%, 70%, 75%, 80%, 85% across specified regions or the entire sequence if not specified) , 90%, 95% or 99% identity) are "substantially the same". Optionally, identity refers to regions that are at least about 30 nucleotides (or 10 amino acids) in length, more preferably 100-500 nucleotides or more than 1000 nucleotides (or 20, 50, 200 amino acids or more) in length. Exist over a certain area.
[0053] For sequence comparisons, typically one sequence serves as a reference sequence to which test sequences are compared. Using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters may be used or alternative parameters may be specified. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence to the reference sequence based on the program parameters.
[0054] As used herein, a "comparison window" is a window within which, after the two sequences have been optimally aligned, a sequence can be compared to a reference sequence at the same number of contiguous positions, from 20 to 600, usually from about 50 to about 200. , further including reference to any one segment with a number of contiguous locations typically selected from the group consisting of about 100 to about 150. Sequence alignment methods for comparison are well known in the art. Optimal sequence alignments for comparison are determined, for example, by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c (1970), by the local homology algorithm of Needleman and Wunsch, J. Mol. Biol. A computerized implementation of these algorithms (Wisconsin Genetics Software Package, Genetics GAP, BESTFIT, FASTA and TFASTA) or by manual alignment and visual inspection (see, eg, Brent et al., Current Protocols in Molecular Biology, 2003).
[0055] Two examples of algorithms suitable for determining percent sequence identity and sequence similarity are the BLAST algorithm and the BLAST 2.0 algorithm, which are described by Altschul et al., Nuc. Acids Res. 25:3389- 3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990. Software for performing BLAST analysis is publicly available from the National Center for Biotechnology Information. The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which correspond to words of the same length in the database sequence. If aligned with , it matches or satisfies some positive value threshold score T. T is called the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits serve as seeds to initiate searches to find longer HSPs containing them. Word hits are extended in both directions along each sequence as long as the cumulative alignment score can be increased. A cumulative score is calculated for a nucleotide sequence using the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for a mismatching residue; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of word hits in each direction stops if: the cumulative alignment score falls by an amount X from its maximum achieved value; If it goes below zero due to accumulation; or if the end of either array is reached. The parameters W, T and X of the BLAST algorithm determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program has a word length of 3 and an expected (E) of 10 as defaults, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, (1989) Proc. Natl. Acad. Sci. USA 89:10915) is Use 50 alignments (B), 10 predictions (E), M=5, N=-4 and comparison of both strands.
[0056] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, eg, Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. do. For example, a nucleic acid is considered similar to a reference sequence if the minimum sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
[0057] Percent identity between two amino acid sequences was determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci. 4:11-17 (1988), which was incorporated into the ALIGN program (version 2.0). ), a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, percent identity between two amino acid sequences can be determined using the Needleman and Wunsch, J. Mol. available on the World Wide Web), Blossom62 matrix or PAM250 matrix and gap weights of 16, 14, 12, 10, 8, 6 or 4 and 1, 2, 3, 4, It can be determined using a length weight of 5 or 6.
[0058] As another indication that two nucleic acid sequences or polypeptides are substantially the same, other than the percentage of sequence identity noted above, if the polypeptide encoded by the first nucleic acid is , immunologically, may be cross-reactive with raised antibodies against the polypeptide encoded by the second nucleic acid. As such, a polypeptide is typically substantially the same as a second polypeptide, eg, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially the same is that the two molecules, or their complements, hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially the same is that the same primers may be used to amplify the sequences.
[0059] The term "nucleic acid" is used herein interchangeably with the term "polynucleotide" and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, including synthetic, naturally occurring and non-naturally occurring nucleic acids, and reference nucleic acids. have similar binding properties and are metabolized in a similar manner to the reference nucleotide. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methyl phosphonates, chiral methyl phosphonates, 2-O-methyl ribonucleotides, peptide nucleic acids (PNAs).
[0060] Unless otherwise specified, a particular nucleic acid sequence also implicitly includes conservatively modified variants thereof (eg, degenerate codon substitutions) and complementary sequences as well as the sequences explicitly set forth. Specifically, as detailed below, degenerate codon substitutions are those in which the third position of one or more selected (or all) codons is a mixed base and / or deoxyinosine residue. This can be achieved by generating sequences that are substituted (Batzer et al., (1991) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) J. Biol. Chem. 260:2605-2608; and Rossolini et al., (1994) Mol. Cell. Probes 8:91-98).
[0061] In the context of nucleic acids, the term "operably linked" refers to a functional relationship between two or more polynucleotide (eg, DNA) segments. Typically refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter or enhancer sequence is operably linked to a coding sequence if it stimulates or regulates transcription of the coding sequence in an appropriate host cell or other expression system. Typically, a promoter transcriptional regulatory sequence operably linked to a transcribed sequence is physically contiguous to the transcribed sequence, ie, is cis-acting. However, some transcriptional regulatory sequences, such as enhancers, do not need to be physically adjacent to or located in close proximity to coding sequences that enhance transcription.
[0062] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. This term is applied to amino acid polymers and naturally occurring and non-naturally occurring amino acid polymers in which one or more amino acid residues are artificial chemical mimetics of the corresponding naturally occurring amino acid. Unless otherwise specified, a particular polypeptide sequence also implicitly includes conservatively modified variants thereof.
[0063] As used herein, the term "conjugate" or "antibody-drug conjugate" refers to the association of an antibody or antigen-binding fragment thereof with another agent, such as chemotherapeutic agents, toxicants, immunotherapeutic agents, and imaging probes. refers to Binding can be through covalent bonds or non-covalent interactions, such as through electrostatic forces. A variety of linkers known in the art can be used to form conjugates. Additionally, the conjugate can be provided in the form of a fusion protein that can be expressed from a polynucleotide encoding the conjugate. As used herein, "fusion protein" refers to a protein produced through the joining of two or more genes or gene fragments that originally encode separate proteins, including peptides and polypeptides. Translation of the fusion gene results in a single protein whose functional properties are derived from each original protein.
[0064] The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates such as mammals and non-mammals such as non-human primates, sheep, dogs, cows, chickens, amphibians and reptiles. Unless indicated, the terms "patient" or "subject" are used interchangeably herein.
[0065] As used herein, the terms "poison," "cytotoxin," or "cytotoxic agent" are harmful to the growth and proliferation of cells and capable of weakening, inhibiting, or destroying cells or malignant tumors. refers to any agent that can act on
[0066] As used herein, the term "anti-cancer agent" refers to any agent that can be used to treat cell proliferative disorders, such as cancer, including, but not limited to, cytotoxic agents, chemotherapeutic agents, radiotherapy and radiotherapy. Includes therapeutic agents, targeted anticancer agents, and immunotherapeutic agents.
[0067] The term "drug moiety" or "payload" as used herein refers to a chemical moiety that is conjugated to an antibody or antigen-binding fragment or is suitable for conjugation to an antibody or antigen-binding fragment; Any therapeutic or diagnostic agent and metabolite of the antibody drug conjugate disclosed herein that has desired therapeutic or diagnostic properties, such as anti-cancer, anti-inflammatory, anti-infective (e.g., anti-fungal, anti-bacterial) agents, anthelmintics, antivirals) or anesthetics. In certain embodiments, the drug moiety is an Eg5 inhibitor, a V-ATPase inhibitor, an HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auristatin, a dolastatin, a maytansinoid, a MetAP (methionine aminopeptidase), inhibitor of nuclear export of protein CRM1, DPPIV inhibitor, inhibitor of phosphoryl transfer reaction in mitochondria, protein synthesis inhibitor, kinase inhibitor, CDK2 inhibitor, CDK9 inhibitor, proteasome inhibitor, kinesin inhibitor, HDAC inhibitor, DNA damaging agent , DNA alkylating agents, DNA intercalating agents, DNA minor groove binders, RNA polymerase inhibitors, amanitin, spliceosome inhibitors, topoisomerase inhibitors, DHFR inhibitors and pro-apoptotic agents.
[0068] As used herein, the term "drug moiety" refers to BH3 mimetic inhibitors (also referred to as MCL-1 inhibitors, BCL-2 inhibitors and BCLXL inhibitors) that specifically inhibit MCL-1, BCL-2 or BCLXL. exclude. As used herein, the term "myeloid cell leukemia 1" or "Mcl-1" or "MCL1" refers to any naturally occurring form of human Mcl-1, including full-length human Mcl-1 (e.g., UniProt reference sequence: Q07820) and all splice variants, allelic variants and isoforms that retain one or more biological functions of human Mcl-1. Specific Mcl-1 inhibitors excluded herein include PCT application numbers PCT / EP 2014 / 078947, PCT / EP 2016 / 064417, PCT / / Europe Patent Application Publication No. 2016 / 064418, PCT / / European Patent Application No. 2016 / 064433, PCT / / European Patent Application No. 2016 / 064436 and PCT / / European Patent Application No. 2016 No. 2006 / 081688, each of which is incorporated herein by reference in its entirety.
[0069] The term "B-cell lymphoma 2" or "Bcl-2" or "BCL2" as used herein refers to any naturally occurring form of human Bcl-2, including full-length human Bcl-2 (e.g., UniProf reference sequence P10415- 1 or P10415-2) and all splice variants, allelic variants and isoforms that retain one or more biological functions of human Bcl-2. Specific Bcl-2 inhibitors excluded herein include PCT application numbers PCT / FR 2013 / 050136; French Patent Application No. 2014 / 051887, PCT / French Patent Application No. 2014 / 051884, PCT / French Patent Application No. 2014 / 051885, PCT / European Patent Application No. 2014 / 051885 2014 / 065764 and PCT / European Patent Application Publication No. 2018 / 079113, each of which is incorporated herein by reference in its entirety.
[0070] As used herein, the term "B-cell lymphoma-extra large" or "Bcl-xL" or "BCLXL" refers to any naturally occurring form of human Bcl-xL, including full-length human Bcl-xL (e.g., from the UniProt reference sequence :Q07817-1) and all splice variants, allelic variants and isoforms that retain one or more biological functions of human Bcl-xL. Specific Bcl-xL inhibitors excluded herein are those disclosed in PCT application numbers PCT / EP 2020 / 071179 and PCT / EP 2020 / 071181. , each of which is incorporated herein by reference in its entirety.
[0071] Methods for attaching each of these drug moieties to linkers that are compatible with the antibodies and methods of this disclosure are known in the art. See, eg, Singh et al., (2009) Therapeutic Antibodies: Methods and Protocols, vol. 525, 445-457. In addition, payloads include biophysical probes, fluorophores, spin labels, infrared probes, affinity probes, chelators, spectroscopic probes, radioactive probes, lipid molecules, polyethylene glycols, polymers, spin labels, DNA, RNA, proteins. , peptides, surfaces, antibodies, antibody fragments, nanoparticles, quantum dots, liposomes, PLGA particles, sugars or polysaccharides.
[0072] The term "cancer" refers to primary malignancies (e.g., cells that have not migrated to other parts of the subject's body than the site of the original tumor) and secondary malignancies (e.g., metastases (e.g., cells that have not migrated to other parts of the subject's body) than the site of the original tumor). (migration of tumor cells to a second, different site). The term "cancer" includes all types of cancer and cancer metastases, including hematologic cancers, solid tumor, sarcoma, carcinoma, and other solid and non-solid tumor cancers. Blood cancers can include B-cell malignancies, cancers of the blood (leukemia), cancers of plasma cells (myeloma, eg, multiple myeloma), or cancers of the lymph nodes (lymphoma). Exemplary B-cell malignancies include chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma. Leukemias include acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and acute monocytic leukemia (CMML). Examples include cell leukemia (AMoL). Examples of lymphoma include Hodgkin's lymphoma and non-Hodgkin's lymphoma. Other blood cancers can include myelodysplastic syndromes (MDS). Solid tumors include carcinomas such as adenocarcinomas, such as breast cancer, pancreatic cancer, prostate cancer, colon or colorectal cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer, glioma, Examples include melanoma. In some embodiments, the cancer is breast cancer, multiple myeloma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain tumor, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, Colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancy derived from T cells or B cells, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cancer Cellular lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or spleen cancer.
[0073] In some embodiments, the cancer is a hematological cancer, eg, leukemia, lymphoma, or myeloma. For example, the combinations described herein can be used to treat acute leukemias, such as B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), acute myeloid leukemia (AML), Leukemia (ALL); chronic leukemia, e.g. chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL); additional blood cancers or blood conditions, e.g. B-cell prolymphocytic leukemia, blastic plasmacytoid Dendritic cell tumor, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone Lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasma cell dendritic cell tumor, Waldenström macroglobulinemia, myelofibrosis, amyloid light chain amyloidosis, chronic neutrophilic leukemia, essential thrombocythemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, Richter's syndrome, mixed-phenotype acute leukemia, and "proleukemia" (which refers to myeloid blood cell It can be used to treat cancers, malignancies, and related disorders, including but not limited to cancer, malignancies, and can.
[0074] As used herein, the term "tumor" refers to any tissue mass resulting from excessive cell growth or proliferation, either benign or malignant, including precancerous lesions. In some embodiments, the tumor is breast cancer, gastric cancer, bladder cancer, brain cancer, cervical cancer, colorectal cancer, esophageal cancer, hepatocellular carcinoma, melanoma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, Small cell lung cancer or spleen cancer. In some embodiments, the tumor is gastric cancer.
[0075] The terms "tumor cell" and "cancer cell" may be used interchangeably herein and refer to individual cells or entire populations of cells derived from a tumor or cancer, including both non-tumorigenic cells and cancer stem cells. refers to The terms "tumor cells" and "cancer cells" are modified by the term "non-tumorigenic" when referring only to cells that lack the capacity for regeneration and differentiation, in order to distinguish these cells from cancer stem cells. be done.
[0076] The term "CD48" refers to Cluster of Differentiation 48 protein, which is also known as B lymphocyte activation marker (BLAST-1) or signal transducing lymphocyte activation molecule 2 (SLAMF2). In some embodiments, CD48 is a human CD48 isoform. In some embodiments, the human CD48 isoform is [ka] It is isoform 1 (NP_001769.2) with the amino acid sequence of
[0077] In some embodiments, the human CD48 isoform is [ka] It is isoform 2 (NP_001242959.1) with the amino acid sequence of
[0078] As used herein, the term "CD48" is used to collectively refer to all naturally occurring isoforms of the CD48 protein or variants thereof.
[0079] The term "variant" refers to a polypeptide that has substantially the same amino acid sequence, or is encoded by substantially the same nucleotide sequence, as a reference polypeptide and is capable of having one or more activities of the reference polypeptide. Point. For example, a variant may have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or less sequence identity to a reference polypeptide. of the reference polypeptide while retaining one or more activities of the reference polypeptide.
[0080] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder include, in one aspect, ameliorating the disease or disorder (i.e., disease progression or (delaying, suppressing, or alleviating at least one of the clinical symptoms of the disease). In another embodiment, "treat," "treating," or "treatment" refers to alleviating or ameliorating at least one physical parameter, including one that may not be discernible by the patient. In yet another embodiment, "treating," "treating," or "treatment" refers to physically (e.g., stabilization of discernible disease symptoms), physiological (e.g., stabilization of a physical parameter) or both, refers to modulating a disease or disorder. In yet another aspect, "treating," "treating," or "treatment" refers to slowing the onset or development or progression of a disease or disorder. In some embodiments, the treatment reduces the disease, disorder, or condition either physically (e.g., stabilizing discernible symptoms), physiologically (e.g., stabilizing physical parameters), or both. Including adjusting with. In some embodiments, the treatment comprises administering a described antibody, antigen-binding fragment thereof, ADC or composition thereof to a subject, e.g., a patient, to obtain the therapeutic benefits recited herein. . Treatment includes a disease, disorder or condition (e.g. cancer), treating, curing, alleviating, delaying, alleviating or altering the symptoms of a disease, disorder or condition (e.g. cancer); It may be for the purpose of alleviating, enhancing, lightening, ameliorating or influencing.
[0081] The terms "therapeutically acceptable amount" or "therapeutically effective dose" are used interchangeably to achieve the desired result (i.e., reduction in tumor size, inhibition of tumor growth, prevention of metastasis, viral, bacterial, fungal or An amount sufficient to inhibit or prevent parasitic infection. In some embodiments, a therapeutically acceptable amount does not induce or cause undesired side effects. A therapeutically acceptable amount can be determined by initially administering a low dose and increasing the dose in stages until the desired effect is achieved. A "therapeutically effective dosage" of a molecule of the present disclosure can prevent the onset of disease symptoms, including those associated with cancer, or can reduce the severity of disease symptoms.
[0082] The term "co-administration" refers to the simultaneous presence of two active agents in the blood of an individual. Co-administered active agents can be delivered simultaneously or sequentially.
[0083] The term "thiolmaleimide" as used herein refers to a group formed by the reaction of a thiol with a maleimide and has the formula: [ka] where Y and Z are groups to be linked via a thiolmaleimide bond and may include a linker moiety, antibody or payload. Thiolmaleimide has the following ring-opened structure [ka] can be formed.
[0084] As used herein, "cleavable" means that the linking group or linker moiety covalently joins two moieties but is capable of degrading under physiologically relevant conditions to break the covalent bond between the moieties. Typically, a cleavable linking group is cleaved more rapidly in vivo in an intracellular environment than in an extracellular environment, causing release of the payload to occur selectively inside the target cell. Cleavage can be enzymatic or non-enzymatic, but usually releases the payload from the antibody without degrading the antibody. Cleavage may leave a portion of the linking group or linker component attached to the payload, or may release the payload without any residue of the linking group.
[0085] As used herein, "non-cleavable" refers to a linking group or linker moiety that is not particularly susceptible to degradation under physiological conditions, e.g., the linking group or linker moiety is at least or as stable as the antigen-binding fragment portion. Such a linking group is sometimes referred to as "stable," meaning that the antibody or antigen-binding fragment itself is at least partially degraded, i.e., degradation of the antibody or antigen-binding fragment is not possible in vivo. means sufficiently resistant to degradation that the payload remains linked to the antibody or antigen-binding fragment prior to cleavage of the binding group of the antibody or antigen-binding fragment. Degradation of an antibody portion of an ADC with a stable or non-cleavable linking group attaches some or all of the linking group, e.g., one or more amino acid groups from the antibody, to the payload or drug moiety to be delivered in vivo. You can leave it alone.
[0086] CD48 antibody Disclosed herein are antibodies or antibody fragments (eg, antigen-binding fragments) that specifically bind human CD48. Antibodies or antibody fragments (eg, antigen-binding fragments) of the present disclosure include, but are not limited to, the human monoclonal antibodies or antigen-binding fragments thereof described herein.
[0087] Amino acid sequences of exemplary anti-CD48 antibodies of the present disclosure are set forth in Table 1, Table 2, and Table 3.
[0088] As described herein, antibodies are designated by their name, eg, NY920. If a modification is made to the antibodies, they are further indicated as having that modification. For example, if selected amino acids in antibodies are changed to cysteine (e.g. E152C, S375C, following EU numbering of the antibody heavy chain to facilitate conjugation to the linker-drug moiety), they are called "CysMab" or "DAPA" is appended to the antibody name if the antibody is modified with the Fc silencing mutations D265A and P329A of the IgG1 constant region according to EU numbering. When antibodies are used in antibody drug conjugates, they are named using the following format: antibody name-linker-payload.
[0089]
table 1
[0090] [Table 2]
[0091] [Table 3]
[0092] [Table 4]
[0093] [Table 5]
[0094] [Table 6]
[0095] [Table 7]
[0096] [Table 8]
[0097] [Table 9]
[0098] [Table 10]
[0099] [Table 11]
[0100] [Table 12]
[0101] [Table 13]
[0102] [Table 14]
[0103] [Table 15]
[0104] [Table 16]
[0105] [Table 17]
[0106] [Table 18]
[0107] [Table 19]
[0108] In some embodiments, the antibodies or antigen-binding fragments thereof disclosed herein are any set of heavy chain variable domains and light chain variable domains listed in the table above or A set of six CDRs from any set of heavy chain variable domains and light chain variable domains may be included. In some embodiments, the antibodies or antigen-binding fragments thereof disclosed herein are such that the antibody retains binding to its target cancer antigen (e.g., 1x10 -8 one or more functional properties of the antibodies disclosed herein (e.g., the ability to internalize and bind to an antigenic target, such as an antigen expressed on a tumor or other cancer cell) ) may contain amino acid sequences that are conservatively modified and / or homologous to the sequences listed in the table above.
[0109] In some embodiments, the antibodies or antigen-binding fragments thereof disclosed herein further comprise human heavy and light chain constant domains or fragments thereof. For example, an antibody or antigen binding fragment of an antibody drug conjugate (ADC) as described herein can include a human IgG heavy chain constant domain (such as IgG1) and a human kappa or lambda light chain constant domain. In some embodiments, an antibody or antigen-binding fragment of an ADC as described herein comprises a human immunoglobulin G subtype 1 (IgG1) heavy chain constant domain along with a human Ig kappa light chain constant domain.
[0110] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO:1. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO:2; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:3; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:16; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 17, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 18.
[0111] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO:4. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO:2; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:3; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:16; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 17, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 18.
[0112] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1 ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO:6; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:3; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:19; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 20, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 21.
[0113] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO:7. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO:8; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:9; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO:22; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 20, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 18.
[0114] In some embodiments, the anti-CD48 anti or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: a heavy chain CDR1 (HCDR1 ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 28; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 29; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 42; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 43, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 44.
[0115] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO: 30. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 28; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 29; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 42; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 43, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 44.
[0116] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO: 31. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 32; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 29; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 45; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 46, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 47.
[0117] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises the following three heavy chain CDRs and three light chain CDRs: heavy chain CDR1 (HCDR1) consisting of the amino acid sequence set forth in SEQ ID NO: 33. ), heavy chain CDR2 (HCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 34; heavy chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 35; light chain CDR3 (HCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 48; chain CDR1 (LCDR1), light chain CDR2 (LCDR2) consisting of the amino acid sequence set forth in SEQ ID NO: 46, and light chain CDR3 (LCDR3) consisting of the amino acid sequence set forth in SEQ ID NO: 44.
[0118] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23. In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof is at least 95 times greater than the heavy chain variable region amino acid sequence of SEQ ID NO: 10 and the light chain variable region amino acid sequence of SEQ ID NO: 23 or disclosed sequences. %Contains sequences that are identical. In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof has a heavy chain variable region amino acid sequence and / or a heavy chain variable region that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:10. or has a light chain variable region amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO:23.
[0119] In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49. In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof is at least 95 times greater than the heavy chain variable region amino acid sequence of SEQ ID NO: 36 and the light chain variable region amino acid sequence of SEQ ID NO: 49 or disclosed sequences. %Contains sequences that are identical. In some embodiments, the anti-CD48 antibody or antigen-binding fragment thereof has a heavy chain variable region amino acid sequence and / or a heavy chain variable region that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 36. or has a light chain variable region amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 49.
[0120] In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence of SEQ ID NO: 12, or a sequence that is at least 95% identical to SEQ ID NO: 12, and a light chain amino acid sequence of SEQ ID NO: 25, or a sequence that is at least 95% identical to SEQ ID NO: 25. and sequences that are at least 95% identical. In some embodiments, the anti-CD48 antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 12 and a light chain amino acid sequence of SEQ ID NO: 25 or sequences that are at least 95% identical to the disclosed sequences. In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 12 and at least 96% identical to SEQ ID NO: 25. %, at least 97%, at least 98% or at least 99% identical to the light chain amino acid sequence.
[0121] In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence of SEQ ID NO: 14, or a sequence that is at least 95% identical to SEQ ID NO: 14, and a light chain amino acid sequence of SEQ ID NO: 25, or a sequence that is at least 95% identical to SEQ ID NO: 14. and sequences that are at least 95% identical. In some embodiments, the anti-CD48 antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 14 and a light chain amino acid sequence of SEQ ID NO: 25 or sequences that are at least 95% identical to the disclosed sequences. In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 14 and at least 96% identical to SEQ ID NO: 25. %, at least 97%, at least 98% or at least 99% identical to the light chain amino acid sequence.
[0122] In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence of SEQ ID NO: 38, or a sequence that is at least 95% identical to SEQ ID NO: 38, and a light chain amino acid sequence of SEQ ID NO: 51, or a sequence that is at least 95% identical to SEQ ID NO: 51. and sequences that are at least 95% identical. In some embodiments, the anti-CD48 antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 38 and a light chain amino acid sequence of SEQ ID NO: 51 or sequences that are at least 95% identical to the disclosed sequences. In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 38 and at least 96% identical to SEQ ID NO: 51. %, at least 97%, at least 98% or at least 99% identical to the light chain amino acid sequence.
[0123] In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence of SEQ ID NO: 40, or a sequence that is at least 95% identical to SEQ ID NO: 40, and a light chain amino acid sequence of SEQ ID NO: 51, or a sequence that is at least 95% identical to SEQ ID NO: 51. and sequences that are at least 95% identical. In some embodiments, the anti-CD48 antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 40 and a light chain amino acid sequence of SEQ ID NO: 51 or sequences that are at least 95% identical to the disclosed sequences. In some embodiments, the anti-CD48 antibody has a heavy chain amino acid sequence that is at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 40 and at least 96% identical to SEQ ID NO: 51. %, at least 97%, at least 98% or at least 99% identical to the light chain amino acid sequence.
[0124] Residues in two or more polypeptides are said to be "corresponding" if they occupy similar positions in the polypeptide structure. Similar positions in two or more polypeptides can be determined by aligning the polypeptide sequences based on amino acid sequence or structural similarity. Those skilled in the art will appreciate that it may be necessary to introduce gaps in either sequence to produce a satisfactory alignment.
[0125] In some embodiments, amino acid substitutions are of single residues. Insertions are typically as small as about 1 to about 20 amino acid residues, although much larger insertions are tolerated as long as biological function (eg, binding to the target antigen) is retained. Deletions typically range from about 1 to about 20 amino acid residues, but optionally, deletions may be larger. Substitutions, deletions, insertions or any combination thereof may be used to arrive at the final derivative or variant. Generally, these changes are made at a few amino acids to minimize molecular changes, particularly immunogenicity and specificity of the antigen binding protein. However, larger changes may be permissible in certain circumstances. Conservative substitutions can be made according to the chart below, displayed in Table 4.
[0126] [Table 20]
[0127] Antibodies or antigen-binding fragments thereof disclosed herein include within their scope any antibody or antigen-binding fragment that specifically binds to a target antigen (eg, human CD48) on cancer cells. The antibody or antigen-binding fragment is capable of binding to a target antigen (e.g., human CD48). In some embodiments, the KD is between 1 pM and 500 pM. In some embodiments, the KD is between 500 pM and 1 μM, between 1 μM and 100 nM, or between 100 mM and 10 nM. In some embodiments, the KD is between 500 nM and 10 pM.
[0128] In some embodiments, the antibody or antigen-binding fragment is a four-chain antibody (also referred to as an immunoglobulin or full-length or intact antibody), comprising two heavy chains and two light chains. In some embodiments, the antibody or antigen-binding fragment is an antigen-binding fragment of an immunoglobulin. In some embodiments, the antibody or antigen-binding fragment is an antigen-binding fragment of an immunoglobulin that retains the ability to bind the target cancer antigen (e.g., CD48) and / or provides at least one function of an immunoglobulin. be.
[0129] In one embodiment, the antibody molecule is a complete antibody or a fragment thereof (e.g., Fab, Fab', F(ab') 2 , dAb, Fd, Fv, disulfide-linked Fv (sdFv) or single chain Fv (scFv) fragment). In other embodiments, the antibody molecule is a half-antibody, one-arm antibody, single-domain antibody, maxibody, minibody, nanobody, intrabody, or bispecific antibody. In yet other embodiments, the antibody molecule is selected from the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE, in particular the heavy chain constant regions of IgG1, IgG2, IgG3 and IgG4. The Fc has a heavy chain constant region (Fc) selected from the constant region, more specifically selected from the heavy chain constant region of IgG1 or IgG4 (eg, human IgG1 or IgG4). In one embodiment, the heavy chain constant region is human IgG1 or human IgG4. In one embodiment, the constant region is used to modify a property of the antibody molecule (e.g., increase or increase one or more of Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function, or (to reduce), e.g. mutated.
[0130] In certain embodiments, the antibody molecule is in the form of a bispecific or multispecific antibody molecule. In one embodiment, the bispecific antibody molecule has a first binding specificity for human CD48 and a second binding specificity for CD3. In one embodiment, the anti-CD48 antibody is a bispecific T cell engager (BiTE) antibody.
[0131] In one embodiment, the antibody or antigen binding fragment thereof (eg, scFv fragment) is in the form of a chimeric antigen receptor T cell (CAR-T or CART).
[0132] The antibodies, antibody fragments (eg, antigen-binding fragments), or functional equivalents of the present disclosure can also be conjugated to radioisotopes to produce cytotoxic radiopharmaceuticals, also referred to as radioimmunoconjugates. Examples of radioisotopes that can be conjugated to antibodies for diagnostic or therapeutic use include, but are not limited to, iodine-131, indium-111, yttrium-90, and lutetium-177. Methods for preparing radioimmunoconjugates are well established in the art. Exemplary radioimmunoconjugates are commercially available, including Zevalin(TM) (DEC Pharmaceuticals) and Bexxar(TM) (Corixa Pharmaceuticals), and similar methods are available using the antibodies disclosed herein. , can be used to prepare radioimmunoconjugates. In certain embodiments, the macrocyclic chelating agent is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), which It can be attached to an antibody via a molecule. Such linker molecules are generally known in the art and are described in Denardo et al., (1998) Clin Cancer Res. 4(10):2483-90; Peterson et al., (1999) Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., (1999) Nucl.Med.Biol.26(8):943-50, each of which is incorporated by reference in its entirety. .
[0133] The antibodies, antibody fragments (e.g., antigen-binding fragments), or functional equivalents of the present disclosure may contain heterologous proteins or polypeptides (or fragments thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, (polypeptides of at least 70, at least 80, at least 90 or at least 100 amino acids) to produce fusion proteins. In particular, the disclosure describes antibody fragments (e.g., antigen-binding fragments) described herein (e.g., Fab fragments, Fd fragments, Fv fragments, Fab' fragments, F(ab') 2 fusion proteins comprising a fragment, VH domain, VH CDR, VL domain or VL CDR) and a heterologous protein, polypeptide or peptide.
[0134] Additional fusion proteins can be generated through the techniques of gene shuffling, motif shuffling, exon shuffling and / or codon shuffling (collectively referred to as "DNA shuffling"). DNA shuffling can be utilized to alter the activity of antibodies or fragments thereof of the present disclosure (eg, antibodies or fragments thereof with higher affinity and lower dissociation rate). Generally, U.S. Patent No. 5,605,793, U.S. Pat. No. 5,811,238, U.S. Pat. .8:724-33;Harayama,(1998)Trends Biotechnol.16(2):76-82;Hansson et al.,(1999)J.Mol.Biol.287:265-76;and Lorenzo and Blasco,( 1998) Biotechniques 24(2):308-313, each of which patents and publications are incorporated herein by reference in their entirety. An antibody or fragment thereof, or an encoded antibody or fragment thereof, may be modified by subjecting it to random mutagenesis by error-prone PCR, random nucleotide insertion, or other methods prior to recombination. A polynucleotide encoding an antibody or fragment thereof that specifically binds an antigen can be recombined with one or more components, motifs, sections, portions, domains, fragments, etc. of one or more heterologous molecules.
[0135] Additionally, the antibodies, antibody fragments (eg, antigen-binding fragments) or functional equivalents of the present disclosure can be conjugated to marker sequences, such as peptides, to facilitate purification. In a preferred embodiment, the marker amino acid sequence is a hexa-histidine peptide (SEQ ID NO: 84), such as the tag provided in the pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others. Many of them are commercially available. For example, hexa-histidine (SEQ ID NO: 84) provides convenient purification of fusion proteins, as described in Gentz et al., (1989) Proc. Natl. Acad. Sci. USA 86:821-824. do. Other peptide tags useful for purification include the hemagglutinin (“HA”) tag (which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., (1984) Cell 37:767)) and the “FLAG ” tag (A. Einhauer et al., J. Biochem. Biophys. Methods 49:455-465, 2001), but is not limited to these. According to the present disclosure, antibodies or antigen-binding fragments can also be conjugated to tumor-penetrating peptides to improve their efficacy.
[0136] In other embodiments, the antibodies, antibody fragments (eg, antigen-binding fragments) or functional equivalents of the present disclosure are conjugated to a diagnostic or detectable agent. Such immune complexes are useful for monitoring or predicting the onset, development, progression and / or severity of a disease or disorder as part of a clinical trial procedure, such as determining the effectiveness of a particular therapy. It can be. Such diagnosis and detection may be performed using various enzymes (such as, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase or acetylcholinesterase); prosthetic groups (such as, but not limited to, streptavidin / biotin and avidin / biotin). Fluorescent substances (including but not limited to Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 750, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin); luminescent substances (such as, but not limited to, luminol); bioluminescent substances (such as, but not limited to, luciferase, luciferin, and aequorin); radioactive substances (such as, but not limited to, iodine ( 131 I, 125 I, 123 I and 121 I), carbon ( 14 C), sulfur (35 S), tritium ( 3 H), indium ( 115 In, 113 In, 112 In and 111 In), technetium ( 99 Tc), thallium ( 201 Ti), gallium ( 68 Ga, 67 Ga), palladium ( 103 Pd), molybdenum ( 99 Mo), xenon ( 133 Xe), fluorine ( 18 F), 153 Sm, 177 Lu, 159 Gd, 149 Pm, 140 La, 175 Yb, 166 Ho, 90 Y, 47 Sc, 186 Re, 188 Re, 142 Pr, 105 Rh, 97 Ru, 68 Ge, 57 Co, 65 Zn, 85 Sr. 32 P, 153 Gd, 169 Yb, 51 Cr, 54 Mn, 75 Se, 64 Cu, 113 Sn and 117 Sn, etc.); and positron-emitting metals and non-radioactive paramagnetic metal ions using positron emission tomography.
[0137] The antibodies, antibody fragments (eg, antigen-binding fragments) or functional equivalents of the present disclosure can also be attached to solid supports, which is particularly useful for immunoassays or purification of target antigens. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
[0138] In some embodiments, the antibody or antigen-binding fragment is an internalizing antibody or an internalizing antigen-binding fragment thereof. In some embodiments, the internalizing antibody or internalizing antigen-binding fragment thereof binds to a target cancer antigen (eg, CD48) expressed on the surface of the cell and upon binding enters the cell. In some embodiments, the drug moiety of the ADC enters the cell in which the ADC expresses the target cancer antigen, e.g., by cleavage, degradation, or any other suitable release mechanism of the antibody or antigen-binding fragment. (ie, after the ADC has been internalized) from the antibody or antigen-binding fragment of the ADC. In some embodiments where variant antibody sequences are used in ADCs, the variants typically exhibit the same qualitative biological activity and elicit the same immune response; may also be selected to modify the properties of the antigen binding protein. Alternatively, variants can be designed such that the biological activity of the antigen binding protein is altered. For example, glycosylation sites can be altered or removed.
[0139] The antibodies, antibody fragments (e.g., antigen-binding fragments) or functional equivalents of the present disclosure may be modified, e.g., further comprising modifications to framework residues within the VH and / or VL, to improve the properties of the antibody. or an antigen-binding fragment thereof. In some embodiments, framework modifications are made to reduce the immunogenicity of the antibody. For example, one approach is to "backmutate" one or more framework residues to the corresponding germline. More specifically, an antibody that has undergone somatic mutation can contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequences to the germline sequence from which the antibody is derived. To return framework region sequences to germline configuration, somatic mutations can be "backmutated" into germline sequences, for example, by site-directed mutagenesis. Such "backmutated" antibodies are also intended to be encompassed herein.
[0140] Another type of framework modification is to mutate one or more residues within the framework region or within one or more CDR regions to eliminate the potential immunogenicity of the antibody. It includes lowering the. This approach, also referred to as "deimmunization," is described in further detail in US Patent Application Publication No. 20030153043 by Carr et al.
[0141] In addition to or in lieu of modifications made within the framework or CDR regions, antibodies of the present disclosure typically have one or more functional properties of the antibody, such as serum half-life, complement fixation, Can be engineered to alter Fc receptor binding and / or antigen-dependent cytotoxic activity (ADCC). Additionally, the antibodies of the present disclosure can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody), again to alter one or more functional properties of the antibody, and its Can be modified to alter glycosylation. Each of these embodiments is described in further detail below.
[0142] In one embodiment, the hinge region of CH1 is modified such that the number of cysteine residues in the hinge region is altered, eg, increased or decreased. This approach is further described in US Pat. No. 5,677,425 by Bodmer et al. The number of cysteine residues in the hinge region of CH1 is altered, for example, to promote light and heavy chain assembly and increase or decrease antibody stability.
[0143] In some embodiments, the antibodies or antibody fragments disclosed herein have modified or engineered amino acid residues, e.g., one or more cysteine residues, as sites for attachment to a drug moiety. (Junutula JR, et al., Nat Biotechnol 2008, 26:925-932). In one embodiment, the present disclosure provides modified antibodies or antibody fragments that include substitution of one or more amino acids with cysteine at a position described herein. Since the site for cysteine substitution is in the constant region of the antibody or antibody fragment, it is applicable to a variety of antibodies or antibody fragments, and the site is selected to provide a stable and homogeneous conjugate. Ru. The modified antibody or fragment can have one, two or more cysteine substitutions, and these substitutions can be used in combination with other modification and conjugation methods as described herein. It can be done. Methods for inserting cysteines at specific positions in antibodies are known in the art, e.g. Lyons et al., (1990) Protein Eng., 3:703-708, WO 2011 / 005481. Please refer to the pamphlet, International Publication No. 2014 / 124316 pamphlet, and International Publication No. 2015 / 138615 pamphlet. In certain embodiments, the modified antibody is modified at positions 117, 119, 121, 124, 139, 152, 153, 155, 157, 164, 169, 171, 174, 189, 191, 195, 197, 205, 207, 246, 258, 269, 274, 286, 288, 290, 292, 293, 320, 322, 326, 333, 334, 335, 337, 344, 355, 360, 375, 382, 390, 392, 398, 400 and 422, the positions of which are numbered according to the EU system. In some embodiments, the modified antibody or antibody fragment is at position 107, 108, 109, 114, 129, 142, 143, 145, 152, 154, 156, 159, 161 of the light chain of the antibody or antibody fragment. , 165, 168, 169, 170, 182, 183, 197, 199 and 203, the positions of which are numbered according to the EU system. The light chain is human kappa light chain. In certain embodiments, the modified antibody or antibody fragment thereof comprises a combination of two or more amino acid substitutions with cysteine on its constant region, the combination being at position 375 of the antibody heavy chain, at position 375 of the antibody heavy chain. including substitutions at position 152, position 360 of the antibody heavy chain or position 107 of the antibody light chain, the positions being numbered according to the EU system. In certain embodiments, the modified antibody or antibody fragment thereof comprises a single amino acid substitution with cysteine on its constant region, the substitution being at position 375 of the antibody heavy chain, position 152 of the antibody heavy chain, heavy chain position 360, antibody light chain position 107, antibody light chain position 165 or antibody light chain position 159, the positions are numbered according to the EU system, and the light chain is kappa light chain. be. In certain embodiments, the modified antibody or antibody fragment thereof comprises a combination of two amino acid substitutions with cysteine on its constant region, the combination being at position 375 of the antibody heavy chain and at position 375 of the antibody heavy chain. Containing substitutions at 152, the positions are numbered according to the EU system. In certain embodiments, the modified antibody or antibody fragment thereof comprises a single amino acid substitution with cysteine at position 360 of the antibody heavy chain, where the position is numbered according to the EU system. In other specific embodiments, the modified antibody or antibody fragment thereof comprises a single amino acid substitution by cysteine at position 107 of the antibody light chain, the position being numbered according to the EU system; The light chain is a kappa chain.
[0144] In additional embodiments, antibodies or antibody fragments (e.g., antigen-binding fragments) useful in the immunoconjugates of the present disclosure include Pcl, pyrrolidine, peptide tags (S6, A1, and ybbR tag) as well as one or more other reactive amino acids (other than cysteine), including non-natural amino acids, thereby binding the drug moiety or linker-drug moiety to a complementary reactive antibody. or antibodies that have been modified or engineered to provide reactive sites on the antigen-binding fragment, such as antibodies that have been modified. For example, the antibody or antibody fragment may be Pcl or pyrrolidine (W. Ou, et al., (2011) PNAS 108 (26), 10437-10442; WO 2014124258) or an unnatural amino acid (J.Y. Axup, et al. .,Proc Natl Acad Sci U S A,109 (2012),pp.16101-16106;Reviews include C.C.Liu and P.G.Schultz (2010)Annu Rev Biochem 79,413-444;C.H.Kim,et al.,(2013) Curr Opin Chem Biol. 17, 412-419) as a site for attachment to the drug. Similarly, peptide tags for enzymatic conjugation can be introduced into antibodies (Strop P., et al., Chem Biol. 2013, 20(2):161-7; Rabuka D., Curr Opin Chem Biol. 2010 Dec;14(6):790-6;Rabuka D, et al., Nat Protoc.2012,7(6):1052-67). Other examples are the use of 4'-phosphopantetheine transferase (PPTase) for the conjugation of coenzyme A analogs (WO 2013184514) and (Gruenewald et al., (2015) Bioconjugate Chem. 26 (12), 2554-62). Methods for attaching such modified or engineered antibodies to payloads or linker-payload combinations are known in the art.
[0145] In another embodiment, the Fc hinge region of the antibody is mutated to reduce the biological half-life of the antibody. More specifically, one or more amino acid mutations cause the CH2-CH3 domain of the Fc-hinge fragment to have defective staphylococcal protein A (SpA) binding compared to the native Fc-hinge domain SpA binding. Introduced into the interface area. This approach is described in further detail in Ward et al., US Pat. No. 6,165,745.
[0146] In yet other embodiments, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector function of the antibody. For example, one or more amino acids can be replaced with a different amino acid residue such that the antibody has altered affinity for the effector ligand, but retains the antigen binding ability of the parent antibody. Effector ligands whose affinity is altered are, for example, Fc receptors or complement C1 components. This approach is described, for example, in US Pat. No. 5,624,821 and US Pat. No. 5,648,260, both by Winter et al.
[0147] In another embodiment, the one or more amino acids selected from the amino acid residues are different such that the antibody has altered C1q binding and / or reduced or abolished complement dependent cytotoxicity (CDC). Can be replaced with amino acid residues. This approach is described, for example, in US Pat. No. 6,194,551 by Idusogie et al.
[0148] In another embodiment, one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described, for example, in PCT Publication No. WO 94 / 29351 by Bodmer et al. Allotypic amino acid residues include the heavy chain constant regions of the IgG1, IgG2, and IgG3 subclasses and the light chain constant regions of the kappa isotype as described in Jefferis et al., MAbs. 1:332-338 (2009). These include, but are not limited to:
[0149] In some embodiments, the antibody comprises a mutation that mediates reduced antigen-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) or the absence thereof. In some embodiments, these mutations are known as Fc silencing, Fc silent or Fc silence mutations. In some embodiments, amino acid residues L234 and L235 of the IgG1 constant region are replaced with A234 and A235 (also known as "LALA"). In some embodiments, amino acid residue N297 of the IgG1 constant region is replaced with A297 (also known as "N297A"). In some embodiments, amino acid residues D265 and P329 of the IgG1 constant region are replaced with A265 and A329 (also known as "DAPA"). Other antibody Fc silencing mutations can be used. In some embodiments, Fc silencing mutations are used in combination, for example, D265A, N297A, and P329A (also known as "DANAPA").
[0150] In another embodiment, one or more amino acid residues are altered to thereby alter the ability of the antibody to fix complement. This approach is described, for example, in PCT Publication No. WO 94 / 29351 by Bodmer et al. In specific embodiments, one or more amino acids of the disclosed antibodies or antigen-binding fragments thereof are replaced by one or more allotypic amino acid residues. Allotypic amino acid residues also include the constant regions of the heavy chains of the IgG1, IgG2 and IgG3 subclasses and the constant regions of the light chains of the kappa isotype as described by Jefferis et al., MAbs. 1:332-338 (2009). These include, but are not limited to:
[0151] In yet another embodiment, the glycosylation of the antibody is modified. For example, an antibody can be made that is glycosylated (ie, the antibody lacks glycosylation). Glycosylation can be altered, for example, to increase the affinity of an antibody for its "antigen." Such carbohydrate modifications can be accomplished, for example, by altering one or more sites of glycosylation within the antibody sequence. For example, one or more amino acid substitutions can be made that result in the elimination of one or more variable region framework glycosylation sites, thereby eliminating glycosylation at that site. Such glycosylation can increase the affinity of the antibody for the antigen. Such approaches are described, for example, in US Pat. No. 5,714,350 and US Pat. No. 6,350,861 to Co et al.
[0152] In another embodiment, the antibody is modified to increase its biological half-life. Various approaches are possible. For example, one or more of the following mutations can be introduced: T252L, T254S, T256F as described in Ward US Pat. No. 6,277,375. Alternatively, to increase biological half-life, antibodies may be combined with IgG in the CH1 or CL region, as described in Presta et al., US Pat. Nos. 5,869,046 and 6,121,022. It can be modified to contain salvage receptor binding epitopes taken from the two loops of the CH2 domain of the Fc region.
[0153] Antibodies that bind to the same epitope The present disclosure provides antibodies or antibody fragments (eg, antigen-binding fragments) that specifically bind to epitopes within the human CD48 extracellular domain. In certain embodiments, the antibody or antibody fragment is capable of binding an epitope within amino acids 29-130 of human CD48. In some embodiments, the epitope is within amino acids 54-64 or amino acids 105-121 of human CD48 (SEQ ID NO: 53). In some embodiments, the epitope is amino acids 54, 58, 60, 61, 62, 64, 105, 107, 119, 111, 114, 115, 117, 119 and 121 of the amino acid sequence set forth in SEQ ID NO: 53. Contains one or more of.
[0154] The present disclosure also provides anti-CD48 antibodies or antibody fragments (e.g., antigen-binding fragments) described in Tables 1, 2, and 3, and antibodies or antibody fragments (e.g., antigen-binding fragments) that bind to the same epitope. . Thus, the additional antibody or antibody fragment (e.g., an antigen-binding fragment) cross-competes (e.g., competitively inhibits the binding of, in a statistically significant manner) another antibody or antibody fragment in a CD48 binding assay. ) can be identified based on ability. A high-throughput process for "binning" antibodies based on cross-competition is described in WO 2003 / 48731. The ability of a test antibody or antibody fragment to inhibit the binding of an antibody or antibody fragment disclosed herein to a CD48 protein (e.g., human CD48) refers to the ability of a test antibody or antibody fragment to inhibit binding of an antibody or antibody fragment disclosed herein to CD48 protein (e.g., human CD48). be able to compete with an antibody fragment; such antibody or antibody fragment is, according to non-limiting theory, the same, overlapping, or related (e.g., structurally similar or spatially similar) to the competing antibody or antibody fragment; (in close proximity) to an epitope on the CD48 protein. In certain embodiments, the antibodies or antibody fragments disclosed herein are human antibodies or human antibody fragments or humanized antibodies or humanized antibody fragments. Such human antibodies or human antibody fragments or humanized antibodies or humanized antibody fragments can be prepared and isolated as described herein.
[0155] Generation of CD48 antibodies or antibody fragments Anti-CD48 antibodies or antibody fragments (e.g., antigen-binding fragments) can be produced by any means known in the art, including, but not limited to, recombinant expression, chemical synthesis, or full-length monoclonal antibodies (e.g., (obtainable by hybridoma production or recombinant production). Recombinant expression may be derived from any suitable host cell known in the art, such as mammalian host cells, bacterial host cells, yeast host cells, insect host cells, or from cell-free systems (e.g. Sutro's Xpress CF™ Platform, World Wide Web at sutrobio.com / technology / ).
[0156] The present disclosure further describes the antibodies or antibody fragments described herein (e.g., antigen-binding fragments), e.g., heavy or light chain variable regions comprising complementarity determining regions as described herein; Polynucleotides encoding variable segments are provided. In some embodiments, the polynucleotide encoding a heavy chain variable region (VH) is at least 85%, 89%, 90%, 91%, 92% selected from the group consisting of SEQ ID NO: 11 and 37. %, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity. In some embodiments, the polynucleotide encoding a light chain variable region (VL) is at least 85%, 89%, 90%, 91%, 92% selected from the group consisting of SEQ ID NO: 24 and 50. %, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity.
[0157] In some embodiments, the polynucleotide encoding the antibody heavy chain has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95% of the polynucleotide of SEQ ID NO: 13 or 15. , 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity. In some embodiments, the polynucleotide encoding the antibody light chain has at least 85%, 89%, 90%, 91%, 92%, 93%, 94%, 95% of the polynucleotide of SEQ ID NO: 26 or 52. , 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity.
[0158] Polynucleotides of the present disclosure may encode only variable region sequences of anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments). They may also encode both the variable and constant regions of antibodies or antibody fragments (eg, antigen-binding fragments). A portion of the polynucleotide sequence encodes a polypeptide that includes both the heavy and light chain variable regions of one of the exemplified anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments).
[0159] Polynucleotide sequences can be generated by de novo solid phase DNA synthesis or PCR mutagenesis of existing sequences encoding anti-CD48 antibodies or binding fragments thereof (eg, sequences described in the Examples below). Direct chemical synthesis of nucleic acids can be accomplished by methods known in the art, such as the phosphotriester method of Narang et al., Meth. Enzymol. 68:90, 1979; Brown et al., Meth. The phosphodiester method of Enzymol. 68:109, 1979; the diethyl phosphoramidite method of Beaucage et al., Tetra. Lett., 22:1859, 1981; and the solid support method of US Pat. No. 4,458,066. Introduction of mutations into polynucleotide sequences by PCR can be performed, for example, in PCR Technology: Principles and Applications for DNA Amplification, H.A. Erlich (Ed.), Freeman Press, NY, NY, 1992; PCR Protocols: A Guide to Methods and Applications. , Innis et al. (Ed.), Academic Press, San Diego, CA, 1990; Mattila et al., Nucleic Acids Res. 19:967, 1991; and Eckert et al., PCR Methods and Applications 1:17, 1991 It may be performed as described in .
[0160] Also provided in this disclosure are expression vectors and host cells for producing any of the anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments) described herein. A variety of expression vectors can be used to express polynucleotides encoding anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments). Both viral-based and non-viral expression vectors can be used to produce antibodies in mammalian host cells. Non-viral vectors and systems include plasmids, episomal vectors (typically carrying an expression cassette for expressing proteins or RNA) and human artificial chromosomes (e.g., Harrington et al., Nat Genet. 15:345, 1997). For example, non-viral vectors useful for the expression of anti-CD48 polynucleotides and polypeptides in mammalian (e.g., human) cells include pThioHis A,B&C, pcDNA3.1 / His, pEBVHis A,B&C (Invitrogen, San Diego, CA); MPSV vectors and numerous other vectors known in the art for expressing other proteins are included. Useful viral vectors include retroviruses, adenoviruses, adeno-associated viruses, herpesvirus-based vectors, SV40, papillomaviruses, HBP Epstein-Barr virus-based vectors, vaccinia virus vectors, and Semliki Forest virus (SFV). See, supra; Smith, Annu. Rev. Microbiol. 49:807, 1995; and Rosenfeld et al., Cell 68:143, 1992.
[0161] The choice of expression vector depends on the intended host cell in which the vector will be expressed. Typically, the expression vector contains a promoter and other regulatory sequences (eg, an enhancer) operably linked to a polynucleotide encoding an anti-CD48 antibody or antibody fragment (eg, antigen-binding fragment). In some embodiments, inducible promoters are used to prevent expression of inserted sequences except under inducing conditions. Inducible promoters include, for example, arabinose, lacZ, metallothionein promoters or heat shock promoters. Cultures of transformed organisms can be grown under non-inducing conditions without biasing the population toward coding sequences whose expression products are better tolerated by the host cell. In addition to the promoter, other regulatory elements may also be required or desirable for efficient expression of anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments). The elements typically include an ATG initiation codon and adjacent ribosome binding sites or other sequences. In addition, the efficiency of expression can be enhanced by the inclusion of enhancers appropriate to the cell line used (e.g. Scharf et al., Results Probl. Cell Differ. 20:125, 1994; and Bittner et al., Meth .Enzymol., 153:516, 1987). For example, the SV40 enhancer or the CMV enhancer can be used to increase expression in mammalian host cells.
[0162] The expression vector may also provide a secretory signal sequence position to form a fusion protein with a polypeptide encoded by the inserted anti-CD48 antibody or antibody fragment (eg, antigen-binding fragment) sequence. In many cases, the inserted anti-CD48 antibody or antibody fragment (eg, antigen-binding fragment) sequence will be linked to a signal sequence prior to inclusion within the vector. Vectors that will be used to receive sequences encoding the light and heavy chain variable domains of anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments) sometimes also encode constant regions or portions thereof. Such vectors can produce intact antibodies or fragments thereof by expressing the variable region as a fusion protein with a constant region.
[0163] Host cells for harboring and expressing chains of anti-CD48 antibodies or antibody fragments (eg, antigen-binding fragments) can be prokaryotic or eukaryotic. E. coli is one prokaryotic host useful for cloning and expressing polynucleotides of the present disclosure. Other microbial hosts suitable for use include bacilli, such as Bacillus subtilis, and other members of the enterobacteriaceae, such as Salmonella, Serratia and various Pseudomonas sp. There are several species. In these prokaryotic hosts, one skilled in the art can also construct expression vectors, which typically contain expression control sequences (eg, origins of replication) that are compatible with the host cell. In addition, any number of a variety of well-known promoters may be present, such as the lactose promoter system, the tryptophan (trp) promoter system, the beta-lactamase promoter system, or the promoter system from phage lambda. A promoter typically controls expression, optionally with operator sequences, and has ribosome binding site sequences and the like to initiate and complete transcription and translation. Other microorganisms, such as yeast, can also be used to express anti-CD48 antibody or antibody fragment (eg, antigen-binding fragment) polypeptides. Insect cells in combination with baculovirus vectors can also be used.
[0164] In other embodiments, mammalian host cells can be used to express and produce anti-CD48 antibodies or antibody fragment (eg, antigen-binding fragment) polypeptides of the present disclosure. For example, the mammalian host cell can be a hybridoma cell line expressing endogenous immunoglobulin genes (e.g., a myeloma hybridoma clone described in the Examples) or a mammalian host cell carrying an exogenous expression vector. It can be a cell line (eg, SP2 / 0 myeloma cells exemplified below). These include any animal or human cell, normal or abnormal, normal or immortal. For example, several suitable host cell lines capable of secreting intact immunoglobulins have been developed, including CHO cell lines, various COS cell lines, HeLa cells, myeloma cell lines, transformed B cells. and hybridomas. The use of mammalian tissue cell culture to express polypeptides is generally discussed in, eg, Winnacker, From Genes to Clones, VCH Publishers, N.Y., N.Y., 1987. Expression vectors for mammalian host cells contain expression control sequences, such as origins of replication, promoters and enhancers (see, eg, Queen et al., Immunol. Rev. 89:49-68, 1986) and essential processing Informational sites may be included, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcription terminator sequences. These expression vectors usually contain promoters derived from mammalian genes or mammalian viruses. Suitable promoters may be constitutive, cell type-specific, stage-specific, and / or tunable or regulatable. Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP polIII promoter, the constitutive MPSV promoter, the tetracycline-inducible CMV promoter (e.g., human immediate early CMV promoters), constitutive CMV promoters, and promoter-enhancer combinations known in the art.
[0165] The method of introducing an expression vector containing a polynucleotide sequence of interest will vary depending on the type of cellular host. For example, calcium chloride transfection is commonly utilized for prokaryotic cells, but calcium phosphate treatment or electroporation may be used for other cellular hosts (see generally Sambrook et al., supra). Other methods include, for example, electroporation, calcium phosphate treatment, liposome-mediated transformation, injection and microinjection, ballistic methods, virosomes, immunoliposomes, polycation:nucleic acid conjugates, naked DNA, artificial virions, herpesvirus structures. These include fusion to the protein VP22 (Elliot and O'Hare, Cell 88:223, 1997), agent-enhanced uptake of DNA, and ex vivo transduction. In many cases, stable expression will be desired for long-term, high-yield production of recombinant proteins. For example, a cell line stably expressing chains of anti-CD48 antibodies or antibody fragments (e.g., antigen-binding fragments) can be prepared using a viral origin of replication or an expression vector containing endogenous expression elements and a selectable marker gene. can be prepared. After vector introduction, cells can be grown for 1-2 days in enriched media before switching to selective media. The purpose of the selectable marker is to confer resistance to selection; its presence allows the growth of cells that successfully express the introduced sequence in a selective medium. Stably transfected cells exhibiting resistance can be expanded using tissue culture techniques appropriate to the cell type.
[0166] Antibody fragments, such as antigen-binding fragments, can be produced by proteolytic cleavage of immunoglobulin molecules using enzymes such as papain (to generate Fab fragments) or pepsin (to generate Fab' fragments), and others. Compared to Fab fragments, Fab' fragments also contain a hinge region containing two natural cysteines that form a disulfide bond between the two heavy chains of the immunoglobulin molecule.
[0167] Drug part (D) In one aspect, the application provides an immunoconjugate that specifically binds human CD48. The antibody-drug conjugates of the present disclosure are conjugated to a drug moiety, such as a diagnostic agent, an anti-cancer agent, an autoimmune therapeutic agent, an anti-inflammatory agent, an anti-fungal agent, an anti-microbial agent, an anti-parasitic agent, an anti-viral agent or an anesthetic agent. anti-CD48 antibodies, antibody fragments (eg, antigen-binding fragments), or functional equivalents. An antibody, antibody fragment (eg, antigen-binding fragment) or functional equivalent thereof can be conjugated to a number of equal or different drug moieties using any method known in the art.
[0168] In certain embodiments, the drug moieties of the immunoconjugates of the present disclosure include Eg5 inhibitors, V-ATPase inhibitors, HSP90 inhibitors, IAP inhibitors, mTor inhibitors, microtubule stabilizers, microtubule destabilizers, auristatin. , dolastatin, maytansinoid, MetAP (methionine aminopeptidase), inhibitor of nuclear export of protein CRM1, DPPIV inhibitor, inhibitor of phosphoryl transfer reaction in mitochondria, protein synthesis inhibitor, kinase inhibitor, CDK2 inhibitor, CDK9 inhibitor, proteasome inhibitor, kinesin inhibitor, HDAC inhibitor, DNA damaging agent, DNA alkylating agent, DNA intercalating agent, DNA minor groove binder, RNA polymerase inhibitor, amanitin, spliceosome inhibitor, topoisomerase inhibitor, DHFR inhibitor, and pro-apoptotic agent. However, BCL-2 inhibitors, MCL-1 inhibitors and BCL-XL inhibitors are excluded.
[0169] In one embodiment, the drug moiety of the immunoconjugate of the present disclosure is a maytansinoid drug moiety, such as, but not limited to, DM1, DM3, or DM4.
[0170] Additionally, the antibodies, antibody fragments (eg, antigen-binding fragments) or functional equivalents of the present disclosure can be conjugated to drug moieties that modify a given biological response. Drug moieties should not be construed as limited to classical chemotherapeutic agents. For example, a drug moiety can be a protein, peptide, or polypeptide that has the desired biological activity. Such proteins include, for example, abrin, ricin A, toxins such as pseudomonas exotoxin, cholera toxin or diphtheria toxin, tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet-derived growth factor, tissue plus Mention may be made of minogen activators, cytokines, apoptotic agents, anti-angiogenic agents or biological response modifiers such as eg lymphokines.
[0171] In one embodiment, an antibody, antibody fragment (eg, antigen-binding fragment) or functional equivalent of the present disclosure is conjugated to a drug moiety, such as a cytotoxin, a drug (eg, an immunosuppressant), or a radiotoxin. Examples of cytotoxins include pyrrolobenzodiazepines (PBDs, e.g., tesirin, described in Tiberghien et al., ACS Med Chem Lett 7(11):983-987 (2016)), indolinobenzodiazepine dimeric payloads (Singh et al. al., Mol Pharm 2020 17(1), 50-58), taxanes (e.g., International (PCT) Patent Application WO 01 / 38318 Brochure and PCT / US Patent Application (see Publication No. 03 / 02675), DNA alkylating agents (e.g. CC-1065 analogs), anthracyclines, tubulysin analogs, duocarmycin analogs, auristatin E (MMAE), auristatin Statin F (MMAF), maytansinoids, and cytotoxic agents containing reactive polyethylene glycol moieties (e.g., Sasse et al., J. Antibiot. (Tokyo), 53, 879-85 (2000), Suzawa et al., Bioorg. Med.Chem., 8, 2175-84 (2000), Ichimura et al., J. Antibiot. (Tokyo), 44, 1045-53 (1991), Francisco et al., Blood (2003) Electronic publication), U.S. Patent No. 5,475,092, U.S. Patent No. 6,340,701, U.S. Patent No. 6,372,738 and U.S. Patent No. 6,436,931, U.S. Patent Application Publication No. 2001 / 0036923 A1, pending U.S. Pat. (Please refer to Patent Application No. 10 / 024,290 and No. 10 / 116,053 and International Patent Application No. WO 01 / 49698 pamphlet), taxon, cytochalasin B, gramicidin D, bromide Ethidium, emetine, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, t.colchicine, doxorubicin, daunorubicin, dihydroxyanthrasyndione, methoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, Includes, but is not limited to, tetracaine, lidocaine, propranolol and puromycin and analogs or homologs thereof. Therapeutic agents include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), ablative agents (e.g., mechlorethamine, thiotepa, chlorambucil, mayphalan, carmustine (BSNU) ) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamineplatinum(II) (DDP), cisplatin, anthracyclines (e.g. daunorubicin (formerly daunomycin) and doxorubicin), These include antibiotics (e.g. dactinomycin (formerly actinomycin), bleomycin, mithramycin and anthramycin (AMC)) and mitotic agents (e.g. vincristine and vinblastine) (e.g. Seattle Genetics' US patent application Please refer to Publication No. 20090304721).
[0172] Other examples of cytotoxins that can be conjugated to antibodies, antibody fragments (antigen-binding fragments) or functional equivalents of the present disclosure include duocarmycin, calicheamicin, maytansine and auristatin and derivatives thereof.
[0173] Various types of cytotoxins, linkers and methods for conjugating therapeutic agents to antibodies are known in the art, for example Saito et al., (2003) Adv.Drug Deliv.Rev.55:199 -215; Trail et al.,(2003)Cancer Immunol.Immunother.52:328-337;Payne,(2003)Cancer Cell 3:207-212;Allen,(2002)Nat.Rev.Cancer 2:750-763 See Pastan and Kreitman, (2002) Curr.Opin.Investig.Drugs 3:1089-1091; Senter and Springer, (2001) Adv.Drug Deliv.Rev.53:247-264.
[0174] In one embodiment, the drug moiety of the present disclosure has formula (A): [ka] is a compound of the formula, R 1 teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 independently selected from alkyl.
[0175] In one embodiment, the drug moiety of the present disclosure has the formula (B) [ka] is a compound of the formula, R 1 teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 independently selected from alkyl.
[0176] Certain aspects and examples of drug moieties of the present disclosure are set forth in the following list of further enumerated embodiments. It will be appreciated that the features identified in each embodiment may be combined with other specific features to provide further embodiments of the present disclosure.
[0177] Embodiment 1. Formula (A-1): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (A) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0178] Embodiment 2. Formula (A-2): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (A) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0179] Embodiment 3. Formula (A-3): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (A) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0180] Embodiment 4. Formula (A-4): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (A) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0181] Embodiment 5.R 2 is H or C 1 ~C 6 A compound of formula (A), formula (A-1), formula (A-2), formula (A-3) or formula (A-4) or a pharmaceutically acceptable salt thereof, which is alkyl.
[0182] Embodiment 6.R 2 is H or methyl, a compound of formula (A), formula (A-1), formula (A-2), formula (A-3) or formula (A-4) or a pharmaceutically acceptable thereof salt.
[0183] Embodiment 7.R 2 is H, a compound of formula (A), formula (A-1), formula (A-2), formula (A-3) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0184] Embodiment 8.R 2 is methyl, a compound of formula (A), formula (A-1), formula (A-2), formula (A-3) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0185] Embodiment 9. The compound is [ka] A compound of formula (A), formula (A-1) or formula (A-3), or a pharmaceutically acceptable salt thereof.
[0186] Embodiment 10. The compound is [ka] A compound of formula (A), formula (A-1) or formula (A-3), or a pharmaceutically acceptable salt thereof.
[0187] Embodiment 11. The compound is [ka] A compound of formula (A), formula (A-1) or formula (A-3), or a pharmaceutically acceptable salt thereof.
[0188] Embodiment 12. The compound is [ka] A compound of formula (A), formula (A-1) or formula (A-3), or a pharmaceutically acceptable salt thereof.
[0189] Embodiment 13. The compound is [ka] A compound of formula (A), formula (A-2) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0190] Embodiment 14. The compound is [ka] A compound of formula (A), formula (A-2) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0191] Embodiment 15. The compound is [ka] A compound of formula (A), formula (A-2) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0192] Embodiment 16. The compound is [ka] A compound of formula (A), formula (A-2) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0193] Embodiment 17. Formula (B-1): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (B) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0194] Embodiment 18. Formula (B-2): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (B) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0195] Embodiment 19. Formula (B-3): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (B) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0196] Embodiment 20. Formula (B-4): [ka] or a pharmaceutically acceptable salt thereof, in which: R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; and Each R 4 are H and C 1 ~C 6 A compound of formula (B) or a pharmaceutically acceptable salt thereof, independently selected from alkyl.
[0197] Embodiment 21.R 2 is H or C 1 ~C 6 A compound of formula (B), formula (B-1), formula (B-2), formula (B-3) or formula (B-4) or a pharmaceutically acceptable salt thereof, which is alkyl.
[0198] Embodiment 22.R 2 is H or methyl, a compound of formula (B), formula (B-1), formula (B-2), formula (B-3) or formula (B-4) or a pharmaceutically acceptable thereof salt.
[0199] Embodiment 23.R 2 is H, a compound of formula (B), formula (B-1), formula (B-2), formula (B-3) or formula (B-4), or a pharmaceutically acceptable salt thereof.
[0200] Embodiment 24.R 2 is methyl, a compound of formula (B), formula (B-1), formula (B-2), formula (B-3) or formula (B-4), or a pharmaceutically acceptable salt thereof.
[0201] Embodiment 25. The compound is [ka] A compound of formula (B), formula (B-1) or formula (B-3), or a pharmaceutically acceptable salt thereof.
[0202] Embodiment 26. The compound is [ka] A compound of formula (B), formula (B-1) or formula (B-3), or a pharmaceutically acceptable salt thereof.
[0203] Embodiment 27. The compound is [ka] A compound of formula (B), formula (B-1) or formula (B-3), or a pharmaceutically acceptable salt thereof.
[0204] Embodiment 28. The compound is [ka] A compound of formula (B), formula (B-1) or formula (B-3), or a pharmaceutically acceptable salt thereof.
[0205] Embodiment 29. The compound is [ka] A compound of formula (B), formula (B-2) or formula (B-4), or a pharmaceutically acceptable salt thereof.
[0206] Embodiment 30. The compound is [ka] A compound of formula (B), formula (B-2) or formula (B-4), or a pharmaceutically acceptable salt thereof.
[0207] Embodiment 31. The compound is [ka] A compound of formula (B), formula (B-2) or formula (B-4), or a pharmaceutically acceptable salt thereof.
[0208] Embodiment 32. The compound is [ka] A compound of formula (A), formula (A-2) or formula (A-4), or a pharmaceutically acceptable salt thereof.
[0209] linker In one aspect, the antibody drug conjugates of the present disclosure can include a linker. As used herein, a "linker" is any chemical moiety that can link an antibody, antibody fragment (eg, antigen-binding fragment), or functional equivalent to another moiety, such as a drug moiety. The linker can be susceptible to cleavage, such as acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage and disulfide bond cleavage, under conditions where the compound or antibody remains active. (cleavable linker). Alternatively, the linker can be substantially resistant to cleavage (eg, a stable linker or a non-cleavable linker). In some embodiments, the linker is a procharged linker, a hydrophilic linker, or a dicarboxylic acid-based linker.
[0210] In one embodiment, the linker used in the invention is N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), -(2-pyridyldithio)butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio)-2-sulfo-butanoate (sulfo-SPDB), N-succinimidyl iodoacetate (SIA), N- Succinimidyl (4-iodoacetyl) aminobenzoate (SIAB), maleimido PEG NHS, N-succinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate (SMCC), N-sulfosuccinimidyl 4-(maleimidomethyl)cyclohexanecarboxylate ( sulfo-SMCC) or 2,5-dioxopyrrolidin-1-yl17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraoxo- Derived from cross-linking reagents such as 4,7,10,13-tetraazaheptadecan-1-oate (CX1-1).
[0211] A non-cleavable linker is a chemical moiety that can link a drug, such as a maytansinoid, to an antibody in a stable and covalent manner and does not fall into the category described above for cleavable linkers. Thus, non-cleavable linkers are substantially resistant to acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage. Additionally, non-cleavable refers to acids, photolabile cleaving agents, peptidases, esterases, or chemical or biological compounds that cleave disulfide bonds under conditions such that the drug, such as maytansinoids or antibodies, does not lose its activity. refers to the ability of a chemical bond within or adjacent to a linker to withstand cleavage caused by.
[0212] Acid-labile linkers are linkers that are cleavable at acidic pH. For example, certain subcellular compartments such as endosomes and lysosomes have acidic pH (pH 4-5), providing suitable conditions for cleavage of acid-labile linkers.
[0213] Photolabile linkers are useful linkers on body surfaces and many body cavities that are accessible to light. Additionally, infrared radiation can penetrate tissue.
[0214] Some linkers can be cleaved by peptidases, ie, are peptidase-cleavable linkers. Only specific peptides are easily cleaved inside or outside the cell, e.g. Trout et al.,79 Proc. Natl. Acad. Sci. USA, 626-629 (1982) and Umemoto et al.43 Int. J. Cancer , 677-684 (1989). Furthermore, peptides are composed of α-amino acids and peptide bonds, which chemically are amide bonds between the carboxylic acid of one amino acid and the amino group of a second amino acid. Other amide bonds, such as the bond between the carboxylic acid and the α-amino group of lysine, are understood not to be peptide bonds and are considered non-cleavable.
[0215] Some linkers can be cleaved by esterases, ie, are esterase-cleavable linkers. Only certain esters can also be cleaved by esterases present inside or outside the cell. Esters are formed by the condensation of carboxylic acids and alcohols. Simple esterases are esters produced from simple alcohols, such as aliphatic alcohols, and small cyclic and small aromatic alcohols.
[0216] Procharge linkers are derived from charged crosslinking reagents that retain their charge after incorporation into antibody drug conjugates. Examples of procharge linkers can be found in US Patent Application Publication No. 2009 / 0274713.
[0217] linker-drug moiety In one embodiment, the linker-drug moiety (L B -(D) n ) is the linker (L B ), the one or more cytotoxins having formula (A), formula (A-1), formula (A-2), formula (A-3) , the compound of formula (A-4), formula (B), formula (B-1), formula (B-2), formula (B-3) and formula (B-4) or any of Embodiments 9 to 16 or any one of the compounds of Embodiments 25-32.
[0218] In one embodiment, the linker-drug moieties of the present disclosure include a linker (L B ), the one or more cytotoxins having formula (A), formula (A-1), formula (A-2), formula (A-3) and a compound of formula (A-4) or any one of Embodiments 7 to 14.
[0219] In one embodiment, the linker-drug moieties of the present disclosure include a linker (L B ), the one or more cytotoxins having formula (B), formula (B-1), formula (B-2), formula (B-3) and a compound of formula (B-4) or any one of Embodiments 23-30.
[0220] In one embodiment, the linker-drug moiety of the present disclosure has the formula (C) [ka] A compound having the structure, or a stereoisomer or pharmaceutically acceptable salt thereof, in which: R A teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 or -L 1 R 44 And; L 1 -X 1 C(=O)((CH 2) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 14 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 14 ,R 24 ,R 34 or R 44 Indicates that it is suitable for; R 14 teeth, [ka] -N 3 ,-ONH 2 ,-NR 6 C(=O)CH=CH 2 ,SH,-SSR 7 , -S(=O) 2 (CH=CH 2 ), -NR 6 S(=O) 2 (CH=CH 2 ), -NR 6 C(=O)CH 2 Br, -NR 6 C(=O)CH 2 I, -NHC(=O)CH 2 Br, -NHC(=O)CH 2 I, -C(=O)NHNH 2 , [ka] -CO 2 H, -NH 2 , [ka] [ka] And; R 24 teeth, [ka] And; R 34 -N 3 ,-ONH 2 ,-NR 7 C(=O)CH=CH 2 , -C(=O)NHNH 2 ,-CO 2 H, -NH 2、 [ka] or -NR 7 C(=O)CH 2 R 8 And; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; R 7 is 2-pyridyl or 4-pyridyl; R 8 is -S(CH 2 ) n CHR 9 N.H. 2 And; R 9 is -C(=O)OR 7 And; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and independently selected from OH; Each R 12 H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and -C(=O)OH 1~4 independently selected from alkyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0221] Particular aspects and examples of linker-drug moieties disclosed herein are set forth in the following list of further enumerated embodiments. It will be appreciated that the features identified in each embodiment may be combined with other specific features to provide further embodiments of the present disclosure.
[0222] Embodiment 33. Formula (C-1): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (C), or a pharmaceutically acceptable salt thereof.
[0223] Embodiment 34. Formula (C-2): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (C), or a pharmaceutically acceptable salt thereof.
[0224] Embodiment 35. Formula (C-3): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (C), or a pharmaceutically acceptable salt thereof.
[0225] Embodiment 36. Formula (C-4): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (C), or a pharmaceutically acceptable salt thereof.
[0226] Embodiment 37.R 2 is H or C 1 ~C 6 A compound of formula (C), formula (C-1), formula (C-2), formula (C-3) or formula (C-4) or a pharmaceutically acceptable salt thereof, which is alkyl.
[0227] Embodiment 38.R 2 is H or methyl, a compound of formula (C), formula (C-1), formula (C-2), formula (C-3) or formula (C-4) or a pharmaceutically acceptable thereof salt.
[0228] Embodiment 39.R 2 is H, a compound of formula (C), formula (C-1), formula (C-2), formula (C-3) or formula (C-4), or a pharmaceutically acceptable salt thereof.
[0229] Embodiment 40.R 2 is methyl, a compound of formula (C), formula (C-1), formula (C-2), formula (C-3) or formula (C-4), or a pharmaceutically acceptable salt thereof.
[0230] Embodiment 41. Formula (C-5): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0231] Embodiment 42. Formula (C-6): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0232] Embodiment 43. Formula (C-7): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0233] Embodiment 44. Formula (C-8): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0234] Embodiment 45. Formula (C-9): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0235] Embodiment 46. Formula (C-10): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0236] Embodiment 47. Formula (C-11): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0237] Embodiment 48. Formula (C-12): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (C), formula (C-1) or formula (C-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (C).
[0238] Embodiment 49. The compound is [ka] A compound of formula (C), formula (C-1) or formula (C-3) or Embodiment 37, which is
[0239] Embodiment 50. The compound is [ka] A compound of formula (C), formula (C-1) or formula (C-3) or Embodiment 37, which is
[0240] Embodiment 51. The compound is [ka] A compound of formula (C), formula (C-1) or formula (C-3) or Embodiment 38, wherein
[0241] Embodiment 52. The compound is [ka] A compound of formula (C), formula (C-1) or formula (C-3) or Embodiment 38, wherein
[0242] In one embodiment, the linker-drug moiety has the formula (C) [ka] A compound having the structure, or a stereoisomer or pharmaceutically acceptable salt thereof, in which: R A teeth, [ka] And; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 or -L 1 R 44 And; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 14 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 14 ,R 24 ,R 34 or R 44 Indicates that it is suitable for; R 14 teeth, [ka] -N 3 ,-ONH 2 ,-NR 6 C(=O)CH=CH 2 ,SH,-SSR 7 , -S(=O) 2 (CH=CH 2 ), -NR 6 S(=O) 2 (CH=CH 2 ), -NR 6 C(=O)CH 2 Br, -NR 6 C(=O)CH 2 I, -NHC(=O)CH 2 Br, -NHC(=O)CH 2 I, -C(=O)NHNH 2 , [ka] -CO 2 H, -NH 2 , [ka] And; R 24 teeth, [ka] And; R 34 -N 3 ,-ONH 2 ,-NR 7 C(=O)CH=CH 2 , -C(=O)NHNH 2 ,-CO 2 H, -NH 2 , [ka] And; R 44 teeth, [ka] or -NR 7 C(=O)CH 2 R 8 And; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; R 7 is 2-pyridyl or 4-pyridyl; R 8 is -S(CH 2 ) n CHR 9 N.H. 2 And; R 9 is -C(=O)OR 7 And; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and independently selected from OH; Each R 12 H, C 1~6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and C(=O)OH 1~4 independently selected from alkyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0243] Specific aspects and examples of linker-drug moieties are described in the following list of additional enumerated embodiments. It will be appreciated that the features identified in each embodiment may be combined with other identified features to provide further embodiments of the disclosure.
[0244] Embodiment 53. A compound of formula (D) or a pharmaceutically acceptable salt thereof having the structure of formula (D-1) or a pharmaceutically acceptable salt thereof: [ka] In the formula, R 2 and R 5 is as defined above for compounds of formula (D).
[0245] Embodiment 54. A compound of formula (A) or a pharmaceutically acceptable salt thereof having the structure of formula (D-2) or a pharmaceutically acceptable salt thereof: [ka] In the formula, R 2 and R 5 is as defined above for compounds of formula (D).
[0246] Embodiment 55. Formula (D-3): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (D), or a pharmaceutically acceptable salt thereof.
[0247] Embodiment 56. Formula (D-4): [ka] or a pharmaceutically acceptable salt thereof, in which R 2 and R 5 is as defined above for a compound of formula (D), or a pharmaceutically acceptable salt thereof.
[0248] Embodiment 57.R 2 is H or C 1 ~C 6 A compound of formula (D), formula (D-1), formula (D-2), formula (D-3) or formula (D-4) or a pharmaceutically acceptable salt thereof, which is alkyl.
[0249] Embodiment 58.R 2 is H or methyl, a compound of formula (D), formula (D-1), formula (D-2), formula (D-3) or formula (D-4) or a pharmaceutically acceptable thereof salt.
[0250] Embodiment 59.R 2 is H, a compound of formula (D), formula (D-1), formula (D-2), formula (D-3) or formula (D-4), or a pharmaceutically acceptable salt thereof.
[0251] Embodiment 60.R 2 is methyl, a compound of formula (D), formula (D-1), formula (D-2), formula (D-3) or formula (D-4), or a pharmaceutically acceptable salt thereof.
[0252] Embodiment 61. Formula (D-5): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0253] Embodiment 62. Formula (D-6): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0254] Embodiment 63. Formula (D-7): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0255] Embodiment 64. Formula (D-8): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0256] Embodiment 65. Formula (D-9): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0257] Embodiment 66. Formula (D-10): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0258] Embodiment 67. Formula (D-11): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0259] Embodiment 68. Formula (D-12): [ka] or a pharmaceutically acceptable salt thereof, in which R 5 is a compound of formula (D), formula (D-1) or formula (D-3), or a pharmaceutically acceptable salt thereof, as defined above for a compound of formula (D).
[0260] Embodiment 69. The compound is [ka] A compound of formula (D), formula (D-1) or formula (D-3) or Embodiment 61, wherein
[0261] Embodiment 70. The compound is [ka] A compound of formula (D), formula (D-1) or formula (D-3) or Embodiment 61, wherein
[0262] Embodiment 71. The compound is [ka] A compound of formula (D), formula (D-1) or formula (D-3) or Embodiment 62, wherein
[0263] Embodiment 72. The compound is [ka] A compound of formula (D), formula (D-1) or formula (D-3) or Embodiment 62, wherein
[0264] In one embodiment, the linker drug moiety of the present disclosure comprises valine-citrulline MMAE (valcit-MMAE). [ka]
[0265] antibody drug conjugate The present disclosure provides antibody-drug conjugates in which an antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds CD48 is optionally linked via a linker to a drug moiety (e.g., , cytotoxic agents). In one embodiment, the antibody or antibody fragment (eg, antigen-binding fragment) is attached to a drug moiety that is a cytotoxic agent through covalent attachment with a linker.
[0266] In some embodiments, provided herein is an antibody that specifically binds to CD48 or A conjugate comprising an antibody fragment (eg, an antigen-binding fragment) (eg, an antigen-binding fragment).
[0267] In one aspect, the present disclosure provides formula (I): A-(L B -(D) n ) y (I); providing a conjugate of A is an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to CD48; L B is a linker; D is a cytotoxic agent; n is an integer from 1 to 10, and y is an integer from 1 to 10, Linker-drug moiety (L B -(D) n ) is covalently attached to the antibody or antibody fragment (A).
[0268] In one aspect, the present disclosure relates to conjugates of formula (II): [ka] A 1 is an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; A 2 is an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; L B is a linker; D is a cytotoxic agent, and n is an integer from 1 to 10, Linker-drug moiety (L B -(D) n ) is an antibody or antibody fragment A 1 and A 2 covalently link.
[0269] In one aspect, the conjugates disclosed herein include a linker (L B ), the one or more cytotoxins having formula (A), formula (A-1), formula (A-2), formula (A-3) , the compound of formula (A-4), formula (B), formula (B-1), formula (B-2), formula (B-3) and formula (B-4) or any of Embodiments 7 to 14 or any one of the compounds of Embodiments 23-30.
[0270] In one aspect, the conjugates of the present disclosure include a linker (L B ), the one or more cytotoxins having formula (A), formula (A-1), formula (A-2), formula (A-3) and a compound of formula (A-4) or any one of Embodiments 7 to 14.
[0271] In one aspect, the conjugates of the present disclosure include a linker (L B ), the one or more cytotoxins having formula (B), formula (B-1), formula (B-2), formula (B-3) and a compound of formula (B-4) or any one of Embodiments 23-30.
[0272] In the conjugates of formula (I), one or more linker-drug moieties (L B -(D) n ) is covalently attached to an antibody or antibody fragment, A (e.g., an antigen-binding fragment) such that one or more drug moieties, D, are attached to the antibody or antibody fragment, A (e.g., an antigen-binding fragment). , linker L B can be covalently attached via. L B is any chemical moiety that can link an antibody or antibody fragment, A (eg, an antigen-binding fragment), to one or more drug moieties, D. Conjugates of formula (I) in which one or more drug moieties, D, are covalently attached to an antibody or antibody fragment, A (e.g., an antigen-binding fragment), have one or more reactive functional groups that may be the same or different. Can be formed using bifunctional linker reagents or multifunctional linker reagents. One of the reactive functional groups of the bifunctional linker reagent or the multifunctional linker reagent is used to form groups on the antibody or antibody fragment A, such as thiols or amines (e.g. cysteine, N-terminus or amino acid side chains, e.g. lysine). ), linker L B forms a covalent bond with one end of Such reactive functional groups of bifunctional or multifunctional linker reagents include, but are not limited to, maleimides, thiols, and NHS esters. Bifunctional linker reagents or other reactive functional groups of multifunctional linker reagents may be used to link one or more drug moieties D to linker L. B covalently attached to.
[0273] In the conjugate of formula (II), the antibody or antibody fragment A 1 and A 2 Ketone crosslinking is achieved by reaction of the above pendant thiols and bissulfonic acid esters of 1,3-dihaloacetones, such as 1,3-dichloroacetone, 1,3-dibromoacetone, 1,3-diiodoacetone, and 1,3-dihydroxyacetone. By forming an antibody or antibody fragment A 1 and A 2 are covalently linked. This ketone bridging moiety links one or more drug moieties D to linker L B Antibody or antibody fragment via A 1 and A 2 used for covalent attachment to L B is an antibody or antibody fragment A 1 and A 2 is any chemical moiety that can be attached to one or more drug moieties D. One or more drug moieties D are antibodies or antibody fragments A 1 and A 2 Conjugates of formula (II) that are covalently attached to can be formed using bifunctional linker reagents or multifunctional linker reagents having one or more reactive functional groups that are the same or different. In one embodiment, one of the reactive functional groups of the bifunctional linker reagent or multifunctional linker reagent is an alkoxyamine, which reacts with the ketone bridge to linker L B is used to form an oxime bond with one end and the other reactive functional group of the bifunctional linker reagent or multifunctional linker reagent is used to attach one or more drug moieties D to the linker L. B covalently attached to. In another embodiment, one of the reactive functional groups of the bifunctional linker reagent or multifunctional linker reagent is hydrazine, which reacts with the ketone bridge to linker L B is used to form a hydrazone bond with one end and the other reactive functional group of the bifunctional linker reagent or multifunctional linker reagent is used to link one or more drug moieties D to the linker L. B covalently attached to.
[0274] In one aspect, L B is a cleavable linker. In another embodiment, L B is a non-cleavable linker. In some embodiments, L B is an acid-labile linker, a photolabile linker, a peptidase-cleavable linker, an esterase-cleavable linker, a glycosidase-cleavable linker, a phosphodiesterase-cleavable linker, a disulfide bond reducible linker, a hydrophilic linker or a dicarboxylic acid-based linker. .
[0275] While the drug-to-antibody ratio has a precise integer value (e.g., the product of n and y in formula (I) and n in formula (II)) for a particular conjugate molecule, the value is often It is understood that due to some heterogeneity, typically associated with the binding process, it will be an average value when used to describe a sample containing many molecules. The average loading for a sample of conjugate is referred to herein as the drug-to-antibody (or antibody fragment) ratio or "DAR." In some embodiments, the DAR is about 1 to about 5, typically about 1, 2, 3, or 4. In some embodiments, at least 50% by weight of the sample is a compound with an average DAR of plus or minus 2, and preferably at least 50% of the sample is a conjugate containing an average DAR of plus or minus 1. Other embodiments include conjugates with a DAR of about 2. In some embodiments, a DAR of "about y" means that the measured value for DAR is within 20% of the product of n and y in Formula (I). In some embodiments, a DAR of "about n" means that the measured value for DAR is within 20% of n in Formula (II).
[0276] In one embodiment, the average molar ratio of drug to antibody or antibody fragment (i.e., the average product of n and y, also known as drug-to-antibody ratio (DAR)) in the conjugate of formula (I) is , about 1 to about 10, about 1 to about 6 (for example, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6 , 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0), about 1 to about 5, about 1.5 to about 4.5, or about 2 to about 4.
[0277] In one embodiment, the antibody or antibody fragment A of the drug in the conjugate of formula (II) 1 and A 2 The average molar ratio (i.e., the average value of n, also known as drug-to-antibody ratio (DAR)) is from about 1 to about 10, from about 1 to about 6, (e.g., 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0), approximately 1~ about 5, about 1.5 to about 4.5, or about 2 to about 4.
[0278] In one embodiment provided by the present disclosure, the conjugate has substantially high purity and has one or more of the following characteristics: (a) greater than about 90% (e.g., about 91%) of the conjugate species; , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% or more), preferably greater than about 95%, is monomeric; The level of unconjugated linker in the product is less than about 10% (e.g., less than about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or 0%) ( (c) less than 10% of the conjugate species are cross-linked (e.g., about 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2 %, 1% or 0%), (d) the level of free drug (e.g., auristatin, amanitin, maytansinoid or saporin) in the conjugate preparation is less than about 2% (e.g., about 1.5%, 1.4%, 1.3%, 1.2%, 1.1%, 1.0%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or 0% or less) (total cytotoxicity mol / mol).
[0279] In one aspect, the conjugates disclosed herein have the formula (E): [ka] It has the structure: A represents an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 )2 S(=O) 2 CH 2 CH 2 - * ,-NR 6 S(=O) 2 CH 2 CH 2 - * ,-NR 6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 independently selected from and -OH; Each R 12 H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and -C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0280] In one aspect, a conjugate of the present disclosure has formula (F): [ka] It has the structure: A represents an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 ) 2 S(=O) 2 CH 2 CH2 - * ,-NR 6 S(=O) 2 CH 2 CH 2 - * ,-NR 6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and independently selected from OH; Each R 12 H, C 1~6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0281] In one aspect, a conjugate of the present disclosure has formula (G): [ka] It has the structure: A represents an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * ,-NR 6 S(=O) 2 CH2 CH 2 - * ,-NR 6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 independently selected from and -OH; Each R 12 H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and -C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0282] In one aspect, the conjugate of the present disclosure has the formula (H): [ka] It has the structure: A represents an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds human CD48; y is an integer from 1 to 10; R 2 H, C 1 ~C 6 Alkyl, -C(=O)R 3 ,-(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 ,-((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 are H and C 1 ~C 6 independently selected from alkyl; L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 2 X 1 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)((CH 2 ) m O) p (CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m NHC(=O)(CH 2 ) m - ** ,-X 3 C(=O)(CH 2 ) m - ** ,-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** ,-X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** ,-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 3 teeth, [ka] and in the formula, ** indicates the point of attachment to -NH-; X 4 teeth, [ka] and in the formula, * The attachment point is R 114 Indicates that it is suitable for; R 114 teeth, [ka] ,-NR 6 C(=O)CH 2 - * , -NHC(=O)CH 2 - * , -S(=O) 2 CH 2 CH 2 - * ,-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * ,-NR 6 S(=O) 2 CH 2 CH 2 - * ,-NR6 C(=O)CH 2 CH 2 - * , -NH-, -C(=O)-, -NHC(=O)- * ,-CH 2 NHCH 2 CH 2 - * ,-NHCH 2 CH 2 - * ,-S-, [ka] and in the formula, * indicates the attachment point to A; Each R 6 are H and C 1 ~C 6 independently selected from alkyl; Each R 10 H, C 1 ~C 6 independently selected from alkyl, F, Cl and -OH; Each R 11 H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 ,-OCH 3 ,-OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and independently selected from OH; Each R 12 H, C 1~6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1~4 C substituted with alkoxy and C(=O)OH 1~4 independently selected from alkyl; Each R 15 is, H, -CH 3 and phenyl; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10; Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0283] Certain aspects and examples of conjugates are described in the following list of additional enumerated embodiments. It will be appreciated that the features identified in each embodiment may be combined with other identified features to provide further embodiments of the disclosure.
[0284] Embodiment 73. The conjugate having the structure of formula (E) is of formula (E-1): [ka] A conjugate having the structure, where R 2 ,R 114 , A, y and L 1 is as defined for the conjugate of formula (E) above.
[0285] Embodiment 74. The conjugate having the structure of formula (F) is of formula (F-1): [ka] A conjugate having the structure, where R 2 ,R 114 , A, y and L 1 is as defined for the conjugate of formula (F) above.
[0286] Embodiment 75. The conjugate having the structure of formula (G) is of formula (G-1): [ka] A conjugate having the structure, where R 2 ,R 114 , A, y and L 1 is as defined for the conjugate of formula (G) above.
[0287] Embodiment 76. The conjugate having the structure of formula (H) is of formula (H-1): [ka] A conjugate having the structure, where R 2 ,R 114 , A, y and L 1 is as defined for the conjugate of formula (H) above.
[0288] Embodiment 77.R 2 is H or C 1 ~C 6 A conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 69-72, which is alkyl.
[0289] Embodiment 78.R 2 is H or methyl, the conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 69-72.
[0290] Embodiment 79.R 2 is H, the conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 69 to 72.
[0291] Embodiment 80.R 2 is methyl, the conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 69-72.
[0292] Embodiment 81. The conjugate having the structure of formula (E) is of formula (E-2): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (E) above.
[0293] Embodiment 82. The conjugate having the structure of formula (E) is of formula (E-3): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (E) above.
[0294] Embodiment 83. The conjugate having the structure of formula (E) or formula (E-1) has formula (E-4): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (E) above.
[0295] Embodiment 84. The conjugate having the structure of formula (E) or formula (E-1) has formula (E-5): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (E) above.
[0296] Embodiment 85. The conjugate having the structure of formula (F) is of formula (F-2): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (F) above.
[0297] Embodiment 86. The conjugate having the structure of formula (F) is of formula (F-3): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (F) above.
[0298] Embodiment 87. The conjugate having the structure of formula (F) or formula (F-1) has formula (F-4): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (F) above.
[0299] Embodiment 88. The conjugate having the structure of formula (F) or formula (F-1) has formula (F-5): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (F) above.
[0300] Embodiment 89. The conjugate having the structure of formula (G) is of formula (G-2): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (G) above.
[0301] Embodiment 90. The conjugate having the structure of formula (G) is of formula (G-3): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (G) above.
[0302] Embodiment 91. The conjugate having the structure of formula (G) or formula (G-1) has formula (G-4): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (G) above.
[0303] Embodiment 92. The conjugate having the structure of formula (G) or formula (G-1) has formula (G-5): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (G) above.
[0304] Embodiment 93. The conjugate having the structure of formula (H) is of formula (H-2): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (H) above.
[0305] Embodiment 94. The conjugate having the structure of formula (H) is of formula (H-3): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (H) above.
[0306] Embodiment 95. The conjugate having the structure of formula (H) or formula (H-1) has formula (H-4): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (H) above.
[0307] Embodiment 96. The conjugate having the structure of formula (H) or formula (H-1) has formula (H-5): [ka] A conjugate having the structure, where R 114 , A, y and L 1 is as defined for the conjugate of formula (H) above.
[0308] Embodiment 97.L 1 -X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** or -X 1 C(=O)(CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; and X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 a conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 73 to 96, showing a point of attachment to the conjugate of formula (E), formula (F), formula (G), formula (H).
[0309] Embodiment 98.L 1 is-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** and in the formula, ** is R 114 indicates the point of attachment to; and X 1 teeth, [ka] and in the formula, ** is -NH- or X 2 a conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 73 to 96, showing a point of attachment to the conjugate of formula (E), formula (F), formula (G), formula (H).
[0310] Embodiment 99. A conjugate of formula (E), formula (F), formula (G), formula (H), or The conjugate of any one of embodiments 73-98.
[0311] Embodiment 100. A conjugate or embodiment of formula (E), formula (F), formula (G), formula (H), wherein each m is independently selected from 1, 2, 3, 4, and 5. A conjugate of any one of 73 to 98.
[0312] Embodiment 101. Conjugates of Formula (E), Formula (F), Formula (G), Formula (H) or Embodiments 73~ where each m is independently selected from 1, 2, 3, and 4. Conjugate of any one of 98.
[0313] Embodiment 102. The conjugate of Formula (E), Formula (F), Formula (G), Formula (H) or the conjugate of Embodiments 73-98, wherein each m is independently selected from 1, 2, and 3. Any one conjugate.
[0314] Embodiment 103. A conjugate of Formula (E), Formula (F), Formula (G), Formula (H) or any of Embodiments 73-98, wherein each m is independently selected from 1 and 2. 1 conjugate.
[0315] Embodiment 104. Formula (E), Formula (F), Formula (F), where each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12. (G), a conjugate of formula (H) or a conjugate of any one of embodiments 73-103.
[0316] Embodiment 105. Formula (E), Formula (F), Formula (G ), a conjugate of formula (H) or a conjugate of any one of embodiments 73 to 103.
[0317] Embodiment 106. Formula (E), Formula (F), Formula (G), where each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. A conjugate of formula (H) or a conjugate of any one of embodiments 73-103.
[0318] Embodiment 107. Formula (E), Formula (F), Formula (G), Formula ( H) or the conjugate of any one of embodiments 73 to 103.
[0319] Embodiment 108. Formula (E), Formula (F), Formula (G), Formula (H), wherein each n is independently selected from 1, 2, 3, 4, 5, 6, 7, and 8. or the conjugate of any one of embodiments 73-103.
[0320] Embodiment 109. A conjugate of formula (E), formula (F), formula (G), formula (H), where each n is independently selected from 1, 2, 3, 4, 5, 6, and 7. A gate or a conjugate of any one of embodiments 73-103.
[0321] Embodiment 110. A conjugate of formula (E), formula (F), formula (G), formula (H), or The conjugate of any one of embodiments 73-103.
[0322] Embodiment 111. Conjugates or embodiments of formula (E), formula (F), formula (G), formula (H), where each n is independently selected from 1, 2, 3, 4, and 5. A conjugate of any one of 73 to 103.
[0323] Embodiment 112. Conjugates of Formula (E), Formula (F), Formula (G), Formula (H) or Embodiments 73~ where each n is independently selected from 1, 2, 3, and 4 Conjugate of any one of 103.
[0324] Embodiment 113. The conjugate of Formula (E), Formula (F), Formula (G), Formula (H) or the conjugate of Embodiments 73-103, wherein each n is independently selected from 1, 2, and 3. Any one conjugate. In any of the previous embodiments, each n is independently selected from 1 and 2.
[0325] Embodiment 114. Each y is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12, Formula (E), Formula (F), Formula (G), a conjugate of formula (H) or a conjugate of any one of embodiments 73-113.
[0326] Embodiment 115. Formula (E), Formula (F), Formula (G ), a conjugate of formula (H) or a conjugate of any one of embodiments 73 to 113.
[0327] Embodiment 116. Formula (E), Formula (F), Formula (G), where each y is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. A conjugate of formula (H) or a conjugate of any one of embodiments 73-113.
[0328] Embodiment 117. Formula (E), Formula (F), Formula (G), Formula ( The conjugate of H) or the conjugate of any one of embodiments 73 to 113.
[0329] Embodiment 118. Formula (E), Formula (F), Formula (G), Formula (H), wherein each y is independently selected from 1, 2, 3, 4, 5, 6, 7, and 8. or the conjugate of any one of embodiments 73-113.
[0330] Embodiment 119. A conjugate of formula (E), formula (F), formula (G), formula (H), where each y is independently selected from 1, 2, 3, 4, 5, 6, and 7. A gate or a conjugate of any one of embodiments 73-113.
[0331] Embodiment 120. A conjugate of formula (E), formula (F), formula (G), formula (H), or The conjugate of any one of embodiments 73-113.
[0332] Embodiment 121. Conjugates or embodiments of formula (E), formula (F), formula (G), formula (H), wherein each y is independently selected from 1, 2, 3, 4, and 5. A conjugate of any one of 73 to 113.
[0333] Embodiment 122. Conjugates of Formula (E), Formula (F), Formula (G), Formula (H) or Embodiments 73~ where each y is independently selected from 1, 2, 3, and 4 Conjugate of any one of 113.
[0334] Embodiment 123. A conjugate of formula (E), formula (F), formula (G), formula (H) or of embodiments 73-113, wherein each y is independently selected from 1, 2, and 3. Any one conjugate.
[0335] Embodiment 124. A conjugate of Formula (E), Formula (F), Formula (G), Formula (H) or any of Embodiments 73-113, wherein each y is independently selected from 1 and 2. 1 conjugate.
[0336] Embodiment 125.L 1 teeth, [ka] and in the formula, ** is -NH- or X 2 a conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 73-124, showing a point of attachment to.
[0337] Embodiment 126.L 1 teeth, [ka] and in the formula, ** is -NH- or X 2 a conjugate of formula (E), formula (F), formula (G), formula (H) or any one of embodiments 73-124, showing a point of attachment to.
[0338] Embodiment 127.R 114 teeth, [ka] and in the formula, * indicates the point of attachment to A, the conjugate of formula (E), formula (F), formula (G), formula (H) or the conjugate of any one of embodiments 73-126.
[0339] Embodiment 128. [ka] selected from Formula (E), Formula (E-1), Formula (E-2) and Formula (E), where y and A are as defined above for the conjugate of Formula (E) E-4) conjugate.
[0340] Embodiment 129. [ka] selected from Formula (E), Formula (E-1), Formula (E-3) and Formula (E), where y and A are as defined above for the conjugate of Formula (E) E-5) conjugate.
[0341] Embodiment 130. [ka] selected from Formula (F), Formula (F-1), Formula (F-2) and Formula (F), where y and A are as defined above for the conjugate of Formula (F) F-4) conjugate.
[0342] Embodiment 131. [ka] selected from Formula (F), Formula (F-1), Formula (F-3) and Formula (F), where y and A are as defined above for the conjugate of Formula (F) F-5) conjugate.
[0343] Embodiment 132. [ka] selected from Formula (G), Formula (G-1), Formula (G-2) and Formula ( G-4) conjugate.
[0344] Embodiment 133. [ka] selected from Formula (G), Formula (G-1), Formula (G-3) and Formula ( G-5) conjugate.
[0345] Embodiment 134. [ka] wherein y and A are as defined above for the conjugate of formula (H), formula (H), formula (H-1), formula (H-2) and formula ( H-4) conjugate.
[0346] Embodiment 135. [ka] wherein y and A are as defined above for the conjugate of formula (H), formula (H), formula (H-1), formula (H-3) and formula ( H-5) conjugate.
[0347] Embodiment 136. [ka] A conjugate selected from.
[0348] Embodiment 137. [ka] A conjugate selected from.
[0349] Formulas disclosed herein, such as formula (A), formula (B), formula (C), formula (D), formula (E), formula (F), formula (G) and formula (H) Any of the compounds can be produced using the methods described in the examples below. The following examples are intended to illustrate the invention and should not be construed as a limitation thereof. Temperature is given in degrees Celsius. Unless otherwise mentioned, all evaporations are performed under reduced pressure, typically around 15 mmHg to 100 mmHg (=20 to 133 mbar). The structure of the final products, intermediates and starting materials is confirmed by standard analytical methods, such as microanalysis and spectroscopic characterization, such as MS, IR, NMR. The abbreviations used are conventional in the art.
[0350] Abbreviation:
[0351] [Table 21]
[0352] All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present disclosure are either commercially available or known to those skilled in the art in organic synthesis. or by the organic synthesis methods described herein.
[0353] Synthesis of intermediates Synthesis of (S)-t-butyl(3-(2-amino-3-hydroxypropyl)phenyl)carbamate (i-1) [ka] Step 1: BH in THF 3 (1M, 10ml) was stirred in (S)-2-((t-butoxycarbonyl)amino)-3-(3-nitrophenyl)propanoic acid (562mg, 1.81mmol) (10ml) in THF at 0°C. I added while doing so. Next, the reaction solution was stirred at 50°C for 1 hour. The reaction mixture was cooled to 0 °C, quenched with water, diluted with EtOAc, and diluted with 10% aqueous K. 2 C.O. 3 Wash with MgSO 4 Dry on top, filter and concentrate. The crude compound was purified by silica gel column (30-70% EtOAc-hexane) to give (S)-t-butyl (1-hydroxy-3-(3-nitrophenyl)propan-2-yl) carbamate as a white Obtained as a solid. MS m / z 319.1(M+Na).Retention time 1.183min.1H NMR(600MHz,chloroform-d)δ 8.13-8.04(m,2H),7.57(d,J=7.7Hz,1H),7.46(dd ,J=8.9,7.6Hz,1H),4.76(s,1H),3.87(dq,J=8.0,4.6,4.1Hz,1H),3.69(dd,J=10.9,3.9Hz,1H),3.58( dd,J=10.8,4.7Hz,1H),2.97(td,J=13.1,12.5,7.3Hz,2H),1.37(s,9H).
[0354] Step 2: To (S)-t-butyl (1-hydroxy-3-(3-nitrophenyl)propan-2-yl)carbamate (0.31 g, 1.0 mmol) (5 ml) in acetonitrile, 10% hydrochloric acid (5 ml) added. The reaction mixture was stirred at rt for 48 h and then concentrated to give (S)-2-amino-3-(3-nitrophenyl)propan-1-ol as the HCl salt. MS m / z 197.2(M+H).Retention time 0.775min.
[0355] Step 3: Dissolve (S)-2-amino-3-(3-nitrophenyl)propan-1-ol HCl salt (0.243 g, 1.046 mmol) in MeOH (10 ml) and add 10% palladium on carbon (50 mg , 0.047 mmol) was added. A 2L hydrogen balloon was attached. The reaction solution was heated with H 2 was flushed three times and then stirred for 1 h at RT. LCMS showed the reaction was complete. The reaction solution was filtered through a pad of Celite and concentrated to obtain (S)-2-amino-3-(3-aminophenyl)propan-1-ol as an HCl salt. MS m / z 167.2(M+H).Retention time 0.373min.
[0356] Step 4: (S)-2-amino-3-(3-aminophenyl)propan-1-ol HCl salt (0.212g, 1.046mmol), Boc 2 O (228 mg, 1.05 mmol) and dioxane-water-AcOH (10:9:1, 20 ml) were combined and stirred at rt for 3 days. LCMS showed the reaction to be 75% complete. Additional Boc 2 O (150 mg) was added and the reaction was stirred for an additional 6 hours. The reaction mixture was then concentrated and purified by preparative HPLC (10-40% acetonitrile in water with 0.05% TFA) to (S)-t-butyl (3-(2-amino-3-hydroxypropyl) ) phenyl)carbamate (i-1) was obtained as an oil. MS m / z 267.2(M+H).Retention time 1.011min.
[0357] (3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide) Butanamido)-3-methoxy-5-methylheptanoic acid (i-2) [ka] synthesis of Step 1: Dil-OtBu HCl salt ( [ka] :388mg, 0.982mmol), (1R,3S,4S)-2-(t-butoxycarbonyl)-2-azabicyclo[2.2.1]heptane-3carboxylic acid ( [ka] 287 mg, 1.19 mmol), HATU (411 mg, 1.08 mmol), DIEA (0.42 ml, 2.38 mmol) and DMF (5 ml) were combined and stirred at rt for 30 min. The reaction mixture was diluted with water (10 ml) and purified by RP-C18 ISCO to give tert-butyl (1R,3S,4S)-3-(((S)-1-(((3R,4S, 5S)-1-(tert-butoxy)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamoyl)-2 -Azabicyclo[2.2.1]heptane-2-carboxylate [ka] I got it. MS(m+1)=582.5, HPLC peak RT=1.542min
[0358] Step 2: The product obtained in step 1 (540 mg, 0.93 mmol) in 4M HCl in 1,4-dioxane (10 ml) was stirred at rt overnight. The reaction mixture was concentrated to yield (3R,4S,5S)-4-((S)-2-((1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carboxamide)-N ,3-dimethylbutanamide)-3-methoxy-5-methylheptanoic acid [ka] I got it. MS(m+1)=426.2, HPLC peak RT=0.736min
[0359] Step 3: Product obtained in step 2 (430 mg, 0.93 mmol), 37% formaldehyde solution (0.38 ml, 4.7 mmol), acetic acid (0.27 ml, 4.65 mmol), NaBH 3 CN (585 mg, 9.31 mmol) and MeOH (10 ml) were combined and stirred at rt for 30 min then concentrated. The residue was purified by RP-C18 ISCO to give 450 mg of (3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl -2-Azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoic acid (i-2) was obtained as a TFA salt. The TFA salt was treated with 10 ml of 12N HCl solution and concentrated twice to (3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S, 4S)-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoic acid HCl salt was obtained. MS(m+1)=440.2, HPLC peak RT=0.754min.
[0360] Dap-OMe:((2R,3R)-Methyl 3-methoxy-2-methyl-3-((S)-pyrrolidin-2-yl)propanoate)(i-3) [ka] synthesis of Step 1: Boc-Dap-OH( [ka] 3.11g, 10.8mmol), K 2 C.O. 3 (2.99g, 21.6mmol), iodomethane (2.95g) and acetone (55mL) were combined. The reaction solution was stirred at 20°C for 2 hours. Additional methyl iodide (2.28g) was added to the reaction and the reaction was stirred at 40°C for 3 hours. The reaction mixture was concentrated. Dissolve the residue in 200mL EtOAc and 100mL H 2 distributed to O. Separate the organic layer and wash with 50 mL saturated aq NaCl and MgSO 4 Dry over water, filter and concentrate to Boc-Dap-OMe. [ka] was obtained as a yellow oil. MS(ESI+) m / z calculated value 324.2, actual value 324.2 (M+23). Retention time 1.245min.
[0361] Step 2: Boc-Dap-OMe (3.107g, 10.3mmol) was combined with HCl in diethyl ether (2M, 10mL) and concentrated. This operation was repeated. The reaction was complete after the 7th treatment. The HCl salt of Dap-OMe(i-3) was obtained as a white solid after concentration. MS(ESI+)m / z Calculated value 202.1, Actual value 202.2(M+1). Retention time 0.486min. 1 H NMR(400MHz, CDCl 3 ):δ 4.065-4.041(m,1H),3.732(br.s,1H),3.706(s,3H),3.615(s,3H),3.368(br.s,1H),3.314(br.s, 1H),2.795(q,1H,J=6.8Hz),2.085-1.900(m,4H),1.287(d,3H,J=7.2Hz).
[0362] tert-Butyl(S)-(3-(2-amino-2-(thiazol-2-yl)ethyl)phenyl)carbamate(i-4) [ka] synthesis of Step 1: HATU (6.93 g, 18.22 mmol), N,O-dimethylhydroxylamine hydrochloride (1.615 g, 16.56 mmol) and DIPEA (14.46 ml, 83 mmol) were added at RT. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated under high vacuum to remove most of the solvent. The residue was then extracted between DCM and water. The aq. phase was extracted 2x by DCM. The combined DCM phases were concentrated under vacuum. The residue was separated by silica gel flash column (EtOAc / heptane 0-70% then 70%) to give 3.5 g of N-methoxy-N-methyl-2-(3-nitrophenyl)acetamide as a white solid. Obtained. MS m / z 225.1(M+1).Retention time 1.09min. 1 H NMR(400MHz,chloroform-d)δ 8.28-8.09(m,2H),7.67(m,1H),7.63-7.46(m,1H),3.90(s,2H),3.74(s,3H),3.24 (s,3H).
[0363] Process 2:N 2 In a THF solution (dry, 30 ml) of TMEDA (2.63 mL, 17.39 mmol) at -78 °C (acetone-dry ice bath) under atmosphere, was added n-butyllithium (2.5 M in hexane) (1.028 g, 16.06 mmol). was added dropwise. Then, at -78°C, 2-bromothiazole (2.63g, 16.06mmol) was also added dropwise to the reaction mixture. The reaction mixture was stirred at -78°C for 1 hour. A THF mixture (30 ml) of N-methoxy-N-methyl-2-(3-nitrophenyl)acetamide (3 g, 13.38 mmol) was added dropwise to the reaction mixture at -78°C. The reaction mixture was stirred at -78°C for 1 hour, then at -10°C (acetone-ice bath) for 2 hours. Reaction mixture sat.KHSO 4 Quenched by adding aq. solution and then extracted 3x with EtOAc. Combined EtOAc phase, sat.NaCl, NaSO 4 Dry on top and concentrate. The residue was separated by silica gel flash column (EtOAc / heptane 0-30% then 30%) to give 1.95 g of 2-(3-nitrophenyl)-1-(thiazol-2-yl)ethane-1- On was obtained as a pale yellow oil. MS m / z 249.0(M+1).Retention time 1.34min. 1 H NMR(400MHz,chloroform-d)δ 8.33-8.22(m,1H),8.17(ddd,J=8.1,2.3,1.0Hz,1H),8.10(d,J=3.0Hz,1H),7.79-7.67 (m,2H),7.54(t,J=7.9Hz,1H),4.62(s,2H).
[0364] Process 3:N 2 2-(3-nitrophenyl)-1-( A solution of thiazol-2-yl)ethan-1-one (2.38 g, 9.59 mmol) in diethyl ether (37 ml) was added dropwise. The reaction mixture was stirred at 0°C for 24 hours. Next, the mixture was mixed with 10% NaOH and 30% H 2 O 2 Neutralized with 30 ml (1:1) of a mixture of 0.05 and 1.00% at 10° C. in a water-ice bath. The mixture was stirred at RT for 1 hour. The mixture was then diluted with water and extracted 3x with EtOAc. The combined EtOAc phase, sat.K 2 C.O. 3 , sat.NaCl wash, NaSO 4 Dry on top and concentrate. The residue was separated by silica gel flash column (EtOAc / heptane 0-60% then 60%) to give 1.639 g of (R)-2-(3-nitrophenyl)-1-(thiazol-2-yl). Ethan-1-ol was obtained as a pale yellow solid. MS m / z 251.1(M+1).Retention time 1.09min. 1 H NMR(400MHz,chloroform-d)δ 8.33-8.07(m,2H),8.07-7.80(m,1H),7.74-7.55(m,1H),7.55-7.36(m,2H),5.55(dd, J=7.9,4.1Hz,1H),4.48(s,1H),3.53(dd,J=13.9,4.0Hz,1H),3.32(dd,J=13.9,8.1Hz,1H).92%e.e. Determined by chiral SFC.
[0365] Step 4: Pd / C (10 %, 0.696g, 0.654mmol) was added. Apply vacuum / H to the reaction mixture. 2 H after 3 cycles of 2 (1 atm) and stirred at RT. After stirring overnight, the reaction mixture was filtered through Celite and washed with MeOH. The filtrate was concentrated under vacuum to yield 1.3 g of (R)-2-(3-aminophenyl)-1-(thiazol-2-yl)ethan-1-ol as a solid, which was further purified. It was used directly in the next step. MS m / z 221.1(M+1).Retention time 0.50min. 1 H NMR(400MHz,DMSO-d 6 )δ 7.72(d,J=3.2Hz,1H),7.59(d,J=3.2Hz,1H),6.88(t,J=7.7Hz,1H),6.46(t,J=1.9Hz,1H), 6.42-6.29(m,2H),6.14(d,J=5.7Hz,1H),5.03-4.78(m,3H),3.03(dd,J=13.7,4.0Hz,1H),2.72(dd,J= 13.7, 8.7Hz, 1H).
[0366] Step 5: Dioxane / water mixture (1 / 1, 16ml / 16ml), Boc 2 O (1.512ml, 6.51mmol) and NaOH (0.284g, 7.10mmol) were added. The reaction mixture was stirred at RT overnight. The reaction mixture was added to 10ml of water and then extracted with EtOAc (3x40ml). Combine the organic phases and add Na 2 S.O. 4 Dry on top then concentrate under vacuum. The residue was then separated by a silica gel flash column (EtOAc / heptane 0-80% then 80%) to remove 1.24 g of tert-butyl(R)-(3-(2-hydroxy-2-(thiazole) -2-yl)ethyl)phenyl)carbamate was obtained as a solid. MS m / z 321.3(M+1).Retention time 1.26min. 1 H NMR(400MHz,DMSO-d 6 )δ 9.24(s,1H),7.73(d,J=3.2Hz,1H),7.60(d,J=3.3Hz,1H),7.39(t,J=1.8Hz,1H),7.25(ddd,J =8.2,2.3,1.1Hz,1H),7.11(t,J=7.8Hz,1H),6.80(dt,J=7.7,1.2Hz,1H),6.20(d,J=5.7Hz,1H),4.97 (ddd,J=8.6,5.7,4.0Hz,1H),3.13(dd,J=13.7,4.0Hz,1H),2.83(dd,J=13.7,8.7Hz,1H),1.47(s,9H).
[0367] Process 6:N 2 An ice-water bath cooled solution of tert-butyl (R)-(3-(2-hydroxy-2-(thiazol-2-yl)ethyl)phenyl)carbamate (1.2 g, 3.75 mmol) in THF (dry, 25 ml) under atmosphere ), PPh 3 (1.670g, 6.37mmol) was added. DEAD (40%wt in toluene) (2.90ml, 6.37mmol) was then added dropwise at 0°C followed by DPPA (1.372ml, 6.37mmol). The cold bath was then removed and the reaction mixture was stirred at RT overnight. The reaction mixture was concentrated in vacuo and then subjected to flash silica gel column separation (EtOAc / heptane 0-30% then 30%) to give 1.03 g of tert-butyl(S)-(3-(2-azido-2 -(thiazol-2-yl)ethyl)phenyl)carbamate was obtained as an oil. MS m / z 346.3(M+1).Retention time 1.55min. 1 H NMR(400MHz,DMSO-d 6 )δ 9.29(s,1H),7.86(d,J=3.2Hz,1H),7.76(d,J=3.2Hz,1H),7.41(t,J=1.9Hz,1H),7.29(ddd,J =8.3,2.2,1.1Hz,1H),7.16(t,J=7.8Hz,1H),6.86(dt,J=7.9,1.2Hz,1H),5.31(dd,J=8.7,5.7Hz,1H) ,3.17(d,J=5.3Hz,1H),3.09(dd,J=13.9,8.7Hz,1H),1.47(s,9H).
[0368] Step 7: Pd / C ( 10% wet, 265 mg, 0.249 mmol) was added. Apply vacuum / H to the reaction mixture. 2 H after 3 cycles of 2 (1 atm) and stirred at RT. After stirring overnight, the reaction mixture was concentrated, then filtered through Celite and washed with MeOH. The filtrate was concentrated under vacuum to give 781 mg of tert-butyl(S)-(3-(2-amino-2-(thiazol-2-yl)ethyl)phenyl)carbamate (i-4) as a sticky Obtained as oil. MS m / z 320.2(M+1).Retention time 0.91min. 1 H NMR(400MHz,DMSO-d 6 )δ 9.26(s,1H),7.71(d,J=3.3Hz,1H),7.55(d,J=3.3Hz,1H),7.36(t,J=1.9Hz,1H),7.26(dt,J =8.3,1.5Hz,1H),7.13(t,J=7.8Hz,1H),6.78(dt,J=7.6,1.3Hz,1H),4.31(dd,J=8.7,4.7Hz,1H),3.14 (dd,J=21.2,5.0Hz,1H),2.73(dd,J=13.4,8.7Hz,1H),2.11(s,2H),1.47(s,9H).
[0369] Synthesis of exemplary drug moieties Example A: (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-( ((S)-2-(3-aminophenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3- Methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3- Carboxamide (C1) [ka] synthesis of Step 1: (2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S) -2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoic acid (250mg) , 0.346 mmol) in DMF solution (4 ml), tert-butyl (S)-(3-(2-amino-2-(thiazol-2-yl)ethyl)phenyl)carbamate (i-4) (110 mg, 0.346 mmol), HATU (158 mg, 0.415 mmol) and DIPEA (362 μl, 2.075 mmol) were added. The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated under vacuum. The residue was then dissolved in MeOH and loaded onto an ISCO gold C-18 100 gram reverse phase column (MeCN / H 2 173 mg of tert-butyl (3-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S) -4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide)butanamide)-3-methoxy- 5-Methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-2-(thiazol-2-yl)ethyl)phenyl)carbamate was obtained as a white powder. MS m / z 911.0(M+1).Retention time 1.15min.
[0370] Step 2: tert-butyl(3((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3 -dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl )-3-Methoxy-2-methylpropanamide)-2-(thiazol-2-yl)ethyl)phenyl)carbamate (173 mg, 0.190 mmol) was dissolved in 1 ml dioxane and then 10 ml 4N HCl in dioxane. was added to the mixture. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under high vacuum and then diluted with sat.NaHCO 3 and DCM to bring the pH of the aq. phase to 8. The basic aq. phase was extracted 3x with DCM. The combined DCM phase was divided into sat.NaCl and Na 2 S.O. 4 dried above and concentrated under high vacuum to give 155 mg of (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S) -2-((1R,2R)-3-(((S)-2-(3-aminophenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3 -oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl -2-Azabicyclo[2.2.1]heptane-3-carboxamide was obtained as a solid. MS m / z 810.5(M+1).Retention time 0.90min.
[0371] Example B: (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-( ((S)-1-(3-aminophenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy- 5-Methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide( C2) [ka] synthesis of Step 1: DIEA (0.105 ml, 0.60 mmol) and HATU (45.5 mg, 0.12 mmol) were dissolved in (3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R ,3S,4S)-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoic acid (i-2) (57mg, 0.12mmol) (2ml) added to. The reaction mixture was stirred at rt for 5 min before DapOMe(i-3) (28.5 mg, 0.12 mmol) in DMF (1 ml) was added. The reaction mixture was stirred at RT for 1 h and then purified by preparative HPLC (10–50% acetonitrile-H containing 0.05% TFA). 2 (2R,3R)-methyl3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R ,3S,4S)-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2- Methylpropanoate was obtained. MS m / z 623.5(M+H).Retention time 1.225min
[0372] Step 2: LiOH (30mg, 1.25mmol) was converted into (2R,3R)-methyl3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl- 2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3 -Methoxy-2-methylpropanoate (43.2 mg, 0.059 mmol) (MeOH-H 2 (1:1, 4 ml). The reaction mixture was stirred at rt for 18 h, concentrated and acidified with HCl (1N, 1 ml). The crude compound was purified by preparative HPLC (10-38% acetonitrile-H containing 0.05% TFA). 2(2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R, 3S,4S)-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methyl Propanoic acid was obtained as TFA salt. MS m / z 609.5(M+H).Retention time 0.962min.
[0373] Step 3: (2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S, 4S)-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanoic acid (45.7 mg, 0.063 mmol) (1 ml) were added DIEA (0.055 ml, 0.32 mmol) and HATU (24.0 mg, 0.063 mmol). The reaction mixture was stirred at rt for 10 min, then (S)-t-butyl(3-(2-amino-3-hydroxypropyl)phenyl)carbamate TFA salt (i-1) (24.1 mg, 0.063 mmol) (1 ml). The reaction mixture was stirred at rt for 1 h and then concentrated. The crude compound was purified by preparative HPLC (20-70% acetonitrile-H containing 0.05% TFA). 2 t-butyl(3-((S)-2-((2R,3R)-3((S)-1-((3R,4S,5S)-4-((S) -N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidine -2-yl)-3-methoxy-2-methylpropanamido)-3-hydroxypropyl)phenyl)carbamate was obtained as a TFA salt. MS m / z 857.5(M+H).Retention time 1.145min.
[0374] Step 4: t-Butyl(3-((S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-N, 3-Dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidine-2- A solution of yl)-3-methoxy-2-methylpropanamido)-3-hydroxypropyl)phenyl)carbamate (61.4 mg, 0.063 mmol) in 5% HCl in acetonitrile-water (1:1, 4 ml) at RT for 24 hours. Stir for hours. The reaction mixture was then concentrated and purified by preparative HPLC (10–30% acetonitrile-H containing 0.05% TFA). 2 (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)- 3-(((S)-1-(3-aminophenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3 -Methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3 -Carboxamide (C2) was obtained as TFA salt. MS m / z 757.5(M+H).Retention time 0.744min.
[0375] Synthesis of Exemplary Linker-Drug Compounds Example C: (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-( ((S)-2-(3-((S)-2-((S)-2-(3-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) )ethoxy)propanamido)-3-methylbutanamido)-5-ureidopentanamido)phenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3-oxopropyl) pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo [2.2.1]Heptane-3-carboxamide (LP1) [ka] synthesis of Step 1: (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(( (S)-2-(3-aminophenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy -5-Methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (C1) (154 mg, 0.190 mmol) and Boc-Val-Cit-OH ( [ka] EEDQ (94 mg, 0.380 mmol) was added to a mixture of 92 mg, 0.247 mmol) in DCM (5 ml) / MeOH (0.1 ml). The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated under vacuum. The residue was then dissolved in MeOH and loaded onto an ISCO gold C-18 50 gram reverse phase column (MeCN / H containing 0.05% TFA). 2 232 mg tert-butyl ((S)-1-(((S)-1-((3((S)-2-((2R,3R)-3 -((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2 .1]Heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-2-(thiazol-2-yl)ethyl ) phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate was obtained as a TFA salt. MS m / z 1167.3(M+1).Retention time 1.10min.
[0376] Step 2: tert-butyl((S)-1-(((S)-1-((3-((S)-2-((2R,3R)-3-((S)-1-(( 3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide)butanamide )-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-2-(thiazol-2-yl)ethyl)phenyl)amino)-1-oxo- 5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (232 mg, 0.181 mmol) was added to a cold solution of TFA / DCM (25%, 6 ml) and the mixture was stirred at 0° C. for 15 min and then warmed to RT. The mixture was stirred for 30 minutes at RT. The reaction mixture was concentrated under vacuum. The residue was then dissolved in DMSO and loaded onto an ISCO gold C-18 50 gram reverse phase column (MeCN / H containing 0.05% TFA). 2 219 mg of ((1R,2R)-3-(((S)-2-(3-((S)-2-((S)-2-amino- 3-Methylbutanamido)-5-ureidopentanamido)phenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)- 3-Methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane- 3-Carboxamide was obtained as TFA salt. MS m / z 1067.2(M+1).Retention time 0.88min.
[0377] Step 3: ((1R,2R)-3-(((S)-2-(3-((S)-2-((S)-2-amino-3-methylbutanamide)-5-ureidopentane Amido)phenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxo Heptane-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (219 mg 0.18 mmol) in DMF (2 ml) and then MAL-PEG1-NHS ester ( [ka] 73.1 mg, 0.236 mmol) and DIPEA (190 μl, 1.087 mmol) were added. The reaction mixture was stirred at RT for 1 hour. The reaction mixture was concentrated under vacuum. The residue was then dissolved in DMSO and loaded onto an ISCO gold C-18 50 gram reverse phase column (MeCN / H containing 0.05% TFA). 2174 mg of (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2- ((1R,2R)-3-(((S)-2-(3-((S)-2-((S)-2-(3-(2-(2,5-dioxo-2,5 -dihydro-1H-pyrrol-1-yl)ethoxy)propanamido)-3-methylbutanamido)-5-ureidopentanamido)phenyl)-1-(thiazol-2-yl)ethyl)amino)-1-methoxy -2-Methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutane-2- yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (LP1) was obtained as a TFA salt. MS m / z 1262.4(M+1).Retention time 1.02min.
[0378] Example D: (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-( ((S)-1-(3((S)-2-((S)-2-(3-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) ethoxy)propanamide)-3-methylbutanamide)-5-ureidopentanamido)phenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidine-1 -yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2. 1]Heptane-3-carboxamide (LP2) [ka] synthesis of Step 1: Fmoc-Cit-OH( [ka] DIEA (13.0 mg, 0.10 mmol) followed by HATU (9.6 mg, 0.025 mmol) was added to a DMF solution (1 ml) of 10.0 mg, 0.025 mmol), the reaction mixture was stirred at RT for 5 min, and then the solution , (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-((( S)-1-(3-aminophenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5- Methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (C2) (20 mg, 0.025 mmol). The reaction mixture was stirred at RT for 1 h and then treated with 10–45% acetonitrile-H containing 0.05% TFA. 2 Purified by reverse phase HPLC using a C18 column, eluting with O. Fractions containing the desired product were concentrated to yield (9H-fluoren-9-yl)methyl((S)-1-((3-((S)-2-((2R,3R)-3 -((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2 .1]Heptane-3-carboxamide)butanamide)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamide)-3-hydroxypropyl)phenyl)amino)- 1-Oxo-5-ureidopentan-2-yl)carbamate was obtained as a TFA salt. LCMS MS m / z 1136.6(M+1), retention time 1.042 minutes.
[0379] Step 2: (9H-fluoren-9-yl)methyl((S)-1-((3-((S)-2-((2R,3R)-3-((S)-1-((3R ,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide)butanamide) -3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-hydroxypropyl)phenyl)amino)-1-oxo-5-ureidopentane-2- yl)carbamate (31.5 mg, 0.025 mmol) TFA salt was dissolved in MeOH (1 mL). Next, Pd / C (10 mg, 9.40 μmol) was added. Attach a 2L hydrogen balloon and evacuate the reaction mixture to H 2 Vacuum flush 3 times with H 2 Stir for 30 minutes at RT. The catalyst was then removed by filtration through Celite and the mixture was concentrated and treated with 1N NaOH. The crude mixture was diluted with 5-37% acetonitrile-H containing 0.05% TFA. 2 Purified by reverse phase HPLC using a C18 column, eluting with O. Fractions containing the desired product were lyophilized to yield (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2 -((1R,2R)-3-(((S)-1-(3-((S)-2-amino-5-ureidopentanamido)phenyl)-3-hydroxypropan-2-yl)amino) -1-Methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1- Oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide was obtained as a TFA salt. LCMS m / z 914.6(M+1), retention time 0.773min.
[0380] Step 3: Cbz-Val-OH( [ka] To a solution of 2.6 mg, 0.011 mmol) in DMF (1 ml) was added DIEA (0.011 ml, 0.061 mmol) followed by HATU (3.86 mg, 0.011 mmol). The reaction mixture was stirred at rt for 5 min, then (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-( (1R,2R)-3-(((S)-1-(3((S)-2-amino-5-ureidopentanamido)phenyl)-3-hydroxypropan-2-yl)amino)-1- Methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutane-2 -yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (11.6 mg, 0.011 mmol) was added to a solution of the TFA salt in DMF (1 ml). The reaction mixture was stirred at RT for 1 h, then the crude compound was dissolved in 10-50% acetonitrile-H containing 0.05% TFA. 2 Purified by reverse phase HPLC using a C18 column, eluting with O. Fractions containing the desired product were lyophilized to yield benzyl ((S)-1-(((S)-1-((3((S)-2-((2R,3R)-3- ((S)-1-((3R,4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2. 1]Heptane-3-carboxamido)butanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-hydroxypropyl)phenyl)amino)-1 -Oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate was obtained as a TFA salt. LCMS m / z 1147.6(M+1), retention time 0.986min.
[0381] Step 4: Benzyl((S)-1-(((S)-1-((3-((S)-2-((2R,3R)-3-((S)-1-((3R, 4S,5S)-4-((S)-N,3-dimethyl-2-((1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide)butanamide)- 3-Methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-hydroxypropyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl )amino)-3-methyl-1-oxobutan-2-yl)carbamate (7.7 mg, 0.006 mmol) TFA salt was dissolved in MeOH (2 ml), then Pd / C (5 mg, 4.70 μmol) was added. Ta. Attach a 2L hydrogen balloon and evacuate the reaction mixture to H 2 Vacuum flush 3 times with H 2 The mixture was stirred for 30 minutes at a lower temperature. LCMS showed the reaction was complete. The catalyst was then removed by filtration through Celite and the mixture was concentrated to (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1 -((S)-2-((1R,2R)-3-(((S)-1-(3-((S)-2-((S)-2-amino-3-methylbutanamide) -5-ureidopentanamido)phenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl- 1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide was obtained as a TFA salt. Ta. LCMS m / z 1013.6(M+1) retention time 0.774min.
[0382] Step 5: MAl-PEG1-acid ( [ka] To a solution of 1.0 mg, 0.005 mmol) in DMF (0.5 ml) was added DIEA (2.8 mg, 0.022 mmol) followed by HATU (1.8 mg, 0.005 mmol). The reaction was stirred at rt for 5 min, then (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2-(( 1R,2R)-3-(((S)-1-(3-((S)-2-((S)-2-amino-3-methylbutanamide)-5-ureidopentanamido)phenyl)- 3-Hydroxypropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)( methyl)amino)-3-methyl-1-oxobutan-2-yl)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide (4.8mg, 0.005mmol) TFA salt in DMF solution (1ml) added to. The reaction was stirred at RT for 1 h, then the crude compound was dissolved in 10-38% acetonitrile-H containing 0.05% TFA. 2 Purified by reverse phase HPLC using a C18 column, eluting with O. Fractions containing the desired product were lyophilized to yield (1R,3S,4S)-N-((S)-1-(((3R,4S,5S)-1-((S)-2 -((1R,2R)-3-(((S)-1-(3-((S)-2-((S)-2-(3-(2-(2,5-dioxo-2, 5-dihydro-1H-pyrrol-1-yl)ethoxy)propanamido)-3-methylbutanamido)-5-ureidopentanamido)phenyl)-3-hydroxypropan-2-yl)amino)-1-methoxy- 2-Methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl )-2-Methyl-2-azabicyclo[2.2.1]heptane-3-carboxamide was obtained as a TFA salt (LP-2). LCMS m / z 1208.5(M+1) retention time 0.882min.
[0383] Conjugation and preparation of ADCs Process for producing antibody conjugates of formula (I) A general reaction scheme for the formation of conjugates of formula (I) is shown in Scheme 1 below. [ka] In the formula, RG 1 is a reactive group (thiol, amine or ketone, just to name a few) and a compatible reactive group RG attached to the linker-drug moiety 2 The antibody or antibody fragment A is covalently linked to one or more linker-drug moieties by reacting with the antibody or antibody fragment A. R.G. 1 Group and RG 2 As a non-limiting example of such a reaction of groups, thiol (RG 1 ) to give a succinimide ring (RG 2 ) or ketone (RG 1 ) to give the oxime (hydroxylamine (RG 2 ).
[0384] A general reaction scheme for the formation of conjugates of formula (II) is shown in Scheme 2 below. [ka] In the formula, A 1 ,A 2 ,L B , D and n are as defined herein, 1,3-dihaloacetone is selected from 1,3-dichloroacetone, 1,3-dibromoacetone and 1,3-diiodoacetone; The reduction step is accomplished using a reducing agent selected from dithiothreitol (DTT) and tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl).
[0385] A general reaction scheme for the formation of conjugates of formula (E) is shown in Scheme 3 below. [ka] In the formula, R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 or -L 1 R 44 and RG 1 is a reactive group (by way of example only a thiol, amine or ketone) and the compatible R of the compound of formula (C-1) 14 ,R 24 ,R 34 or R 44 reacts with the group to form the corresponding R 114 form a group. An example is maleimide which reacts with a thiol to give a succinimide ring or hydroxylamine which reacts with a ketone to give an oxime. A, y, L 1 ,R 2 ,R 5 and R 114 is as defined herein.
[0386] A general reaction scheme for the formation of conjugates of formula (F) is shown in Scheme 4 below. [ka] In the formula, R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 Or L 1 R 44 and R.G. 1 is a reactive group, by way of example only a thiol, amine or ketone, which corresponds to the corresponding R of the compound of formula (C-2). 14 ,R 24 ,R 34 or R 44 reacts with the group to form the corresponding R 114 form a group. As an example, maleimide reacts with a thiol to give a succinimide ring, or hydroxylamine reacts with a ketone to give an oxime. A, y, L 1 ,R 2 ,R 5 and R 114 is as defined herein.
[0387] A general reaction scheme for the formation of conjugates of formula (G) is shown in Scheme 5 below. [ka] In the formula, R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 Or L 1 R 44 and R.G. 1 is a reactive group, by way of example only a thiol, an amine or a ketone, which corresponds to the corresponding R of the compound of formula (D-1). 14 ,R 24 ,R 34 or R 44 reacts with the group to form the corresponding R 114 form a group. As an example, maleimide reacts with a thiol to give a succinimide ring, or hydroxylamine reacts with a ketone to give an oxime. A, y, L 1 ,R 2 ,R 5 and R 114 is as defined herein.
[0388] A general reaction scheme for the formation of conjugates of formula (H) is shown in Scheme 6 below. [ka] In the formula, R 5 -L 1 R 14 ,-L 1 R 24 ,-L 1 R 34 Or L 1 R 44 and R.G. 1 is a reactive group, by way of example only, a thiol, or an amine, or a ketone, which corresponds to the corresponding R of the compound of formula (D-2). 14 ,R 24 ,R 34 or R 44 reacts with the group to form the corresponding R 114 form a group. As an example, maleimide reacts with a thiol to give a succinimide ring, or hydroxylamine reacts with a ketone to give an oxime. A, y, L 1 ,R 2 ,R 5 and R 114 is as defined herein.
[0389] therapeutic use The antibodies, antibody fragments (eg, antigen-binding fragments) and antibody-drug conjugates disclosed herein are useful in treating any CD48-expressing cancer, such as hematologic diseases or hematologic malignancies. Hematologic diseases / malignancies that can be treated with the antibodies, antibody fragments (e.g., antigen-binding fragments) and antibody-drug conjugates disclosed herein include multiple myeloma, acute lymphoblastic leukemia (ALL); , acute myeloid leukemia (AML), acute monocytic leukemia (AMoL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), hairy cell leukemia (HCL), T-cell prolymphocytic leukemia (T -PLL), large granular lymphocytic leukemia and adult T-cell leukemia, lymphoma, B-cell lymphoma. Precursor T-cell leukemia / lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic leukemia / lymphoma, MALT lymphoma, mycosis fungoides, peripheral T-cell Lymphomas, unless otherwise specified, include Hodgkin's lymphoma, non-Hodgkin's lymphoma, nodular sclerosing form of Hodgkin's lymphoma, mixed cell subtypes of Hodgkin's lymphoma, and myelodysplastic syndromes.
[0390] In some embodiments, the antibodies, antibody fragments (e.g., antigen-binding fragments) and antibody drug conjugates disclosed herein are useful in treating any CD48-expressing solid tumor selected from: Useful for: lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), colorectal cancer, colorectal cancer, rectal cancer, renal cell carcinoma, liver cancer, hepatocellular carcinoma, small intestine cancer, esophageal cancer, pancreatic cancer , breast cancer, head and neck cancer, head and neck squamous cell carcinoma, thyroid cancer, cervical cancer, ovarian cancer, skin cancer, melanoma and prostate cancer. The cancer may be early, intermediate, late stage or metastatic cancer.
[0391] In some embodiments, the antibodies, antibody fragments (e.g., antigen-binding fragments) and antibody-drug conjugates disclosed herein are suitable for breast cancer, multiple myeloma, B-cell lymphoma, plasma cell myeloma, leukemia, Lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain tumor, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, T cell or Useful in treating lymphoid malignancies of B cell origin, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or splenic cancer. be.
[0392] combination therapy In certain examples, the antibodies, antibody fragments (eg, antigen-binding fragments), and antibody-drug conjugates of the present disclosure may be used in combination with another conditioning regimen, such as radiation therapy or chemotherapy.
[0393] In certain instances, the antibodies, antibody fragments (e.g., antigen-binding fragments), and antibody-drug conjugates of the present disclosure may be used in combination with another therapeutic agent, such as an anticancer agent, an antiemetic (or antiemetic) agent, an analgesic, a mobilizing agent, or the like. Can be used in combination with combinations of.
[0394] Common chemotherapy drugs that may be considered for use in combination therapy include anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), and busulfan (Myleran®). Busulfan injection (Busulfex®), capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine ( BiCNU(R)), chlorambucil (Leukeran(R)), cisplatin (Platinol(R)), cladribine (Leustatin(R)), cyclosporine (Sandimmune(R), Neoral(R) or Restasis(R)) ), cyclophosphamide (Cytoxan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposome injection (DepoCyt®), dacarbazine (DTIC-Dome®), dactinomycin D, Cosmegan, daunorubicin hydrochloride (Cerubidine®), daunorubicin citrate liposome injection (DaunoXome®), dexamethasone, docetaxel (Taxotere®), Doxorubicin hydrochloride (Adriamycin®, Rubex®), Etoposide (Vepesid®), Fludarabine phosphate (Fludara®), 5-fluorouracil (Adrucil®) , Efudex®), flutamide (Eulexin®), tezacytibine, gemcitabine (difluorodeoxycytidine), hydroxyurea (Hydrea®), idarubicin (Idamycin®), ifosfamide (IFEX®) ), irinotecan (Camptosar®), L-asparaginase (ELSPAR®), leucovorin calcium, melphalan (Alkeran®), 6-mercaptopurine (Purinethol®), Methotrexate (Folex®), Mitoxantrone (Novantrone®), Mylotarg, Paclitaxel (Taxol®), Fenix (Yttrium90 / MX-DTPA), Pentostatin, Polyfeprosan 20 Carmustine Implant (polifeprosan 20 with carmustine implant) (Gliadel®), tamoxifen citrate (Nolvadex®), teniposide (Vumon®), 6-thioguanine, thiotepa, tirapazamine (Tirazone®), Topotecan hydrochloride (Hycamptin®), vinblastine (Velban®), vincristine (Oncovin®) and vinorelbine (Navelbine®) for injection.
[0395] In one embodiment, the antibodies, antibody fragments (e.g., antigen-binding fragments) and antibody-drug conjugates of the present disclosure are combined with a second compound having anti-cancer properties in a dosing regimen as a pharmaceutical combination formulation or combination therapy. . The second compound of the pharmaceutical combination formulation or dosing regimen may have complementary activities to the combination conjugate so that they do not adversely affect each other.
[0396] The term "pharmaceutical combination" as used herein refers to a fixed combination in the form of a single dosage unit or an unfixed combination or kit of parts for combined administration, in which two or more therapeutic agents are administered at the same time. They may be administered independently or separately within a certain time interval, inter alia due to which time intervals the combination partners may exhibit a cooperative effect, for example a synergistic effect.
[0397] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat the symptoms or disorders of therapy described in this disclosure. Such administration includes co-administration of the therapeutic agents substantially simultaneously, eg, in a single capsule in which the ratio of active ingredients is fixed. Alternatively, such administration includes simultaneous administration of each active ingredient in multiple or separate containers (eg, capsules, powders, and liquids). Powders and / or liquids may be reconstituted or diluted to the desired dose prior to administration. In addition, such administration also encompasses the use of each type of therapeutic agent sequentially at about the same time or at different times. In any event, the treatment regimen will provide the beneficial effects of the drug combination in treating the symptoms or disorders described herein.
[0398] Combination therapy can provide a "synergistic effect" and is "synergistic," meaning that the effect achieved when the active ingredients are used together is greater than the effect resulting from using the compounds separately. It can be proven that the sum is greater than the sum. The active ingredients may be: (1) co-formulated and administered or delivered simultaneously in a combined, unit-dose formulation; (2) delivered simultaneously in alternating or separate formulations; or (3) in any other regimen. synergistic effects may be achieved. When delivered in alternating therapy, a synergistic effect may be achieved if the compounds are administered or delivered sequentially, eg, by different injections in separate syringes. Generally, during alternation therapy, effective dosages of each active ingredient are administered sequentially, ie, sequentially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.
[0399] In some embodiments, the present disclosure provides methods of treatment in which an antibody-drug conjugate disclosed herein is administered in combination with one or more additional therapeutic agents. Exemplary combination partners are disclosed herein.
[0400] In certain embodiments, the combinations described herein include a PD-1 inhibitor. In some embodiments, the PD-1 inhibitor is PDR001 (Novartis), nivolumab (Bristol-Myers Squibb), pembrolizumab (Merck&Co), pidilizumab (CureTech), MEDI0680 (Medimmune), REGN2810 (Regeneron), TSR-042 ( Tesaro), PF-06801591 (Pfizer), BGB-A317 (Beigene), BGB-108 (Beigene), INCSHR1210 (Incyte) or AMP-224 (Amplimmune). In some embodiments, the PD-1 inhibitor is PDR001. PDR001 is also known as Spartalizumab.
[0401] In certain embodiments, the combinations described herein include a LAG-3 inhibitor. In some embodiments, the LAG-3 inhibitor is selected from LAG525 (Novartis), BMS-986016 (Bristol-Myers Squibb) or TSR-033 (Tesaro).
[0402] In certain embodiments, the combinations described herein include a TIM-3 inhibitor. In some embodiments, the TIM-3 inhibitor is MBG453 (Novartis), TSR-022 (Tesaro), LY-3321367 (Eli Lily), Sym23 (Symphogen), BGB-A425 (Beigene), INCAGN-2390 (Agenus ), BMS-986258 (BMS), RO-7121661 (Roche) or LY-3415244 (Eli Lilly). MBG453 is also known as sabatolimab.
[0403] In certain embodiments, the combinations described herein include a PDL1 inhibitor. In one embodiment, the PDL1 inhibitor is selected from FAZ053 (Novartis), atezolizumab (Genentech), durvalumab (Astra Zeneca) or avelumab (Pfizer).
[0404] In certain embodiments, the combinations described herein include a GITR agonist. In some embodiments, the GITR agonist is GWN323 (NVS), BMS-986156, MK-4166 or MK-1248 (Merck), TRX518 (Leap Therapeutics), INCAGN1876 (Incyte / Agenus), AMG 228 (Amgen) or Selected from INBRX-110 (Inhibrx).
[0405] In some embodiments, the combinations described herein include an IAP inhibitor. In some embodiments, the IAP inhibitor comprises LCL161 or a compound disclosed in WO 2008 / 016893.
[0406] In certain embodiments, the combination includes an mTOR inhibitor, such as RAD001 (also known as everolimus).
[0407] In certain embodiments, the combination includes an HDAC inhibitor, such as LBH589. LBH589 is also known as panobinostat.
[0408] In certain embodiments, the combination includes an IL-17 inhibitor, eg, CJM112.
[0409] In certain embodiments, the combinations described herein include an estrogen receptor (ER) antagonist. In some embodiments, estrogen receptor antagonists are used in combination with PD-1 inhibitors, CDK4 / 6 inhibitors, or both. In some embodiments, the combination is used to treat ER-positive (ER+) cancer or breast cancer (eg, ER+ breast cancer).
[0410] In some embodiments, the estrogen receptor antagonist is a selective estrogen receptor degrading drug (SERD). SERD is an estrogen receptor antagonist that binds to the receptor and results in, for example, degradation or downregulation of the receptor (Boer K. et al., (2017) Therapeutic Advances in Medical Oncology 9(7):465-479) . ER, for example, is a hormone-activated transcription factor important for the growth, development, and physiology of the human reproductive system. The ER is activated, for example, by the estrogen hormone (17 beta estradiol). ER expression and signaling is associated with cancer (eg, breast cancer), such as ER-positive (ER+) breast cancer. In some embodiments, the SERD is selected from LSZ102, fulvestrant, brillanestrant, or elacestrant.
[0411] In some embodiments, the SERD comprises a compound disclosed in International Application Publication No. WO 2014 / 130310, which is incorporated herein by reference in its entirety.
[0412] In some embodiments, the SERD includes LSZ102. LSZ102 has the chemical name: (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiopen-3-yl) It has oxy)phenyl)acrylic acid. In some embodiments, the SERD is Fulvestrant (CAS Registration Number: 129453-61-8) or as disclosed in International Application No. WO 2001 / 051056, which is incorporated herein by reference in its entirety. Contains compounds that are In some embodiments, the SERD comprises elacestrant (CAS Registration Number: 722533-56-4) or a compound disclosed in US Pat. No. 7,612,114, which is incorporated by reference in its entirety. Elassestrant is RAD1901, ER-306323 or (6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5, Also known as 6,7,8-tetrahydronaphthalen-2-ol. Elcestrant is an orally bioavailable, non-steroidal combination selective estrogen receptor modulator (SERM) and SERD. Elassestrant is also disclosed, for example, in Garner F et al., (2015) Anticancer Drugs 26(9):948-56. In some embodiments, the SERD is Brylanestrant (CAS Registration Number: 1365888-06-7) or a compound disclosed in International Application Publication No. WO 2015 / 136017, which is incorporated by reference in its entirety. be.
[0413] In some embodiments, the SERD is, for example, RU58668, GW7604, AZD9496, bezedoxifene, pipendoxifene, as disclosed in McDonell et al. (2015) Journal of Medicinal Chemistry 58(12)4883-4887. selected from arzoxifene, OP-1074 or acolbifene.
[0414] Other exemplary estrogen receptor antagonists are, for example, WO 2011 / 156518, WO 2011 / 159769, WO 2012 / 037410, WO 2012 / 037411, and US Pat. No. 2012 / 0071535, all of which are incorporated herein by reference in their entirety.
[0415] In certain embodiments, the combinations described herein include an inhibitor of cyclin dependent kinase 4 or 6 (CDK4 / 6). In some embodiments, CDK4 / 6 inhibitors are used in combination with PD-1 inhibitors, estrogen receptor (ER) antagonists, or both. In some embodiments, the combination is used to treat ER-positive (ER+) cancer or breast cancer (eg, ER+ breast cancer). In some embodiments, the CDK4 / 6 inhibitor is selected from ribociclib, abemaciclib (Eli Lilly) or palbociclib.
[0416] In some embodiments, the CDK4 / 6 inhibitor is ribociclib (CAS Registration Number: 1211441-98-3) or as disclosed in U.S. Pat. Contains compounds that
[0417] In some embodiments, the CDK4 / 6 inhibitor includes the compounds disclosed in WO 2010 / 020675 and U.S. Patent Nos. 8,415,355 and 8,685,980, which Incorporated by reference in its entirety.
[0418] In some embodiments, the CDK4 / 6 inhibitor comprises ribociclib (CAS Registry Number: 1211441-98-3). Ribociclib is LEE011, KISQALI® or 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3 -d] Also known as pyrimidine-6-carboxamide.
[0419] In some embodiments, the CDK4 / 6 inhibitor comprises abemaciclib (CAS Registration Number: 1231929-97-7). Abemaciclib is LY835219 or N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl )-1H-benzimidazol-6-yl]-2-pyrimidineamine. Abemaciclib is a CDK inhibitor selective for CDK4 and CDK6 and is disclosed, for example, in Torres-Guzman R et al. (2017) Oncotarget 10.18632 / oncotarget.17778.
[0420] In some embodiments, the CDK4 / 6 inhibitor comprises palbociclib (CAS Registration Number: 571190-30-2). Palbociclib is PD-0332991, IBRANCE® or 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d ] Also known as pyrimidin-7(8H)-one. Palbociclib inhibits CDK4 with an IC50 of 11 nM and CDK6 with an IC50 of 16 nM and is disclosed, for example, in Finn et al. (2009) Breast Cancer Research 11(5):R77.
[0421] In certain embodiments, the combinations described herein include an inhibitor of chemokine (C-X-X motif) receptor 2 (CXCR2). In some embodiments, the CXCR2 inhibitor is 6-chloro-3-((3,4-dioxo-2-(pentan-3-ylamino)cyclobut-1-en-1-yl)amino)-2-hydroxy -N-methoxy-N-methylbenzenesulfonamide, danilixin, laparixin or navarixin.
[0422] In some embodiments, the CSF-1 / 1R binding agent is an inhibitor of macrophage colony stimulating factor (M-CSF), e.g., a monoclonal antibody or Fab to M-CSF (e.g., MCS110), a CSF-1R tyrosine kinase inhibitor. (e.g. 4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide or BLZ945), a receptor tyrosine kinase inhibitor (RTK) (eg pexidartinib) or an antibody targeting CSF-1R (eg emactuzumab or FPA008). In some embodiments, the CSF-1 / 1R inhibitor is BLZ945. In some embodiments, the CSF-1 / 1R binding agent is MCS110. In other embodiments, the CSF-1 / 1R binding agent is pexidartinib.
[0423] In certain embodiments, the combinations described herein include a c-MET inhibitor. c-MET, a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis. Inhibition of c-MET can induce cell death in tumor cells that overexpress c-MET protein or constitutively express activated c-MET protein. In some embodiments, the c-MET inhibitor is selected from capmatinib (INC280), JNJ-3887605, AMG337, LY2801653, MSC2156119J, crizotinib, tivantinib, or golvatinib.
[0424] In certain embodiments, the combinations described herein include a transforming growth factor beta (also known as TGF-β, TGFβ, TGFb, or TGF-beta, used interchangeably herein) inhibitor including. In some embodiments, the TGF-β inhibitor is selected from fresolimumab or XOMA089.
[0425] In certain embodiments, the combinations described herein include an adenosine A2a receptor (A2aR) antagonist (eg, an inhibitor of the A2aR pathway, eg, an adenosine inhibitor, eg, an inhibitor of A2aR or CD-73). In some embodiments, the A2aR antagonist is a PD-1 inhibitor and one or more of a CXCR2 inhibitor, a CSF-1 / 1R binder, a LAG-3 inhibitor, a GITR agonist, a c-MET inhibitor, or an IDO inhibitor (e.g., (one, three, four, five or all). In some embodiments, the combination is used to treat pancreatic cancer, colorectal cancer, gastric cancer or melanoma (eg, refractory melanoma). In some embodiments, the A2aR antagonist is PBF509 (NIR178) (Palobiofarma / Novartis), CPI444 / V81444 (Corvus / Genentech), AZD4635 / HTL-1071 (AstraZeneca / Heptares), Vipadenant (Redox / Juno), GBV- 2034 (Globavir), AB928 (Arcus Biosciences), Theophylline, Istradefylline (Kyowa Hakko Kogyo), Tozadenant / SYN-115 (Acorda), KW-6356 (Kyowa Hakko Kogyo), ST-4206 ( Leadiant Biosciences) or Preladenant / SCH 420814 (Merck / Schering). Without wishing to be bound by theory, it is believed that in some embodiments inhibition of A2aR leads to upregulation of IL-1b.
[0426] In certain embodiments, the combinations described herein include an inhibitor of indoleamine 2,3-dioxygenase (IDO) and / or tryptophan 2,3-dioxygenase (TDO). In some embodiments, the IDO inhibitor is one or more (e.g., 2, 3 (one, four or all). In some embodiments, the combination is used to treat pancreatic cancer, colorectal cancer, gastric cancer or melanoma (eg, refractory melanoma). In some embodiments, the IDO inhibitor is (4E)-4-[(3-chloro-4-fluoroanilino)-nitrosomethylidene]-1,2,5-oxadiazol-3-amine (epacadostat) (also known as INCB24360), Indoximod (NLG8189), (1-methyl-D-tryptophan), α-cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol (also known as NLG919) , indoximod, BMS-986205 (formerly F001287).
[0427] In certain embodiments, the combinations described herein include a galectin, eg, galectin-1 or galectin-3, inhibitor. In some embodiments, the combination includes a galectin-1 inhibitor and a galectin-3 inhibitor. In some embodiments, the combination includes a bispecific inhibitor (eg, a bispecific antibody molecule) that targets both galectin-1 and galectin-3. In some embodiments, galectin inhibitors are used in combination with one or more therapeutic agents described herein. In some embodiments, the galectin inhibitor is selected from anti-galectin antibody molecules, GR-MD-02 (Galectin Therapeutics), Galectin-3C (Mandal Med), Anginex or OTX-008 (OncoEthix, Merck).
[0428] In some embodiments, the combinations described herein include a MEK inhibitor. In some embodiments, the MEK inhibitor is selected from Trametinib, selumetinib, AS703026, BIX02189, BIX02188, CI-1040, PD0325901, PD98059, U0126, XL-518, G-38963 or G02443714. In some embodiments, the MEK inhibitor is telametinib.
[0429] In one embodiment, the combination described herein includes an interleukin-1 beta (IL-1β) inhibitor. In some embodiments, the IL-1β inhibitor is selected from canakinumab, gevokizumab, anakinra, or Rilonacept.
[0430] In certain embodiments, the combinations described herein include an IL-15 / IL-15Ra complex. In some embodiments, the IL-15 / IL-15Ra complex is selected from NIZ985 (Novartis), ATL-803 (Altor) or CYP0150 (Cytune).
[0431] In certain embodiments, the combinations described herein include a mouse double minute chromosome 2 homolog (MDM2) inhibitor. The human homolog of MDM2 is also known as HDM2. In some embodiments, the MDM2 inhibitors described herein are also known as HDM2 inhibitors. In some embodiments, the MDM2 inhibitor is selected from HDM201 or CGM097.
[0432] In certain embodiments, the MDM2 inhibitor is (S)-1-(4-chlorophenyl)-7-isopropoxy-6-methoxy-2- to treat a disorder, such as a disorder described herein. (4-(Methyl(((1r,4S)-4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl)methyl)amino)phenyl)-1,2-dihydroisoquinoline-3(4H)- (also known as CGM097) or the compounds disclosed in PCT Publication No. WO 2011 / 076786. In one embodiment, a therapeutic agent disclosed herein is used in combination with CGM097.
[0433] In some embodiments, the combinations described herein include a hypomethylating agent (HMA). In some embodiments, the HMA is selected from decitabine or azacitabine.
[0434] pharmaceutical composition To prepare a pharmaceutical or sterile composition comprising one or more antibodies, antibody fragments (e.g., antigen-binding fragments) or antibody-drug conjugates described herein, the provided conjugates may be may be mixed with an acceptable carrier or excipient.
[0435] Formulations of therapeutic and diagnostic agents are prepared by mixing with physiologically acceptable carriers, excipients or stabilizers, e.g. in the form of lyophilized powders, slurries, aqueous solutions, lotions or suspensions. (e.g., Hardman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y., 2001; Gennaro, Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York ,N.Y.,2000;Avis,et al.(eds.),Pharmaceutical Dosage Forms:Parental Medications,Marcel Dekker,NY,1993;Lieberman,et al.(eds.),Pharmaceutical Dosage Forms:Tablets,Marcel Dekker,NY, 1990; see Lieberman, et al. (eds.) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY, 1990; Weiner and Kotkoskie, Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, N.Y., 2000).
[0436] In some embodiments, a pharmaceutical composition comprising an antibody, antibody fragment (eg, antigen-binding fragment), or antibody drug conjugate of the present disclosure is a lyophilized preparation. In certain embodiments, a pharmaceutical composition comprising an antibody, antibody fragment (e.g., antigen-binding fragment), or antibody-drug conjugate is provided in a vial containing the antibody, antibody fragment (e.g., antigen-binding fragment), or antibody-drug conjugate. It is a freeze-dried product. Lyophilized products can be reconstituted for injection, eg, with water, saline. For intravenous administration, the resulting solution can be further diluted in a carrier solution.
[0437] The choice of dosing regimen for a therapeutic agent depends on several factors, including the entity's serum or tissue turnover rate, the level of disease symptoms, the immunogenicity of the entity, and the accessibility of target cells within the biological matrix. . In certain embodiments, the dosing regimen maximizes the amount of therapeutic agent delivered to the patient with acceptable levels of side effects. Accordingly, the amount of biologic delivered will depend in part on the particular entity and severity of the condition being treated. Guidance on selecting appropriate doses of antibodies, cytokines and small molecules is available (e.g. Wawrzynczak, Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK, 1996; Kresina (ed.), Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, N.Y., 1991; Bach (ed.), Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, N.Y., 1993; Baert et al., New Engl. J. Med. 348 :601-608,2003;Milgrom et al.,New Engl.J.Med.341:1966-1973,1999;Slamon et al.,New Engl.J.Med.344:783-792,2001;Beniaminovitz et al .,New Engl.J.Med.342:613-619,2000;Ghosh et al.,New Engl.J.Med.348:24-32,2003;Lipsky et al.,New Engl.J.Med.343 :1594-1602,2000).
[0438] Determination of the appropriate dose may be determined by the clinician using, for example, parameters or factors known in the art or inferred that affect or are expected to affect the treatment. It will be done. Usually, the dose is started somewhat below the optimum dose and then increased in small increments to account for any negative side effects until the desired or optimal effect is achieved. Important diagnostic measures include, for example, measures of disease symptoms of inflammation or levels of inflammatory cytokines produced.
[0439] The actual dosage level of the active ingredients in the pharmaceutical compositions of the present disclosure will be determined to be effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration without being toxic to the patient. The amounts of ingredients may vary to obtain. The selected dosage level will depend on the activity of the particular composition of the present disclosure employed, the route of administration, the time of administration, the rate of excretion of the particular compound to be employed, the duration of treatment, the particular Other drugs, compounds and / or materials used in combination with the composition, the age, sex, weight, symptoms, health condition and previous medical history of the patient to be treated and as known in the medical art. It will depend on various pharmacokinetic factors, including:
[0440] The antibodies, antibody fragments (e.g., antigen-binding fragments), or antibody-drug conjugates disclosed herein can be administered in continuous flow or, for example, daily, at weekly intervals, or from 1 to 7 times per week, biweekly, 3 times per week, etc. It may be provided in doses of once every week, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks or once every 8 weeks. Doses may be provided intravenously, subcutaneously or intraosseously. Specific dosing protocols include maximum doses or dosing frequencies that avoid major undesirable side effects.
[0441] For antibodies, antibody fragments (eg, antigen-binding fragments), or antibody-drug conjugates of the present disclosure, the dosage administered to a patient can be from 0.0001 mg / kg to 100 mg / kg of patient body weight. The dosage is 0.001mg / kg of patient body weight~50mg / kg, 0.005mg / kg~20mg / kg, 0.01mg / kg~20mg / kg, 0.02mg / kg~10mg / kg, 0.05~5mg / kg, 0.1 It can be mg / kg~10mg / kg, 0.1mg / kg~8mg / kg, 0.1mg / kg~5mg / kg, 0.1mg / kg~2mg / kg, 0.1mg / kg~1mg / kg. Dosages of antibodies, antibody fragments (eg, antigen-binding fragments), or antibody-drug conjugates can be calculated by multiplying the patient's body weight in kilograms (kg) by the dose in mg / kg to be administered.
[0442] Dosing of the antibodies, antibody fragments (e.g., antigen-binding fragments) or antibody-drug conjugates of the present disclosure may be repeated, with administrations administered for less than 1 day, at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days. It can be separated by days, 30 days, 45 days, 2 months, 75 days, 3 months, 4 months, 5 months or at least 6 months. In some embodiments, the antibodies, antibody fragments (e.g., antigen-binding fragments) or antibody-drug conjugates of the present disclosure are administered twice a week, once a week, once every two weeks, once every three weeks. once every 4 weeks or less frequently.
[0443] The effective amount for a particular patient may vary depending on factors such as the condition being treated, the patient's overall health, the method, route, and dose of administration, and the severity of side effects (e.g., Maynard et al. (See Dent, Good Laboratory and Good Clinical Practice, Urch Publ., London, UK, 2001).
[0444] Routes of administration include, for example, by topical or cutaneous application, subcutaneous or subcutaneous injection, intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, intracerebrospinal, intralesional administration, or by sustained release. systems or implants (e.g., Sidman et al., Biopolymers 22:547-556, 1983; Langer et al., J. Biomed. Mater. Res. 15:167-277, 1981; Langer, Chem. Tech.12:98-105,1982;Epstein et al.,Proc.Natl.Acad.Sci.USA 82:3688-3692,1985;Hwang et al.,Proc.Natl.Acad.Sci.USA 77:4030- 4034,1980; see U.S. Pat. No. 6,350,466 and U.S. Pat. No. 6,316,024). Where necessary, the composition can include a solubilizing agent or a local anesthetic, such as lidocaine to ease pain at the site of the injection, or both. In addition, pulmonary administration may also be used, eg, by use of an inhaler or nebulizer and formulation with an aerosolizing agent. For example, U.S. Patent No. 6,019,968, U.S. Patent No. 5,985,320, U.S. Patent No. 5,985,309, U.S. Patent No. 5,934,272, U.S. Patent No. 5,874,064, U.S. Patent No. 5,855,913, US Patent No. 5,290,540 and US Patent No. 4,880,078; and WO 92 / 19244 pamphlet, WO 97 / 32572 pamphlet, WO 97 / 44013 pamphlet, WO 98 / 31346 and WO 99 / 66903, each of which is incorporated herein by reference in its entirety.
[0445] Methods of co-administration or co-treatment with second therapeutic agents, such as cytokines, steroids, chemotherapeutics, antibiotics, or radiation (e.g., total body irradiation (TBI)) are known in the art (e.g., Hardman et al. al.,(eds.)(2001)Goodman and Gilman's The Pharmacological Basis of Therapeutics,10.sup.th ed., McGraw-Hill,New York,N.Y.;Poole and Peterson (eds.)(2001)Pharmacotherapeutics for Advanced Practice : A Practical Approach, Lippincott, Williams & Wilkins, Phila., Pa.; see Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., Pa.). An effective amount of the therapeutic agent may reduce disease symptoms by at least 10%; at least 20%; at least about 30%; at least 40% or at least 50%.
[0446] Additional treatments that may be administered in combination with the antibodies, antibody fragments (e.g., antigen-binding fragments) or antibody-drug conjugates of the present disclosure may include less than a minute away, less than 30 minutes apart, 1 hour apart, about 1 hour apart, about 1 to about 2 hours apart, about 2 hours to about 3 hours apart, about 3 hours to about 4 hours apart , about 4 hours to about 5 hours away, about 5 hours to about 6 hours away, about 6 hours to about 7 hours away, about 7 hours to about 8 hours away, about 8 hours to about 9 hours away , about 9 hours to about 10 hours away, about 10 hours to about 11 hours away, about 11 hours to about 12 hours away, about 12 hours to 18 hours away, 18 hours to 24 hours away, 24 hours away ~36 hours away, 36 hours ~ 48 hours away, 48 hours ~ 52 hours away, 52 hours ~ 60 hours away, 60 hours ~ 72 hours away, 72 hours ~ 84 hours away, 84 hours ~ 96 hours away Can be administered hours apart or 96 hours to 120 hours apart. Two or more treatments may be administered during the same patient visit.
[0447] The present disclosure provides protocols for the administration of pharmaceutical compositions, including antibodies, antibody fragments (e.g., antigen-binding fragments), or antibody-drug conjugates, alone or in combination with other treatments, to a subject in need thereof. Provide administration protocols. The combination therapy disclosed herein can be administered to a subject simultaneously or sequentially. The combination therapy of the present disclosure may also be administered periodically. Cycling treatment involves administering a first treatment for a period of time, followed by a second treatment for a period of time, and repeating this sequential application (i.e., a cycle) to develop resistance to one of the treatments (e.g., an agent). This includes reducing expression to avoid or alleviate one side effect of a treatment (eg, an agent) and / or to improve the effectiveness of the treatment.
[0448] Combination therapy treatments disclosed herein may be administered to a subject simultaneously.
[0449] The term "simultaneously" is not limited to administering the treatments at exactly the same time, but rather refers to the application of the antibodies, antibody fragments (e.g., antigen-binding fragments) and antibody-drug conjugates in conjunction with the other treatments that would normally be administered. Pharmaceutical compositions comprising the antibodies, antibody fragments (e.g., antigen-binding fragments), and antibody-drug conjugates disclosed herein are administered to a subject in an order and within a time interval such that the benefit is increased over the administration of the pharmaceutical compositions disclosed herein. means to be For example, each therapy may be administered to a subject sequentially in any order at the same time or at different times; however, if not at the same time, they should be administered sufficiently close in time to produce the desired therapeutic effect. Each therapy may be administered to the subject separately, in any suitable form, and by any suitable route. In various embodiments, the treatments occur less than 5 minutes apart, less than 15 minutes apart, less than 30 minutes apart, less than 1 hour apart, about 1 hour apart, about 1 hour to about 2 hours apart, about 2 hours to about 3 hours away, about 3 hours to about 4 hours away, about 4 hours to about 5 hours away, about 5 hours to about 6 hours away, about 6 hours to about 7 hours away, about 7 hours to about 8 hours away, about 8 hours to about 9 hours away, about 9 hours to about 10 hours away, about 10 hours to about 11 hours away, about 11 hours to about 12 hours away, 24 hours away Subjects are administered hours apart, 48 hours apart, 72 hours apart or one week apart. In other embodiments, two or more treatments are administered during the same patient visit.
[0450] Combination therapy may be administered to a subject with the same pharmaceutical composition. Alternatively, the therapeutic agents of a combination therapy may be administered to a subject simultaneously in separate pharmaceutical compositions. The therapeutic agents may be administered to a subject by the same route of administration or by different routes of administration.
[0451] The examples and embodiments described herein are for illustrative purposes only; various modifications or changes in light of the same will suggest themselves to those skilled in the art, and are intended to be understood by those skilled in the art. It is understood that it may be included within the spirit and scope of the claims.
Example
[0452] Example 1: Generation of anti-CD48 antibodies Generation of expression constructs for human CD48-mouse IgG1 fusion protein as immunogen Human CD48 was amplified from the commercially available vector "Trueclone, CD48 (untagged)-human CD48 molecule" (Origene, NM_001778.2). The amplified DNA fragments were cloned into appropriate expression vectors.
[0453] HEK293T cells were plated at 1 6 Cells / well were seeded. The next day, for each well, dilute 3 μg of DNA construct separately in 150 μL Opti-MEM (Gibco, 31985070) and add 12 μL Lipofectamine™ 2000 (Thermofischer Scientific, 1051561) in 150 μL Opti-MEM. did. Diluted DNA was added to each corresponding tube of diluted Lipofectamine™ 2000 transfection reagent and incubated for 5 minutes at RT. Add 250 μL of DNA / Lipofectamine™ 2000 reagent complex per well and incubate at 37°C, 5% CO. 2 and incubated for 6 hours in culture medium. After 6 hours, the culture medium was replaced with pre-warmed DMEM + 10% FBS and the cells were incubated at 37°C, 5% CO. 2 and further incubated for 72 hours.
[0454] Human CD48-mouse IgG recombinant protein was purified using "Serum Antibody Purification Kit-Protein G" (Abcam #ab128751). Conditioned medium was mixed with binding buffer and incubated with protein G resin for 2 hours at RT before loading onto the column, according to the supplier's recommendations. The column was washed to remove unbound protein and the huCD48-mouse IgG protein was eluted at low pH and immediately neutralized. The presence of protein in the eluted fractions was confirmed by determination of A280 OD. The eluted fractions were desalted, pooled, and concentrated using an Amicon Ultra-15 centrifugal filter device (30K). Quantification of purified protein was performed by anti-mouse IgG ELISA.
[0455] Expression of recombinant human and cynomolgus monkey CD48 proteins Human and cynomolgus proteins were gene synthesized (GeneArt, Switzerland) based on amino acid sequences (see Table 5). All synthesized DNA fragments were cloned into appropriate expression vectors with different C-terminal tags (hFc1P, APP6-Avi, His) to allow purification and labeling.
[0456] [Table 22]
[0457] HEK293T cells were cultured at 1 6 Cells / well were seeded. The next day, for each well, 2 μg of DNA construct was diluted separately in 100 μL Opti-MEM (Gibco, 31985070) and 7 μL FuGENE HD (Promega, 104810) was added. The mixture was incubated for 15 minutes at room temperature and added to the cells. Place the plate at 37°C, 5% CO 2 and incubated for 72 hours in culture medium.
[0458] Human and cynomolgus monkey CD48-huIgG-Fc and APP-tagged recombinant proteins were purified by anti-APP or protein-A columns. The column was washed and equilibrated to remove unbound protein with PBS, pH 7.4. Bound proteins were eluted with 0.1 M glycine, pH 2.7 and immediately neutralized. Protein concentration was determined by A280 OD measurements.
[0459] Cell lines overexpressing human and cynomolgus monkey CD48 proteins CHO and 300.19 cells were engineered to express human CD48 in combination with the GFP marker. HKB11 cells were transfected with either human or cynomolgus CD48 expression vectors. For CHO and 300.19 cell lines, the CD48-EGFP encoding expression plasmid was facilitated by applying Amaxa 4D Nucleofection. 2.5×10 per sample 5 Cells were suspended in 20 μL of 4D Nucleofector™ solution (Lonza, V4XC-9064), DNA was added, and placed into cuvettes. After electroporation, cuvettes were incubated for 10 minutes at room temperature. Cells were suspended in pre-warmed culture medium (RPMI 1640, (Gibco, 72400-021), 10% FBS (Gibco, 16000044), penicillin-streptomycin (Gibco, 15140122) and 2-mercaptoethanol (Gibco, 31350010). Humidified at 37℃ / 5%CO 2 Incubated in an incubator. For selection, G418 (Gibco, 10131-027) was added at a final concentration of 1 mg / ml. After staining the cells with a fluorescently labeled anti-human CD48 antibody, non-transfected 300.19, which served as a CD48 negative control cell, or loan CD48A-PE (PE-labeled antibody from Molecular Probes, A15768) applied to CHO cells, the cell pool was Analyzed by flow cytometry. For both cell lines, one pool was identified that showed high and uniform expression of the respective target proteins. Vials of this pool were frozen and the stability of recombinant CD48 overexpression was confirmed after culturing in G418-containing culture medium for 2 weeks.
[0460] For overexpressing HKB11 cell line, human full-length CD48 was gene synthesized based on the amino acid sequence from Uniprot database. A sequence encoding full-length cynomolgus monkey CD48 was gene synthesized using mRNA isolated from various cynomolgus monkey tissues based on the generated amino acid sequence information. All sequences were synthesized by GenArt (Switzerland). To engineer the HKB11 cell line, the synthesized DNA fragment was cloned into the pD2529-CMVa Leap-In transposon vector (Atum, Newark / CA, USA). HKB11 (ATCC, CRL-12568) cells were transfected three times using JetMessenger transfection reagent (Polyplus, 150-07). The transposon vector was co-transfected into cells with mRNA encoding the Leap-In transposase enzyme (Atum, Newark / CA, USA). Transfected cells were cultured in culture medium in the presence of the antibiotic puromycin for 4 weeks to select for stable transfected cells. After staining the cells with an anti-CD48 primary antibody (CD48A) and a fluorescently labeled secondary antibody, the cell pool was analyzed by flow cytometry with non-transfected HKB11 cells serving as CD48 negative control cells. For both human and cynomolgus monkey CD48, we identified pools showing high and uniform expression of each target protein. Vials of this pool were frozen to confirm the stability of recombinant CD48 overexpression after two weeks of continuous culture of cells in puromycin-containing cell culture medium.
[0461] All synthesized DNA fragments were cloned into pD2529-CMVa Leap-In transposon vector (Atum, Newark / CA, USA). HKB11 (ATCC, CRL-12568) cells were transfected three times using JetMessenger transfection reagent. The transposon vector was co-transfected into cells with mRNA encoding the Leap-In transposase enzyme (Atum, Newark / CA, USA). Transfected cells were cultured for 4 weeks in the presence of the antibiotic puromycin in culture medium to select stably transfected cells. After staining the cells with an anti-CD48 primary antibody (MEM-102, PE-labeled, Molecular Probes, A15768) and a fluorescently labeled secondary antibody, cells were isolated using non-transfected HBK11 cells, which served as CD48 negative control cells. Pools were analyzed by flow cytometry. One pool was identified for both human and cynomolgus CD48 that showed high and uniform expression of each target protein. Vials of this pool were frozen to confirm the stability of recombinant CD48 overexpression after two weeks of continuous culture of cells in puromycin-containing cell culture medium.
[0462] [Table 23]
[0463] Culture of Raji and U266 cell lines expressing CD48 Raji, ATCC(R) CCL-86(TM) and U266 ATCC(R) TIB-196(TM), which highly express CD48, were treated with 10% FCS (Gibco, 16000-044), 10mM HEPES (Gibco, 15630080) and Glutamax (Gibco, 11835-063) supplemented with penicillin / streptomycin (Gibco, 15140-122) in RPMI with 5% CO at 37°C. 2 and grown under well-humidified conditions. Expression of CD48 was highly variable in Raji cells. Cells were stained with α-CD48-PE (Invitrogen A-15768) and α-CD45-APC (BD Pharmingen, 555485). Cells highly expressing CD48 were sorted by FACS ARIA and then incubated at 37°C with 5% CO at different low and high seeding concentrations in the medium described above supplemented with ZellShield, Minerva Biolabs 13-0150. 2 and cultured as Raji-CD48high under sufficiently humidified conditions. After expansion, Raji CD48high+ cells seeded at both low and high density showed equally high CD48 expression.
[0464] Immunization of mice and generation of hybridomas Antigen solutions were prepared in PBS. For recombinant human CD48 (R&D, 3644-CD-050) it was 125 μg / ml and for cell lines it was 200 × 10 6 cells / ml. BALB / c and Biozzi ABH / RjiHSD mice, 3 male and 3 female, respectively, were primed with antigen in either recombinant human CD48 (R&D, 3644-CD-050), Raji or U266 cells. , boosted twice. Four mice were selected for fusion. Spleens not used for fusion were frozen as single cell suspensions.
[0465] Hybridoma screening by measuring serum antibodies and ELISA For titration, F96 cent Maxisorp Nunc immunoplates (Thermo Scientific, 439454) were coated with recombinant human CD48 at 1 μg / ml in 100 μl / well in coating buffer (Biolegend, 421701) overnight at 4°C. Incubated. Murine α-human CD48 antibody, clone MEM-102 (Invitrogen, MA-19119S) (also referred to herein as “CD48A”) and mouse α-human CD48, clone 156-4H9 (eBioscience, 16-0489- (85) was applied as a calibrator and diluted in assay diluent (PBS with 2% FCS and 0.05% Tween20) to 1000 ng / ml. A 1:3 serial dilution step was performed down to 1.37ng / ml. No antibody was used as background in coated wells. To exclude non-specific effects, wells without protein coating containing antibody dilutions served as negative controls. For hybridoma screening, supernatants were diluted 1:10. For each calibrator concentration and mouse serum or hybridoma supernatant dilution, 100 μl / well was applied in duplicate. Plates were incubated for 1 hour at 37°C on an orbital shaker at 300x rpm.
[0466] After incubation, the plates were gently swirled to remove the supernatant and each well was washed five times with 300 μl wash buffer. The secondary antibody goat α-mouse IgG (H+L) HRP (Invitrogen, 31430) was diluted 1:10000 in assay diluent and 100 μl was applied to each well. Plates were incubated for 1 hour at RT on an orbital shaker at 300× rpm. Again, the plate was gently swirled to remove the supernatant and each well was washed seven times with 300 μl wash buffer. The detection reaction was started by adding 100 μl of substrate solution (Life Technology, 002023) to each well. Plates were incubated for 15-30 minutes in the dark at RT without agitation. Depending on the rate of color development, the assay was stopped by adding 100 μl / well of stop solution (Life Technology, SS04). Within 30 minutes of stopping the reaction, absorbance was read at 450 nm and 570 nm using SpectraMax.
[0467] Measurement of serum antibodies and hybridoma screening by FACS All sera were analyzed for their specificity for native CD48 protein by incubation with the cell lines used for immunization, RajiCD48high+ and U266, and FACS analysis. The CD48 negative T cell line CEM (ATCC, CCL-119™) served as a control. 1 μl of undiluted serum, 1:10 diluted serum and 1:100 diluted serum from each mouse was diluted in FACS buffer (AutoMACS Rinse Buffer, Milteny; 130-091-222 and 1:20). 0.5 × 10 in BSA stock solution; Milteny; 130-091-376) 6 Cells / well were incubated with corresponding cell lines on ice for 30 minutes. After incubation, samples were washed twice with FACS buffer and stained with secondary antibody α-mouse IgG-FITC; BD Pharmingen, 554001 (diluted 1:50 in FACS buffer) and incubated on ice in the dark for 30 min. did. After incubation, cells were washed twice with FACS buffer, cell pellets were suspended in FACS buffer and measured on a FACS CANTO II.
[0468] For hybridoma screening, 1.5 x 10 5 300-19WT and 0.5×10 5 huCD48 GFP transfectant was applied. Cells were suspended in 100 μl of hybridoma supernatant (pure or diluted 1:10). As a control, 0.2 μl / well of unlabeled CD48A (MEM-102, Invitrogen, A-15768) was applied and detection was performed using 0.1 μl / well of anti-mouse IgG APC (BD Bioscience, 550826).
[0469] Generation of hybridomas A single cell solution of the spleen of CD48-immunized mice was prepared. HAT medium (Glutamax and 25mM HEPES, 50μM β-mercaptoethanol, 100μM hypoxanthine, 400nM aminopterin, 16μM thymidine) containing 50μl feeder cell layer of mouse peritoneal cells (BALB / c, Request ID107701). Fusions were performed with PEG Hybrimax solution (Sigma, P7181) and cells plated on 96-well plates in RPMI 1640 containing 10% ultra-low IgG FCS and 100 μg / ml normocin (100 ml / well). . The fused cells were grown at three different concentrations: 10 x 10 4 , 3×10 4 and 5×10 3 Cells / well were seeded.
[0470] Screening was started on day 13 after fusion by adapting ELISA and FACS. On day 15, HAT medium was replaced with HT medium without aminopterin.
[0471] ELISA and FACS positive clones were cultured in feeder-free cloning and growth medium (Glutamax and 25mM HEPES, 10% ultra-low IgG FCS, 50μM β-mercaptoethanol, 100μg / ml normosin, HT supplement (Gibco, 41056-012) and Prepared H1 hybridoma cloning supplement; subcloned into RPMI 1640 containing Roche Diagnostics 11088947001), adjusted to a cell concentration of 2.5 cells / ml, and plated on two 96-well plates for each hybrid.
[0472] Cloning of selected hybridoma clones RNA isolation of hybridoma cells on pellets was performed using the RNeasy Mini Kit according to the manufacturer's protocol (Qiagen, 74104). RNA yield was determined using NanoDrop (Thermo Fischer).
[0473] RNA was converted to cDNA using the Superscript III First-Strand Synthesis System for RT PCR (180880-051) from LifeTechnologies according to the manufacturer's instructions. Amplification of the synthesized cDNA was performed applying the mouse Ig-primer set (69831-3) from Novagen and Taq polymerase (K0171) from Fermentas according to the manufacturer's instructions. 25 μl of PCR reactions were analyzed on a 1.2% agarose gel and stained with ethidium bromide. The band was excised with a scalpel and gel extraction of DNA was performed using the QIAquick Gel Extraction kit (28704) from Qiagen according to the manufacturer's protocol. The extracted DNA was used for PCR cloning using the PCR cloning kit from Qiagen (231122) according to the manufacturer's instructions, and the final plasmid product was transformed into TOP10 chemically competent cells (Invitrogen, C-404010). Used for conversion. Transformed cells were spread on LB-kanamycin plates (Invitrogen, R-0402) treated with X-gal. Cells transformed with the pDrive cloning vector containing no PCR product express LacZ α-peptide and form blue colonies when grown in the presence of X-gal. Therefore, only white colonies were picked and cultured for plasmid preparation using the QIAprep Spin Miniprep Kit (Qiagen 27106) according to the manufacturer's protocol.
[0474] Transfection of HEK cells for antibody expression and purification was performed as described for the generation of CD48 immunogen.
[0475] Generation of humanized sequences DNA sequences encoding humanized VL and VH domains, including codon optimization for humans (Homo sapiens), were ordered at GeneArt (Life Technologies Inc. Zug, Switzerland). Sequences encoding the VL and VH domains were subcloned by cutting and pasting from the GeneArt-derived vector into an expression vector suitable for secretion in mammalian cells. Heavy and light chains were cloned into separate expression vectors to allow co-transfection. The elements of the expression vector include a promoter (cytomegalovirus (CMV) enhancer-promoter), a single sequence to facilitate secretion, a polyadenylation signal and a transcription terminator (bovine growth hormone (BGH) gene), episomal replication and prokaryotic It contains elements that allow replication in the organism (eg those of SV40 origin and ColE1 or others known in the art) and elements to allow selection (ampicillin resistance gene).
[0476] Antibody expression and purification CAP-T® cells (human amniotic cells; CEVEC Pharmaceuticals GmbH, Cologne, Germany) were cultured using 40 kDa linear PEI (PEI Max, Polysciences, VWR, POLS24765-2) as the gene delivery vehicle. Transiently transfected with appropriate heavy and light chain expression plasmids in FreeStyle293™ expression medium (Invitrogen, 12338).
[0477] Briefly, 30ug of light and heavy chain plasmid DNA in 1ml of OptiMEM medium (Invitrogen, 51985) was added dropwise to a 250ml shake flask containing 1E+8 cells in 18ml of FreeStyle medium, followed by 1 ml of Pei Max solution was added while shaking. The flask was then heated at 37°C and 6% CO at 100 rpm. 2 , and incubated for 4 hours at 85% humidity. This was followed by 20ml of pre-warmed protein expression medium (PEM, Invitrogen, 12661) containing 4mM L-glutamine and 5ug / ml blasticidin (Invitrogen R21001) and valproic acid (Sigma-Aldrich) to a final concentration of 4mM. , P4543) was added to the culture. Cell culture at 37°C, 6% CO 2 , 85% humidity and 115 rpm for 7 days.
[0478] The supernatant was filtered with a Steri-Flip and the antibody was purified using a Tecan robot MabSelect Sure on 200 μl resin. Briefly, the column was washed with 10 volumes of water and PBS (Novartis). The sample was loaded and washed again with 10 times the volume of water. Antibody elution was performed with 3 volumes of 50 mM citrate, 70 mM NaCl pH 3.2, followed by neutralization with 140 μl of 1M Tris pH 9.0 and filtration through a 0.22 μm membrane (Millipore Steriflip).
[0479] For concentration determination, antibodies were measured on a spectrophotometer ND-1000 (NanoDrop) at 280 nm and protein concentration was calculated based on sequence data. The eluent was tested for aggregation (SEC-MALS).
[0480] Antibodies panned from Novartis' Pallas phage library A synthetic human Fab phagemid library (Novartis Institutes for BioMedical Research) was used for phage display selection. Gene fragments encoding the germline framework combinations IGHV3-23 and IGKV1-39, IGHV3-23 and IGLV3-9, IGHV1-46 and IGKV1-39, IGHV3-15 and IGLV1-47 were generated in Fab format by GeneArt (Life Technologies Inc. (Zug, Switzerland) and cloned into a phagemid vector that served as the base template. These human germlines were used as the preferred display framework combination for the phage display library. The phagemid vector contains OmpA-light chain followed by phoA-heavy chain-Flag-6×His (SEQ ID NO: 84)-Amber, along with ampicillin resistance, CilE1 origin of replication, M13 origin of replication and a bicistronic expression cassette under the lac promoter. Consists of stop-truncated pIII (amino acids 231-406).
[0481] HCDR3 is only diversified and primed with up to 11 amino acids in defined ratios that mimic their natural occurrence: aspartic acid, glutamic acid, arginine, histidine, serine, glycine, alanine, proline, valine, tyrosine and tryptophan. designed to incorporate. Leucine and phenylalanine were also tolerated at specific positions in HCDR3. Certain residues were omitted to remove potential post-translational modification sites. Randomized primer synthesis was performed using Trinucleotide technology (ELLA Biotech) to exclude stop codons, methionine, cysteine and asparagine.
[0482] Lengths of 8, 10, 12, 14, 16-20 amino acids are allowed, with at least 2 amino acids constant in the sequence Asp-Tyr for lengths 8-16 and Asp-Val for length 20. was kept. The final two HCDR3 amino acid designs reflect human VDJ recombination. Shorter HCDR3s use J-fragment IGHJ4 with "DY" at the end of HCDR3 more frequently, while longer HCDR3s (here, 20 aa) use IGHJ6 with "DV" at the end of HCDR3 more frequently. Use frequently. Library inserts were generated by PCR using Phusion High-Fidelity DNA polymerase (NEB Biolabs). The resulting HCDR3 library inserts were ligated to the base template and transformed into E. coli TG1F+DUO (Lucigen) with a minimum library size of 3E+08 transformants per HCDR3 length. Phage were generated using VCSM13 helper phage (Agilent Technologies) using a standard protocol.
[0483] Whole cell panning was used for isolation of antibodies that recognize human CD48. The phage library was blocked in 1 ml PBS / 5% FBS (Gibco, 16000044) for 2 hours at room temperature, followed by addition of 1E+07 CHO wild type cells. The mixture was incubated overnight at 4°C, 30 rpm, followed by centrifugation at 300g for 5 min at 4°C. The preadsorbed phage supernatant was added to target cells.
[0484] CHO wild-type cells and human CD48 overexpressing cells were labeled with different fluorescent dyes (Vibrant Cell-Labeling solution, Invitrogen, #V22885, #V22886, #V22887) and mixed at different ratios. Panning proceeded for 4 hours at 4°C on a rotor. Cells were washed three times in 5 ml of 5% FBS / PBS and centrifuged at 300 g at 4°C. Cells were suspended in FACS buffer (PBS, 0.5% FBS) and filtered into FACS tubes. Cells were FACS sorted on a BD Aria II according to color into two tubes - WT CHO and CD48+CHO cells.
[0485] To elute bound phages, the cell pellet was suspended in 1 ml of 100 mM Glycine-HCl, 500 mM NaCl pH 2.2 (GE Healthcare, BR-1003-55). After incubating for 10 min at room temperature and centrifuging at 300 g for 2 min, the eluted phages (supernatant) were transferred to a new tube containing 110 μl of 1M Tris pH8 (Fluka, 93350) for neutralization.
[0486] The eluted phages were used to infect exponentially growing amber suppressor TG1F+ cells (Lubio Science). Infected bacteria were treated with 2YT (16 g / l bactotryptone; Becton-Dickinson 211699, 10 g / l bactoyeast extract; Becton-Dickinson 212720), 5 g / l NaCl; Merck 6404), 100 μg / ml ampicillin (Sigma, A0166) and 1% glucose (Sigma, G8270) medium at 37°C and 200 rpm and superinfected with VCSM13 helper phage.
[0487] The superinfected bacteria were then incubated at 22°C in 2YT / ampicillin / kanamycin (Calbiochem, 420411) medium containing 0.25 mM isopropyl b-D-1 thiogalactopyranoside (IPTG, Roche, 11 411 446 001). The production of phage particles was induced by overnight incubation at 180 rpm. Phage-containing supernatants from overnight cultures were purified by PEG / NaCl precipitation, titrated, and selected for the next round.
[0488] Recovery of enriched antibody sequences by NGS screening After each round of phage selection, polyclonal plasmid DNA of the recovered binders for wild-type and CD48-expressing CHO cells was prepared using the QIAprep Spin Miniprep kit (Qiagen). In the first PCR, CDR-H3 was amplified over nine cycles using overhanging primers that allowed annealing of standard TruSeq primers in successive steps. In the second PCR, primers with a TruSeq universal forward adapter and one or more of the 24 TrueSeq index reverse primers were used for 12 cycles. The resulting fragment was purified using a 1.5% agarose gel and Wizard SV Gel and PCR cleanup system (Promega, A9282). DNA concentration was measured using the Qubit DNA High sensitivity kit (Invitrogen, Q32B54). Samples were analyzed on MiSeq using MiSeq Reagent 5 Kit v3 (Illumina) with 150 forward cycles.
[0489] Data analysis of NGS FastQ output files was performed as described (Liu et al, 2019, BMC Bioinformatics, 20,401.). For each panning output, 100,000 sequences were analyzed to find and segment HCDR3 sequences using fixed flanking sequences at the boundaries of the variable regions as templates. Approximately 40,000-70,000 HCDR3 sequences were identified depending on the panning output pool and included in frequency reports in CSV format. Regarding antibody expression, clones with an appearance rate of more than 2% were selected.
[0490] Phage affinity maturation and hybridoma-derived / humanized antibodies The Pallas selected antibody NOV3731 was further engineered in Fab format to improve affinity by using an affinity maturation cassette library with diversification in HCDR1, HCDR2 and all light chain CDRs. The CDRs were diversified according to the naturally occurring repertoire of rearranged human CDR sequences. Primers to incorporate the amino acids of each heavy and light chain CDR in defined ratios that mimic the naturally occurring aspartate, glutamate, arginine, histidine, threonine, serine, glycine, alanine, leucine, valine and tyrosine. Designed. Glutamine, proline and tryptophan were also tolerated at specific positions in LCDR3.
[0491] For the CDR mutation cassette, randomized primer synthesis was performed using Trinucleotide technology (ELLA Biotech) to exclude stop codons, methionine, cysteine and asparagine. CDR randomization was performed by two-step PCR using Phusion High-Fidelity DNA polymerase (NEB Biolabs). First, a randomized PCR was performed, followed by applying primers that introduced restriction sites at both ends to amplify the randomized fragment. This amplified PCR was then ligated into the base template phagemid vector using appropriate restriction sites and transformed into E. coli TG1F+DUO (Lucigen) using a minimum library size of 1E+08 transformants. transformed into.
[0492] Heavy and light chain CDR-specific affinity mutation libraries were restricted with relevant enzymes and individually cloned into parent antibodies replacing the parent CDRs with randomized cassettes of diverse sequences. The library was transformed into TG1F+ competent cells (Invitrogen). Phage particles were generated by superinfection with VCSM13 helper phage and subsequent precipitation with PEG / NaCl.
[0493] The hybridoma-derived, humanized antibody NY258 was further engineered in Fab format by generating NNK libraries against LCDR1 and LCDR3 and HCDR1, HCDR2 and HCDR3. The amplified library was cloned into a phagemid vector via appropriate restriction sites and transformed into E. coli TG1F+DUO (Lucigen) using a minimum library size of 1E+08 transformants. did. Phage particles were generated by superinfection with VCSM13 helper phage and subsequent precipitation with PEG / NaCl.
[0494] These five affinity mutation libraries for each candidate, NOV3731 and NY258, were subjected to two rounds of solid phase analysis against recombinant human (Acrobiosystems, BC1-H5255) and cynomolgus monkey (in-house iProt 112617) CD48-huIgG-FC. It was panned. 5 x 10 per library 9 Phages were blocked overnight in 2.5% milk powder (PanReac AppliChem, A0830), 0.05% Tween (Sigma, P9416) in PBS in a volume of 500 μL. A 96-well Maxisorb plate (Nunc, 442404) was coated with 300 uL of irrelevant FC protein (5 ug / ml in PBS). Plates were washed three times with 300 μL of PBS and the blocked phage library was incubated at 250 μL / well for 30 minutes at room temperature with rocking to pread...
Claims
1. An anti-CD48 antibody or antigen-binding fragment, comprising the following three heavy chain CDRs and three light chain CDRs: (i) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 1, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (ii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 4, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (iii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO:5, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO:6, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO:3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO:19, a light chain CDR2 (LCDR2) consisting of SEQ ID NO:20, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:21; (iv) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 7, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 8, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 9; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 22, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 20, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (v) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO:27, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO:28, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO:29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO:42, a light chain CDR2 (LCDR2) consisting of SEQ ID NO:43, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:44; (vi) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 30, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 28, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 42, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 43, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 44; (vii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 31, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 32, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 45, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 47; or (viii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 33, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 34, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 35; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 48, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:
44. The anti-CD48 antibody or antigen-binding fragment thereof.
2. (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23; or (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49 The antibody or antigen-binding fragment thereof of claim 1 .
3. The anti-CD48 antibody (a) a heavy chain amino acid sequence of SEQ ID NO: 12 and a light chain amino acid sequence of SEQ ID NO: 25; (b) a heavy chain amino acid sequence of SEQ ID NO: 14 and a light chain amino acid sequence of SEQ ID NO: 25; (c) a heavy chain amino acid sequence of SEQ ID NO:63 and a light chain amino acid sequence of SEQ ID NO:25; (d) a heavy chain amino acid sequence of SEQ ID NO:38 and a light chain amino acid sequence of SEQ ID NO:51; (e) a heavy chain amino acid sequence of SEQ ID NO: 40 and a light chain amino acid sequence of SEQ ID NO: 51; or (f) a heavy chain amino acid sequence of SEQ ID NO:65 and a light chain amino acid sequence of SEQ ID NO:
51.
3. The antibody or antigen-binding fragment of claim 1 or 2, comprising:
4. Fab fragment, Fab' fragment, F(ab') 2 4. The antibody or antigen-binding fragment thereof of any one of claims 1 to 3, comprising a fragment, a single chain Fv (scFv), a disulfide-linked Fv (sdFv), an Fd fragment, an Fv fragment, a maxibody, a minibody, an intrabody, a bispecific antibody, a half antibody, a one-arm antibody, a monoclonal antibody, a bispecific antibody, a bispecific T cell engaging antibody, a multispecific antibody, a chimeric antigen receptor T cell, or a radioimmunoconjugate.
5. A nucleic acid encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4.
6. 6. The nucleic acid of claim 5, comprising the nucleic acid sequence of SEQ ID NO: 11, SEQ ID NO: 37, SEQ ID NO: 24 or SEQ ID NO: 50, or the nucleic acid sequence of SEQ ID NO: 13, 15, 39, 41, 75, 77, 26 or 52.
7. A vector comprising the nucleic acid of claim 5 or 6.
8. A cell line comprising the nucleic acid described in claim 5 or 6, or the vector described in claim 7.
9. 10. A method for producing an antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, comprising growing a cell line according to claim 8 under conditions suitable for expressing said antibody or antigen-binding fragment thereof, and subsequently purifying and isolating said antibody or antigen-binding fragment thereof.
10. Formula (I): A-(L B -(D) n ) y (I) (In the formula, A is an antibody or antigen-binding fragment thereof that specifically binds to human CD48; L B is a linker; D is a cytotoxic agent, said D being not a BCL-2 inhibitor, an MCL-1 inhibitor or a BCL-XL inhibitor; n is an integer from 1 to 10; and y is an integer from 1 to 10; The linker drug moiety (L B - (D) n (A) is covalently attached to the antibody or antigen-binding fragment thereof. Antibody drug conjugates.
11. The D is an Eg5 inhibitor, a V-ATPase inhibitor, an HSP90 inhibitor, an IAP inhibitor, an mTor inhibitor, a microtubule stabilizer, a microtubule destabilizer, an auristatin, a dolastatin, a maytansinoid, MetAP (methionine aminopeptidase), an inhibitor of the nuclear export of protein CRM1, a DPPIV inhibitor, an inhibitor of phosphoryl transfer reaction in mitochondria, a protein synthesis inhibitor, a kinase inhibitor, a CDK2 inhibitor, a CDK 9 inhibitors, proteasome inhibitors, kinesin inhibitors, HDAC inhibitors, DNA damaging agents, DNA alkylating agents, DNA intercalating agents, DNA minor groove binders, RNA polymerase inhibitors, amanitin, spliceosome inhibitors, topoisomerase inhibitors, DHFR inhibitors or pro-apoptotic agents, but excluding BCL-2 inhibitors, MCL-1 inhibitors and BCL-XL inhibitors.
12. 12. The antibody drug conjugate of claim 10 or 11, wherein D is an auristatin.
13. D is a compound of formula (A): 【Chemistry 1】 (In the formula, R 1 teeth, 【Chemistry 2】 and R 2 is H, C 1 ~C 6 Alkyl, -C(=O)R 3 , -(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 , -((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 is H and C 1 ~C 6 alkyl; and Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. or D is a compound of formula (B): 【Chemistry 3】 (In the formula, R 1 teeth, 【Chemistry 4】 and R 2 is H, C 1 ~C 6 Alkyl, -C(=O)R 3 , -(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 , -((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxyls 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 is H and C 1 ~C 6 alkyl; and Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.
11. The antibody drug conjugate of claim 10, wherein the cytotoxic agent is selected from the compounds of (a) n is 1, 2, 3, 4, 5, 6, 7 or 8; (b) y is 1, 2, 3 or 4; and / or (c) L B is independently selected from a cleavable linker or a non-cleavable linker; The antibody-drug conjugate according to any one of claims 10 to 13.
15. Formula (E): 【Chemistry 5】 (In the formula, A represents an antibody or antigen-binding fragment thereof that specifically binds to human CD48; y is an integer from 1 to 10; R 2 is H, C 1 ~C 6 Alkyl, -C(=O)R 3 , -(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 , -((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 is H and C 1 ~C 6 independently selected from alkyl; L 1 は、-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 1 C(=O)(CH 2 ) m - ** 、-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 2 X 1 C(=O)(CH 2 ) m - ** 、-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m I'm sorry 2 ) m O) p (CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m I'm sorry 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m - ** 、-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** , -X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** , -X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** Or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** where: ** is R 114 indicates the point of attachment to; X 1 teeth, 【Chemistry 6】 where: ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, 【Chemistry 7】 where: ** indicates the point of attachment to -NH-; X 3 teeth, 【Chemistry 8】 where: ** indicates the point of attachment to -NH-; X 4 teeth, 【Chemistry 9】 where: * The attachment point is R 114 indicates that it is suitable for; R 114 teeth, 【Chemistry 10】 -NR 6 C(=O)CH 2 - * -NHC(=O)CH 2 - * 、-S(=O) 2 CH 2 CH 2 - * 、-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * -NR 6 S(=O) 2 CH 2 CH 2 - * -NR 6 C(=O)CH 2 CH 2 - * 、-NH-,-C(=O)-,-NHC(=O)- * 、-CH 2 P.O. 2 CH 2 - * 、-NHCH 2 CH 2 - * 、-S-、 【Chemistry 11】 where: * indicates the attachment point to A; Each R 6 is H and C 1 ~C 6 independently selected from alkyl; Each R 10 is H, C 1 ~C 6 independently selected from alkyl, F, Cl, and —OH; Each R 11 is H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 , -OCH 3 , -OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and -OH; Each R 12 is H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1 ~ 4 Alkoxy and -C(=O)OH substituted C 1 ~ 4 independently selected from alkyl; Each R 15 is H, -CH 3 and phenyl; each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14. An antibody-drug conjugate comprising the structure:
16. 【Chemical 12】 The antibody drug conjugate of claim 15, selected from:
17. Formula (G): 【Chemistry 13】 (In the formula, A represents an antibody or antigen-binding fragment thereof that specifically binds to human CD48; y is an integer from 1 to 10; R 2 is H, C 1 ~C 6 Alkyl, -C(=O)R 3 , -(CH 2 ) m OH, -C(=O)(CH 2 ) m OH, -C(=O)((CH 2 ) m O) n R 4 , -((CH 2 ) m O) n R 4 or optionally -CN, -C(=O)NH 2 or C substituted with 1 to 5 hydroxy 1 ~C 6 is alkyl; Each R 3 is C 1 ~C 6 C substituted with alkyl and optionally 1 to 5 hydroxyl 1 ~C 6 independently selected from alkyl; Each R 4 is H and C 1 ~C 6 independently selected from alkyl; L 1 は、-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 1 C(=O)(CH 2 ) m - ** 、-X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 2 X 1 C(=O)(CH 2 ) m - ** 、-X 3 C(=O)((CH 2 ) m O) p (CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m I'm sorry 2 ) m O) p (CH 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m I'm sorry 2 ) m - ** 、-X 3 C(=O)(CH 2 ) m - ** 、-X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** , -X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** , -X 2 X 1 C(=O)((CH 2 ) m O) p (CH 2 ) m X 4 (CH 2 ) m - ** Or -X 2 X 1 C(=O)(CH 2 ) m X 4 (CH 2 ) m - ** where: ** is R 114 indicates the point of attachment to; X 1 teeth, 【Chemistry 14】 where: ** is -NH- or X 2 indicates the point of attachment to; X 2 teeth, 【Chemistry 15】 where: ** indicates the point of attachment to --NH--; X 3 teeth, 【Chemistry 16】 where: ** indicates the point of attachment to --NH--; X 4 teeth, 【Chemistry 17】 where: * The attachment point is R 114 indicates that it is suitable for; R 114 teeth, 【Chemistry 18】 -NR 6 C(=O)CH 2 - * -NHC(=O)CH 2 - * 、-S(=O) 2 CH 2 CH 2 - * 、-(CH 2 ) 2 S(=O) 2 CH 2 CH 2 - * -NR 6 S(=O) 2 CH 2 CH 2 - * -NR 6 C(=O)CH 2 CH 2 - * 、-NH-,-C(=O)-,-NHC(=O)- * 、-CH 2 P.O. 2 CH 2 - * 、-NHCH 2 CH 2 - * 、-S-、 【Chemistry 19】 where: * indicates the attachment point to A; Each R 6 is H and C 1 ~C 6 independently selected from alkyl; Each R 10 is H, C 1 ~C 6 independently selected from alkyl, F, Cl, and —OH; Each R 11 is H, C 1 ~C 6 Alkyl, F, Cl, -NH 2 , -OCH 3 , -OCH 2 CH 3 , -N(CH 3 ) 2 , -CN, -NO 2 and -OH; Each R 12 is H, C 1 ~ 6 Alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C substituted with -C(=O)OH 1 ~ 4 Alkoxy and -C(=O)OH substituted C 1 ~ 4 independently selected from alkyl; Each R 15 is H, -CH 3 and phenyl; each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; and Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14. An antibody-drug conjugate comprising the structure:
18.
20. 18. The antibody drug conjugate of claim 17, selected from:
19.
21. The antibody-drug conjugate of claim 10, wherein the antibody-drug conjugate is selected from the group consisting of
20. The antibody drug conjugate of any one of claims 10 to 19, wherein A is an antibody or antigen-binding fragment of any one of claims 1 to 4.
21. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 or the antibody-drug conjugate according to any one of claims 10 to 20, and a pharma- ceutically acceptable carrier.
22. The pharmaceutical composition of claim 21, further comprising one or more additional therapeutic agents, and optionally, the pharmaceutical composition is a lyophilized product.
23. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, the antibody drug conjugate according to any one of claims 10 to 20 or the pharmaceutical composition according to claim 21 or 22 in the manufacture of a medicament, composition or product for the treatment of cancer in a patient in need thereof.
24. 23. A pharmaceutical composition according to claim 21 or 22 for use in treating cancer in a patient in need thereof.
25. (a) the cancer expresses CD48, and / or (b) the cancer is a tumor, a blood cancer, a breast cancer, a multiple myeloma, a B-cell lymphoma, a plasma cell myeloma, a leukemia, a lymphoma, a gastric cancer, an acute myeloid leukemia, a bladder cancer, a brain tumor, a bone marrow cancer, a cervical cancer, a chronic lymphocytic leukemia, a colorectal cancer, an esophageal cancer, a hepatocellular carcinoma, a lymphocytic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myeloid leukemia, a myeloma, an oral cancer, an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a prostate cancer, a small cell lung cancer, or a splenic cancer, 25. The use according to claim 23 or the pharmaceutical composition according to claim 24.
26. The use described in claim 23 or the pharmaceutical composition described in claim 24, wherein the medicament, composition or product further comprises one or more additional therapeutic agents.
27. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, the antibody drug conjugate according to any one of claims 10 to 20 or the pharmaceutical composition according to claim 21 or 22 in the manufacture of a medicament, composition or product for reducing or inhibiting tumor growth in a subject in need thereof.
28. 23. A pharmaceutical composition according to claim 21 or 22 for use in reducing or inhibiting the growth of a tumor in a subject in need thereof.
29. (a) the tumor expresses CD48, and / or (b) use of the antibody or antigen-binding fragment thereof, antibody drug conjugate, or pharmaceutical composition reduces or inhibits the growth of the tumor by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 99%.
29. The use according to claim 27 or the pharmaceutical composition according to claim 28.
30. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, an antibody drug conjugate according to any one of claims 10 to 20 or a pharmaceutical composition according to claim 21 or 22 in the manufacture of a medicament, composition or product for reducing or slowing the proliferation of a cancer cell population in a subject.
31. A pharmaceutical composition as described in claim 21 or 22 for use in reducing or slowing the proliferation of a cancer cell population in a subject.
32. (a) the cancer cell population expresses CD48. (b) the cancer cell population is derived from a tumor, a blood cancer, breast cancer, multiple myeloma, B cell lymphoma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain tumor, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphocytic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or splenic cancer; and / or (c) use of said antibody drug conjugate, composition or pharmaceutical composition reduces said cancer cell population or slows the proliferation of said cancer cell population by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99%.
32. The use according to claim 30 or the pharmaceutical composition according to claim 31.
33. An antibody that competes with NY920 or NY938 for binding to human CD48.
34. An antibody that competes with the antibody or antigen-binding fragment thereof of any one of claims 1 to 4 for binding to human CD48.
35. The antibody binds to the same or overlapping epitope on human CD48 as NY920 or NY938, and optionally (a) binds to one or more amino acids within residues 54-64 or 105-121 of human CD48 (SEQ ID NO:53); and / or (b) binds to one or more amino acids selected from residues 54, 58, 60, 61, 62, 64, 105, 107, 119, 111, 114, 115, 117, 119, and 121 of human CD48 (SEQ ID NO:53), and optionally contacts said one or more amino acids within 4.0 Å; 35. The antibody of claim 33 or 34.
36. A diagnostic agent comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 4 or the antibody-drug conjugate according to any one of claims 10 to 20.
37. 37. The diagnostic reagent of claim 36, wherein the antibody or antigen-binding fragment thereof or the antibody-drug conjugate is labeled with a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion.
38. A method for detecting human CD48 in a tissue or cell, the method comprising contacting the tissue or cell with a diagnostic agent described in claim 36 or 37 and detecting binding of the diagnostic agent to the tissue or cell.
